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Abstract 
Ovarian cancer is the most leathal cancer among gynecologic cancers in the United States and is 
the fifth leading cause of cancer death among American women. Approximately sixty percent of 
women with ovarian cancer are diagnosed with advanced stage diseases. High-grade serous 
ovarian carcinoma (HGS-OvCa) is the most common subtype of epithelial ovarian cancer and 
accounts for around 70% of all ovarian cancers in the U.S. Although the platinum-taxane 
combination has been the standard of care for treatment of ovarian cancer for over 15 years, an 
emerging science indicates poly (ADP-ribose) polymerase inhibitors (PARPi) are also active in a 
substantial portion of HGS-OvCa. Cancer cells that show “BRCAness” are highly sensitive to 
PARPi, including those with deleterious mutations in BRCA1/2 or defects in other components 
that are crucial for homologous recombination (HR) repair pathway. In HGS-OvCa, genes 
involved in HR are altered in about 50% of cases, making these cancers sensitive to PARPi. 
However, FOXM1 transcription factor network is activated in more than 84% of cases in HGS-
OvCa, and activation of the FOXM1 pathway has been shown to upregulate genes involved in HR. 
Yet, the role of FOXM1 in PARPi response is not well studied. The MYC proto-oncogene is 
reported to be amplified in a significant number of epithelial ovarian cancer, and its role in the 
regulation of DNA repair and the PARPi response is not yet characterized. Therefore, we evaluated 
the roles of FOXM1 and MYC in PARPi response and explored ways to target them and develop 
new combinational therapies to overcome PARPi resistance. Besides, our understanding of PARPi 
resistance mechanism is not complete, and there is an urgent need to identify other potential 
regulators of PARPi response. So, we performed a genome-wide CRISPR knockout screen to 
identify novel regulators of PARPi response in ovarian cancer cells. 
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 To identify potential regulators of PARPi response, we first evaluated the role of FOXM1 
and found that PARPi olaparib induced the expression and nuclear localization of FOXM1, 
suggesting FOXM1 might play an important role in the adaptive response to PARPi. Using ChIP-
qPCR, we observed that olaparib treatment enhanced the binding of FOXM1 to genes involved in 
HR. Using qRT-PCR, we found FOXM1 knockdown by RNAi or treatment with thiostrepton, a 
natural peptide thiazole antibiotic, led to significantly decreased expression of FOXM1 and HR 
repair genes, such as BRCA1, FANCF, BRCC3, BRIP1, NBS1 and Csk1. Consequently, with short 
term SRB assay and long-term colony formation assay, both FOXM1 knockdown and thiostrepton 
treatment showed enhanced sensitivity to olaparib. Using comet and PARP trapping assays, we 
also observed increased DNA damage and PARP1 trapping in FOXM1-inhibited cells treated with 
olaparib. Finally, thiostrepton treatment lead to the decreased expression of BRCA1 in rucaparib-
resistant breast cancer cells and enhanced sensitivity to rucaparib. Collectively, these results 
suggest that FOXM1 plays an important role in the adaptive response induced by olaparib and that 
FOXM1 downregulation by siRNAs or thiostrepton treatment contributes to “BRCAness” and 
enhances sensitivity to PARP inhibitors. 
 Second, we found that FOXM1 silencing results in c-MYC upregulation, and that FOXM1 
knockdown in itself is not sufficient to downregulate several HR genes, including BRCA1, BRCA2, 
FANCF and BRIP1. Analysis of the ENCODE (Encyclopedia of DNA Elements) database found 
that both FOXM1 and c-MYC bind to overlapping regions in the promoters of HR genes, such as 
BRCA1 and RAD51, suggesting that these HR genes may be co-regulated by FOXM1 and c-MYC. 
In addition, using the Cancer Genome Atlas (TCGA) database we discovered that FOXM1, c-MYC, 
and BRD4 are highly expressed in ovarian cancer and are related to each other, making them 
relevant therapeutic targets to explore. Using Western blot, we showed that BET bromodomain 
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inhibitor, (+)-JQ1, suppresses the expression of c-MYC and FOXM1 as well as BRCA1 and 
RAD51. By chromatin immunoprecipitation and quantitative polymerase chain reaction (ChIP-
qPCR), we saw decreased binding of both FOXM1 and c-MYC to the promoters of BRCA1 and 
RAD51, suggesting a direct regulation of these genes by FOXM1 and c-MYC. Treatment of three 
cancer cell lines (ES-2, OV90 and OVCA420*) with (+)-JQ1, lead to decreased cell viability in a 
dose-dependent manner for all cell lines. With SRB assay, we also observed mild to moderate 
synergistic effects of PARP inhibitors and (+)-JQ1 in cancer cells with primary resistance to 
olaparib as well as in cancer cells with acquired resistance to rucaparib. Strikingly, adding sub-
lethal doses of (+)-JQ1 and olaparib completely inhibited colony formation. Taken together, these 
data suggest that inhibition of FOXM1 and c-MYC by BET inhibitor, (+)-JQ1, induces 
“BRCAness” by downregulating BRCA1 and RAD51, and sensitizes resistant cancer cells to PARP 
inhibitors.  
 Third, using the sensitivity of PARPi olaparib as a surrogate, we performed a CRISPR/Cas9 
based genome-scale loss-of-function screen and identified C12orf5, a gene that encodes a 
metabolic regulator, TP53 induced glycolysis and apoptosis regulator (TIGAR) as a potential 
genetic determinant of PARPi response. To unveil the mechanisms involved in this process, further 
studies showed that TIGAR knockdown induces apoptosis, elevates the production of reactive 
oxygen species (ROS), and arrests cells at S-phase. These effects collectively contribute to 
accumulation of DNA damage and sensitize cancer cells to olaparib. More interestingly, RNA-
sequencing analysis showed that TIGAR knockdown leads to decreased expression of BRCA1, and 
GSEA analysis indicates that TIGAR knockdown unexpectedly produces a gene signature that is 
similar to BRCA1-downregulated cells. Furthermore, TIGAR knockdown results in 
downregulation of genes associated with the Fanconi Anemia (FA) pathway. Collectively, these 
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findings provide us new insights into the molecular mechanisms involved in sensitization of 
olaparib after TIGAR knockdown. In addition to enhanced sensitivity to PARPi, TIGAR 
knockdown also inhibits cell growth by induction of cellular senescence as shown by SA-β-Gal 
staining analysis. Concomitantly, TIGAR knockdown resulted in the reduced efficacy in spheroid 
formation and the enhanced therapeutic effects of olaparib. Finally, analysis of TCGA database 
demonstrated that TIGAR amplification was found in different types of cancer including ovarian 
cancer (amplification was seen in about 11% of cases), and that elevated expression levels of 
TIGAR mRNA is associated with poor overall survival in high-grade serous ovarian cancer. Taken 
together, our data suggest that TIGAR negatively regulates PARPi sensitivity and is a relevant 
therapeutic target in ovarian cancer. 
 In summary, our studies showed that FOXM1 plays an important role in the adaptive 
response to PARPi and a potential role in the resistance to PARPi by positively regulating HR 
repair pathway through upregulation of BRCA1, RAD51, and other HR genes, such as FANCD2, 
FANCF, and RAD51D. Targeting FOXM1 with siRNA or treatment with thiostrepton induces a 
“BRCAness” phenotype and sensitizes cancer cells with either primary or acquired resistance to 
PARP inhibitors. The combination of FOXM1 inhibitor thiostrepton and PARPi enhances the 
cytotoxic effects and represents a new strategy to overcome PARPi resistance. We also showed 
that c-MYC works together with FOXM1 to regulate HR genes, including BRCA1 and RAD51. 
Inhibition of FOXM1 and c-MYC by BET inhibitor downregulates HR genes, such as BRCA1 and 
RAD51, and enhances cytotoxic effects of PARPi in resistant cells, suggesting that the combination 
of BET inhibitor with PARPi represents another effective strategy to induce “BRCAness” to 
overcome PARPi resistance in HR-proficient cancer cells. Lastly, we identified TIGAR as a novel 
regulator of PARPi response. Our data suggest that TIGAR negatively regulates PARPi sensitivity, 
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and TIGAR knockdown leads to increased cytotoxicity to olaparib by enhancing DNA damage, 
induction of apoptosis, and most importantly induction of “BRCAness” by downregulating BRCA1 
and the FA pathway. We also found that efficient TIGAR knockdown leads to cellular senescence. 
Collectively, TIGAR knockdown represents the third strategy to induce “BRCAness” to enhance 
sensitivity to PARPi. Considering that TIGAR knockdown also induces senescence and spheroid 
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Chapter 1. Introduction  
 2 
1.1 Background: Ovarian Cancer Facts and Figures 
According to the SEER Cancer Statistics Review (CSR) 1975-2014, ovarian cancer is the most 
lethal gynecological cancer and the fifth leading cause of deaths among women in the United States 
(Howlader N 1975-2014). According to the same report, ovarian cancer is relatively rare, 
representing only 1.3% of all new cancer cases in the United States in 2017. In 2018, it is estimated 
that 22,240 women will be diagnosed with ovarian cancer and 14,070 deaths will result from 
complications associated with this disease. The lifetime risk of a woman to develop ovarian cancer 
is approximately 1 in 79 and to die from her disease is 1 in 108. Ovarian cancer is most frequently 
diagnosed among women aged between 55 and 64, and the median age at diagnosis is 63. The 
overall five-year survival rate for ovarian cancer is 46.5%. However, if diagnosed at early stages, 
the 5-year survival is up to 92.5% for women with stage I and 80% for stage II.  The outcome 
decreases dramatically for advanced stage diseases, with a 5-year survival of 20-50% for women 
diagnosed with stage III and only 1-5% for those with stage IV. Unfortunately, only around 20% 
of patients are diagnosed at an early stage due to the lack of obvious symptoms. In general, death 
rates also increase with age, with the highest rate seen in women between 65 and 74 years of age. 
Although improved screening and advances in treatment are reducing the death rate by 
approximately 2.2% each year, concerted efforts are still needed to develop better screening to 
increase early diagnosis and to develop more effective treatments to improve survival of cancer 
patients.  
 Ovarian cancer was originally described as cancer that begins in ovaries (American Cancer 
Society 2017), which are the female reproductive glands. It was originally proposed to originate 
from one of the three cell types that constitute the ovaries: epithelial cells, stromal cells, or germ 
cells (Reid, Permuth et al. 2017). Epithelial ovarian cancer (EOC) accounts for more than 90% of 
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ovarian cancer, whereas stromal and germ cell-originated ovarian cancers represent 5-6% and 2-
3%, respectively (Sankaranarayanan and Ferlay 2006). This dissertation focuses on EOC, which 
was originally proposed to originate from the surface epithelium of the ovary (Auersperg, Wong 
et al. 2001). However, emerging evidence suggest various subtypes of EOC have different tissues 
and cells of origin (Vaughan, Coward et al. 2011).  
 According to International Federation of Gynecology and Obstetrics (FIGO) staging system 
(Prat, Belhadj et al. 2015, Prat and Oncology 2015), there are four stages of EOC, namely stages 
I, II, III and IV. At stage I, ovarian cancer is confined to one or both ovaries. At stage II, cancer is 
regional, involving one or both ovaries and the uterus and/or fallopian tubes or other sites in the 
pelvis. Stage III is characterized by peritoneal metastases outside the pelvis whereas Stage IV is 
characterized by distant metastases, excluding peritoneal metastases. 
 EOC is a heterogeneous disease (Wang, Li et al. 2005). It can be histologically characterized 
into five main subtypes, which differ in their profiles of pathogenesis, cellular origin, genetic 
alterations, molecular changes and prognosis (Cancer Genome Atlas Research 2011, McCluggage 
2011, Prat 2012, Song, Lee et al. 2013, Reid, Permuth et al. 2017). The five main subtypes are 
serous, mucinous, endometrioid, clear cell, and transitional (Brenner) cell (Chen, Ruiz et al. 2003). 
Based on distinctive morphologic and molecular genetic features, EOC is also classified into two 
different groups, type I and type II (Shih Ie and Kurman 2004, Kurman and Shih Ie 2010). Type I 
tumors usually have precursor lesions, often present at a low grade, and some are clinically 
indolent (Koshiyama, Matsumura et al. 2014). They include low-grade serous, low-grade 
endometrioid, clear cell, mucinous and transitional carcinomas. Type I tumors are commonly 
diagnosed at early stages and characterized by relatively stable genetic, lack of TP53 mutations, 
and frequent mutations in BRAF, KRAS, PTEN, CTNNB1, and/or PIK3CA (Shih Ie and Kurman 
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2004). In contrast, type II carcinomas are more aggressive and highly genetically unstable with the 
majority possessing TP53 mutations (Merajver, Pham et al. 1995, Salani, Kurman et al. 2008, Cho 
and Shih Ie 2009). Type II carcinomas are usually found at advanced stages and are composed of 
high-grade serous carcinoma, undifferentiated carcinoma, and malignant mixed mesodermal 
tumors. High-grade serous carcinoma (HGSC) makes up the majority of advanced-stage ovarian 
cancer cases and have the lowest survival rates (Dao, Schlappe et al. 2016). According to the 
Cancer Genome Atlas (TCGA) report, TP53 is mutated in more than 95% of HGSCs (Cancer 
Genome Atlas Research 2011), and BRCA1/2 mutations are found in approximately 25% of 
HGSCs. Mutations in other tumor suppressors,  such as CDK12, RB, are reported in less than 10% 
of cases (Cancer Genome Atlas Research 2011).  
 For ovarian cancer, different treatment options are chosen depending on the histologic 
subtypes and the stages at diagnosis (Kim, Ueda et al. 2012, Trimbos 2017). Surgery, 
chemotherapy, and radiation are three basic forms of treatment for ovarian cancer. Surgery is still 
considered to be the main treatment for most ovarian cancers, with a goal to reduce the tumor 
burden to a nonvisible disease state. Moreover, the subtype and stage information are determined 
at the time of surgery, which includes removal of the ovaries and fallopian tubes, uterus, and 
portions of the omentum or other involved tissues which are feasible to remove (Shepherd 1989, 
Benedet, Bender et al. 2000, Weber, McCann et al. 2011). It is recommended that patients see a 
gynecologic oncologist for surgery, who has training and experience in treating, staging, and 
debulking ovarian cancer (Junor, Hole et al. 1999, Trope and Kaern 2006, du Bois, Rochon et al. 
2009). Patients whose tumors have been optimally cytoreduced have a better outcome (Schorge, 
McCann et al. 2010) than those sub-optimally debulked patients. Women who have minimal 
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residual tumor after surgery have a median survival of 39 months versus 17 months for sub-
optimally debulked individuals (Hoskins, McGuire et al. 1994, Bristow, Tomacruz et al. 2002).  
 The front-line chemotherapy for ovarian cancer patients is usually a combination of two or 
more drugs, which is given every 3-4 weeks. The standard systemic chemotherapy is the 
combination of a platinum agent, such as carboplatin or cisplatin, and a taxane agent, such as 
paclitaxel or docetaxel (Cannistra 2004). The use of carboplatin was shown to have less severe 
side effects than cisplatin while proven to be as effective (du Bois, Luck et al. 2003, Ozols, Bundy 
et al. 2003). Most often, the systemic chemotherapy for ovarian cancer can be administered by 
intravenous injection (IV) or intraperitoneal (IP) injection. Studies have shown that IP route has a 
better prognosis for progression-free survival and overall survival (Howell, Zimm et al. 1987, 
Armstrong, Bundy et al. 2006). However, due to complications, that included catheter infection, 
blockage, and leakage, this route of drug administration is not widely adopted as the standard of 
care. Standard chemotherapy is usually effective at initial treatment, and a pathologic or 
radiographic complete response is achievable in the majority of patients. However, the tumor 
relapse after several rounds of chemotherapy is common, and the acquired resistance eventually 
leads to treatment failure (Cannistra 2004, Chien, Kuang et al. 2013). A major issue associated 
with chemotherapeutic drugs in ovarian cancer is the severe side effects caused by damages to 
normal cells (Desoize and Madoulet 2002, du Bois, Luck et al. 2003, Gordon and Butler 2003, 
Ozols, Bundy et al. 2003, Shah and Dizon 2009). Some severe side effects, such as nausea and 
vomiting, loss of hair, hand and foot rashes, and mouth sores are temporary and dissipate once 
treatment is ceased. Chemotherapy can also cause damage to bone marrow (Florea and Busselberg 
2011), leading to increased risk of infection, bleeding or bruising with minor cuts or injuries, and 
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fatigue. In addition, cisplatin has been shown to cause permanent kidney damage (Chu, Mantin et 
al. 1993, Meyer and Madias 1994).  
 Radiation therapy was used more often in the past to treat ovarian cancer (Arian-Schad, Kapp 
et al. 1990), and it is now rarely used as the first-line treatment for ovarian cancer (Lee, Park et al. 
2011). It uses high energy x-rays or particles to kill cancer cells and also result in damage to 
surrounding normal cells. It can be useful in treating recurrent ovarian cancer that is refractory to 
chemotherapy (Lee, Park et al. 2011).  
 For patients with advanced-stage ovarian cancers, the current standard of care is surgical 
debulking followed by adjuvant chemotherapy to kill the residual cancer cells. In some cases, if 
the tumor burden is so extensive, neoadjuvant chemotherapy may be used to reduce tumor burden 
before the primary surgery. Although these chemotherapies are effective, they are not typically 
curative due to the development of acquired resistance. In the search for more effective treatments, 
targeted therapies have also been evaluated in patients with ovarian cancer. For example, 
bevacizumab, as a VEGF (Vascular Endothelial Growth Factor) inhibitor, has been tested in 
advanced EOCs and has been shown to shrink and slow tumor growth (Burger, Brady et al. 2011).  
These types of therapies in general were designed to be more specific in killing cancer cells while 
causing little damage to normal cells (Zhang, Yang et al. 2009). The first molecular targeted 
therapies were developed to target over-activated oncogenic proteins in cancer cells, such as 
Herceptin to target HER2-positive breast cancer (Slamon, Eiermann et al. 2011), vemurafenib to 
target the BRAF V600E mutants in melanoma (Tsai, Lee et al. 2008, Bollag, Hirth et al. 2010, 
Joseph, Pratilas et al. 2010, Chapman, Hauschild et al. 2011), imatinib mesylate to target BCR-
ABL fusion proteins in leukemia (Druker, Tamura et al. 1996, Deininger, Goldman et al. 1997, 
Gambacorti-Passerini, le Coutre et al. 1997, Druker, Talpaz et al. 2001) and oncogenic 
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KIT/PDGFRA in gastrointestinal stromal tumor (van Oosterom, Judson et al. 2001, Demetri, von 
Mehren et al. 2002), and gefitinib to target the epidermal growth factor receptor (EGFR) tyrosine 
kinase in non-small cell lung cancer (NSCLC) (Lynch, Bell et al. 2004, Paez, Janne et al. 2004, 
Maemondo, Inoue et al. 2010). In high-grade serous ovarian cancer, copy number alteration (CNA) 
and genetic alterations in HR pathway are characteristic features of the disease (Cancer Genome 
Atlas Research 2011, Zack, Schumacher et al. 2013) and these features affect treatment options. 
Focal amplification of CCNE1 was seen in ~20% of cases (Patch, Christie et al. 2015), and it was 
shown to be associated with primary treatment failure (Etemadmoghadam, deFazio et al. 2009) 
and reduced survival (Mayr, Kanitz et al. 2006). In addition, tumor suppressor genes (Cancer 
Genome Atlas Research 2011), such as TP53, BRCA1/2, NF1, CDK12, and RB are the most 
frequently mutated genes in high-grade serous ovarian cancer (Ahmed, Etemadmoghadam et al. 
2010, Cancer Genome Atlas Research 2011). These mutations result in the loss of function, and 
gene therapies to restore the wild-type copy of mutated tumor suppressor genes have thus been 
unsuccessful.  
 Fortunately, recent advances provided a new approach to target the loss of function mutations 
associated with tumor suppressor genes. The functional loss associated with mutations in tumor 
suppressor genes may be targeted through synthetic lethal approach. Recently, PARP inhibitors 
have been developed to target BRCA-mutated cancer cells and have shown activity in a subset of 
ovarian cancers with a deficiency in homologous recombination repair (Vaughan, Coward et al. 
2011). The mechanism of action associated with PARP inhibitors, such as olaparib (Lynparza), 
rucaparib (Rubraca), and niraparib (Zejula), and their FDA-approved indications for ovarian 
cancer patients will be discussed in the following sections.  
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1.2 Homologous recombination repair (HRR) 
1.2.1 HRR is important in maintaining genome stability 
Cancer is the disease of the genome, and loss of genome integrity is a hallmark of cancer (Hanahan 
and Weinberg 2011). Cells in our bodies are exposed to various sources of DNA-damaging agents, 
such as ultraviolet (UV), ionizing radiation, genotoxic chemicals, and reactive oxygen species 
(ROS) that are generated by cellular metabolism (Lindahl and Barnes 2000, Jackson and Bartek 
2009). Exposure to these agents can lead to various types of DNA damages (Lindahl and Barnes 
2000) and cells have evolved different and partially overlapping DNA repair mechanisms to repair 
these DNA damages (Hoeijmakers 2001). Briefly, nuclear excision repair (NER) repairs helix-
distorting lesions that interfere with base pairing and generally obstruct transcription and normal 
replication (Marteijn, Lans et al. 2014). Base excision repair (BER) is used to fix single-strand 
breaks (SSBs) (David, O'Shea et al. 2007). Mismatch repair (MMR) is responsible for detection 
and repair of mispaired nucleotides generated from replication error (Kunkel and Erie 2015). DNA 
double-strand breaks (DSBs) are the most deleterious DNA damages, and if they are left 
unrepaired, it may lead to chromosomal rearrangement, genome instability, and finally cell death 
(van Gent, Hoeijmakers et al. 2001). In mammalian cells, DSBs are mainly repaired by HRR and 
non-homologous end joining (NHEJ) pathways (Pfeiffer, Goedecke et al. 2000). NHEJ is active 
throughout the cell cycle and predominantly used in the G1 phase of cell cycle. It is error-prone 
because DSBs are fixed by simply ligating the breaks. This type of repair results in insertions, 
deletions, and translocations. In contrast, HRR is the most conservative and error-free repair 
mechanism for DSBs, and is preferentially used during S and G2 phases of cell cycle, when the 
homologous templates on the sister chromatid are available (Paques and Haber 1999, Rothkamm, 
Kruger et al. 2003, Aylon, Liefshitz et al. 2004, Ira, Pellicioli et al. 2004, Moynahan and Jasin 
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2010). Therefore, HRR plays important roles in maintaining genome stability in mammalian cells. 
HRR is also the predominant mechanism for replication-associated DSBs repair that is activated 
when the replication machinery encounters SSBs or interstrand crosslinks (ICLs) (Arnaudeau, 
Lundin et al. 2001, Saintigny, Delacote et al. 2001). SSBs and ICLs produce stalled or collapsed 
replication forks when DNA polymerases encountered these sites. HRR plays an important role in 
the restart of the stalled or collapsed replication forks (Saleh-Gohari, Bryant et al. 2005). In 
mammalian cells, the important components involved in HRR pathways include Rad51, BRCA1/2, 
the Mre1/Ras50/Nbs1 complex, CtIP, and others. Mutations in any of these components have the 
potential to cause dysfunction in HRR, which can lead to reduced tolerance of DNA damage, and 
contribute to many human diseases, such as Fanconi Anemia, familial breast and ovarian cancer, 
and neurodegenerative diseases, suggesting that a faithful repair of DNA DSBs by HRR is essential 
for maintaining genome integrity, stability, and normal functions of the cell. 
1.2.2 HRR process and its regulation 
HRR-mediated DSB repair is a multi-step process (Jasin and Rothstein 2013). Firstly, DSBs are 
recognized by the Mre11/RAD50/Nbs1 (MRN) complex (Lee and Paull 2005), which serves to 
sense, stabilize and recruit other effector proteins (Figure 1.2.1). Then ataxia telangiectasia 
mutated (ATM), which is a serine-threonine kinase, phosphorylates the downstream effectors, 
such as H2AX, BRCA1, p53, 53BP1, Chk-2 and SMC1 (Shiloh 2003, Berkovich, Monnat et al. 
2007). Secondly, 5’ to 3’ end resection to form 3’-end single stranded DNA (ssDNA) is mediated 
through multiple proteins and protein complexes (Symington and Gautier 2011), including MRN 
complex, C-terminal-binding protein interacting protein (CtIP), exonuclease 1 (EXO1), DNA 2 
nuclease/helicase, Bloom syndrome protein (BLM), and other chromatin remodeling factors 
(Mimitou and Symington 2009, Liu and Huang 2016). Thirdly, RAD51 protein associates with 
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ssDNAs to facilitate the formation of nucleoprotein filament. During this process, RAD54, 
BRCA1, PABL2, and BRCA2 proteins participate in promoting RAD51 assembly at the ssDNA 
(Mazin, Alexeev et al. 2003, Sung and Klein 2006, Moynahan and Jasin 2010, O'Donovan and 
Livingston 2010, Holloman 2011). Fourthly, strand invasion after a search for homology region 
mediates the formation of D-loop, which is mediated by RAD51 and promoted by 
Mre11/Rad50/Xrs2 (MRX) complex. Next, an extension of the 3’ end of the invading strand using 
homology template is achieved by several DNA polymerases but preferentially by DNA 
polymerase δ (Maloisel, Fabre et al. 2008). The 3' extensions by DNA polymerases produce double 
Holliday junctions that proceeds with branch migration, followed by DNA ligation by DNA ligase 
I. Finally, Holliday junctions are resolved by resolvase that separates the repaired DNA and the 
template (Figure 1.2.1). 
 HR pathway is extensively regulated, and it is dependent on the activity of various other 
pathways (Krajewska, Fehrmann et al. 2015), including DNA damage response, cell cycle 
regulation, protein stability control pathways, and growth factor-activated receptor signaling 
pathways. Components that regulate these related pathways will also regulate HR function. For 
example, Mre11/Rad50/Nbs1 (MRN) complex, ATM, ATR, CHK1 and others in DNA damage 
response pathway (Morrison, Sonoda et al. 2000, Sorensen, Hansen et al. 2005, Kozlov, Graham 
et al. 2011, Kocher, Rieckmann et al. 2012, Prevo, Fokas et al. 2012), cyclin-dependent kinases 
(CDKs) (i.e., CDK2, 4, 6) in the cell cycle pathway (Aylon, Liefshitz et al. 2004, Branzei and 
Foiani 2008), heat-shock protein (HSP) family members (such as HSP90) and ubiquitination-
related enzymes in the protein stability control pathway (Noguchi, Yu et al. 2006, Dungey, 
Caldecott et al. 2009, Zaidi, McLaughlin et al. 2012, Lafranchi, de Boer et al. 2014), and epidermal 
growth factor receptor (EGFR) pathway regulators (EGFR, HER2, IGF1R, etc.) in cell 
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proliferation pathway (Golding, Morgan et al. 2009, Mukherjee, McEllin et al. 2009, Myllynen, 
Rieckmann et al. 2011). However, the knowledge of how HR is regulated is thus far not complete. 
New knowledge and advances are being made using genetic screens with small interfering RNA 
(siRNA) or short hairpin RNA (shRNA) libraries to identify potential regulators of HR pathway 






Figure 1.2.1: Schematic demonstration of HRR process. 1) DSB recognition; 2) End resection; 3) 
Formation of nucleoprotein filament; 4) Strand invasion and D-loop formation; 5) Formation of Double 
Holliday junctions; and 6) Resolution of Holliday junction. DSB, double strand break; UV, ultraviolet; IR, 
ionizing radiation; ATM, serine/threonine kinase Ataxia-Telangiectasia mutated; BLM, Bloom Syndrome 
RecQ-like Helicase; EXO1, exonuclease I; RPA, single strand DNA binding protein Replication Protein A; 
DNA pol 1, DNA polymerase I.  
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1.2.3 Loss-of-function BRCA1/2 mutations are associated with higher risks for ovarian and breast 
cancer 
Breast cancer 1, early onset and breast cancer 2, early onset (BRCA1 and BRCA2) are tumor 
suppressors, which are encoded by BRCA1 and BRCA2 genes, respectively. They play important 
roles in DNA repair through HRR pathway (Silver and Livingston 2012). Inherited BRCA1/2 
mutations are associated with the majority of hereditary breast and ovarian cancer (HBOC), and 
are also associated with increased risk of other cancers and diseases, such as prostate cancer, 
pancreatic cancer, fallopian tube cancer, peritoneal cancer and Fanconi anemia (Brose, Rebbeck 
et al. 2002, Howlett, Taniguchi et al. 2002, Finch, Beiner et al. 2006, Levy-Lahad and Friedman 
2007, Ferrone, Levine et al. 2009, Alter 2014, Sawyer, Tian et al. 2015). Together, BRCA1 and 
BRCA2 mutations account for 20-25% of hereditary breast cancers (Easton 1999) and 
approximately 15% of ovarian cancers (Pal, Permuth-Wey et al. 2005). A woman’s lifetime risk 
of developing breast and/or ovarian cancer is greatly increased if she inherits a pathogenic mutation 
in BRCA1 or BRCA2. About 12% of women in the general population will develop breast cancer 
sometime in their lives (Howlader N 2014). By contrast, 55-65% of women who inherited harmful 
BRCA1 mutations and around 45% of women who inherited deleterious (disease-associated)  
BRCA2 mutations will develop breast cancer by the age of 70 (Antoniou, Pharoah et al. 2003, Chen 
and Parmigiani 2007). About 1.3% of women in the general population will develop ovarian cancer 
sometime during their lives (Howlader N 2014). By contrast, 39% of women who inherited 
deleterious  BRCA1 mutations and 11-17% of women who inherited  deleterious BRCA2 mutations 
will develop ovarian cancer by the age of 70 (Antoniou, Pharoah et al. 2003, Chen and Parmigiani 
2007). A recent study by Rebbeck and colleagues have described the characteristics of the 1,650 
unique BRCA1 and 1,731 unique BRCA2 deleterious mutations identified in the Consortium of 
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Investigators of Modifiers of BRCA1/2 (CIMBA) database (Rebbeck, Friebel et al. 2018). 
However, not all BRCA1/2 mutations are harmful or associated with increased risk of developing 
cancers. Moreover, in the clinic, there are some BRCA1/2 mutations that are known as variants of 
unknown significance (VUS) because of not enough available clinical data to evaluate cancer risks 
associated with these mutations. The functional characterization of VUS in BRCA1 and BRCA2 is 
also an active area of research. 
1.3 Poly (ADP-ribose) polymerase inhibitor (PARPi) 
1.3.1 Synthetic lethality and therapeutic exploration of HR defects in the development of targeted 
therapy for cancer 
The concept of synthetic lethality was first introduced in Drosophila melanogaster to describe the 
lethal relationship between two genes (Bridges 1922). As illustrated in Figure 1.3.1, synthetic 
lethality is defined as a type of genetic interaction in which the co-occurrence of two genetic events 
results in organismal or cellular death while the presence of only one genetic alteration will not 





Figure 1.3.1: The concept of synthetic lethality. Two genes are synthetic lethal if the loss of expression 
of both leads to organismal or cell death while the loss of either of them is compatible with viability.  
Synthetic lethality also occurs between genes and small molecules, and can be used to elucidate the 
mechanism of action of drugs.  
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More recently, the concept of synthetic lethality has been extended to cancer cells, and the potential 
clinical utility of synthetic lethal-based targeted cancer therapy was best illustrated by two 
landmark studies by Bryant et al. (2005) and Farmer et al. (2005) (Bryant, Schultz et al. 2005, 
Farmer, McCabe et al. 2005). According to their studies, BRCA1 or BRCA2 dysfunction 
exquisitely sensitizes cancer cells to the inhibition of PARP1 enzymatic activity with PARP 
inhibitors, resulting in chromosomal instability, cell cycle arrest, and subsequent apoptosis of 
cancer cells. PARP1 inhibition specifically kills tumor cells while with minimal effects on normal 
cells (Bryant, Schultz et al. 2005, Farmer, McCabe et al. 2005). PARP1, poly (ADP-ribose) 
polymerase 1, is the founding member of a family of enzymes that exhibit homology in their active 
sites, where the dinucleotide NAD+ binds and is cleaved during mono- or poly- (ADP-ribosyl) 
action of protein substrates (Scott, Swisher et al. 2015). It is the best-understood enzyme among 
the three PARPs (PARP1, 2, 3) involved in BER-mediated SSB DNA repair (De Vos, Schreiber 
et al. 2012, Sousa, Matuo et al. 2012). At the sites of SSB, PARP1 binds to damaged DNA and 
undergoes a conformational change that realigns critical residues in the enzyme active site (Hassler 
and Ladurner 2012, Langelier, Planck et al. 2012, Langelier and Pascal 2013) to activate PARP1. 
After activation, PARP1 synthesizes poly-ADP-ribosylation (pADPr) chains to covalently bind to 
a variety of chromatin proteins, resulting in recruitment of additional DNA repair proteins to the 
damaged sites. In general, in the presence of PARP inhibitor, BER will be inactivated and this 
inhibition shifts the dependency on other essential DNA repair mechanisms, such as HRR, to fix 
DNA damages. 
1.3.2 Mechanisms of PARP inhibitors 
Several mechanisms were proposed to explain the synthetic lethality between BRCA mutations 
and PARP1 inhibition, and one mechanism is related to the inhibition of PARP enzymatic activity, 
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which is illustrated in Figure 1.3.2.A. In this model, unrepaired SSBs are converted to DSBs during 
DNA synthesis. DSBs are generally repaired by HRR during DNA replication. However, DSBs 
are not repaired by HRR due to HR defects caused by BRCA mutations. Unrepaired DSBs trigger 




Figure 1.3.2: Mechanisms of PARP inhibitor. A) PARP inhibitor inhibits PARP1 enzymatic activity that 
is needed for BER to repair SSBs. PARP1 inhibition is synthetic lethal with BRCA mutations because 
unrepaired SSBs produce DSBs during DNA synthesis and these DSBs are not fixed by HRR due to HR 
deficiency caused by BRCA mutations. Unresolved DSBs induce cell death. B) PARP inhibitor leads to 
PARP1 trapping preventing DNA repair machinery recruitment to the damaged DNA. C) PARP inhibitor 
inhibits the pADPr formation and leads to impaired BARD1-mediated BRCA1 recruitment. D) PARP 
inhibitor reactivates NHEJ and promotes error-prone repair leading to genomic instability and cell death.  
  
 20 
Another proposed mechanism (Figure 1.3.2.B) is that PARP1 trapping caused by PARP inhibitors 
at the damaged DNA inhibits the recruitment of BRCA1 and favors the NHEJ to promote genome 
instability (Scott, Swisher et al. 2015). PARP trapping by PARP inhibitors has gained increasing 
attention because studies show that PARP inhibitors that trap PARP proteins are more cytotoxic 
than genetic depletion of PARP (Horton, Stefanick et al. 2005, Heacock, Stefanick et al. 2010, 
Kedar, Stefanick et al. 2012, Murai, Huang et al. 2012). Moreover, the extent of SSB repair defects 
caused by PARP depletion is not as great as PARP inhibition by the inhibitors (Strom, Johansson 
et al. 2011). In the PARP trapping model, the resulting PARP-DNA complexes were considered 
to be more cytotoxic due to inhibition of recruitment of DNA repair machinery (Helleday 2011, 
Kedar, Stefanick et al. 2012). Murai et al. showed that the potency of PARP trapping is different 
among PARP inhibitors, and the one that is more potent to cause PARP trapping is more cytotoxic. 
Niraparib was shown to be more capable of PARP trapping than olaparib and veliparib, and it is 
the most cytotoxic among the three followed by olaparib and veliparib (Murai, Huang et al. 2012).  
 In addition, two other mechanisms have been proposed for PARP inhibitor (Scott, Swisher 
et al. 2015). One mechanism involves a deficiency in BRCA1 recruitment to damaged DNA 
(Figure 1.1.3.2.C). In the presence of PARP inhibitor, pADPr level decreases, leading to limited 
recruitment of pADPr-interacting protein BARD1, which is a BRCA1 binding partner, and the 
decrease in BARD1 recruitment to the damage sites results in a decrease in BRCA1 recruitment 
to the damaged DNA. In this case, the interaction between BARD1 and pADPr becomes especially 
critical for DNA repair process while BRCA1 mutations impair the BRCA1/gH2AX interaction 
(Paull, Rogakou et al. 2000, Krum, la Rosa Dalugdugan et al. 2010), since both processes are 
needed for BRCA1 recruitment to the damaged DNA (Paull, Rogakou et al. 2000, Krum, la Rosa 
Dalugdugan et al. 2010, Li and Yu 2013). This potential mechanism can explain why cancer cells 
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haboring certain BRCA1 mutations are hypersensitive to PARP1 inhibition. On the other hand, 
another mechanism suggests that the activation of NHEJ by PARP inhibitor in HR-deficient cells 
contributes to synthetic lethality between PARP inhibitor and HR defects (Patel, Sarkaria et al. 
2011) (Figure 1.3.2.D). NHEJ components Ku70 and Ku80 were shown to interact with pADPr to 
suppress NHEJ (Hochegger, Dejsuphong et al. 2006, Wang, Wu et al. 2006, Paddock, Bauman et 
al. 2011), and this interaction will be reversed by a decrease of pADPr in the presence of a PARP 
inhibitor, thus leading to activation of NHEJ.  
 
1.3.3 “BRCAness” and broader therapeutic scope for PARP inhibitors 
Emerging evidence show that PARP inhibitor sensitivity is not restricted to BRCA1/2 mutated 
cells. The term “BRCAness” was introduced to describe a phenomenon observed in some non-
BRCA mutated sporadic cancers that display the clinical properties similar to hereditary BRCA-
mutated cancers (Lord and Ashworth 2016). These cancers display HRR defects even in the 
absence of a germline BRCA1 or BRCA2 mutation. Several mechanisms have been identified to 
contribute to this BRCA-like phenotype, including genetic or epigenetic alterations in individual 
genes in HRR pathway and the Fanconi anemia pathway (Turner, Tutt et al. 2004). In high-grade 
serous ovarian cancer, around 50% of cases display HR deficiency (Cancer Genome Atlas 
Research 2011), and both germline and somatic BRCA1/2 mutations only account for around 22% 
of ovarian cancers, indicating that there are other factors affecting HR function besides BRCA1/2 
mutations. The depletion of HR repair components other than BRCA1/2 (i.e., the MRN complex, 
PALB2, RAD51,  RAD54, NBS1, ATR, ATM,  CHK1/2, FANCD2, FANCA and FANCC) shows 
synthetic lethality with PARP inhibition (McCabe, Turner et al. 2006, Dedes, Wilkerson et al. 
2011, Lupo and Trusolino 2014). In addition, the amplification of EMSY gene, which encodes a 
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BRCA2-interacting protein that suppresses BRCA2 transcription, also leads to “BRCAness” 
(Hughes-Davies, Huntsman et al. 2003). Finally, alterations in other non-HR genes were also 
shown to confer PARP inhibitor sensitivity, such as transmembrane protease serine 2 (TMPRSS2)-
ERG translocation in prostate cancer (Brenner, Ateeq et al. 2011) and EWS-FL11 or EWS-ERG 
(Brenner, Feng et al. 2012) translocations in Ewing sarcoma. These findings suggest that 
“BRCAness” resulted from direct or indirect alterations of HR components and other non-HR 
components, leads to sensitivity to PARP inhibitor and PARP inhibitor have a broader therapeutic 
scope beyond BRCA dysfunction.  
1.3.4 PARP inhibitors in the clinic 
The landmark pre-clinical studies have led to the rapid clinical development of PARP inhibitors 
as targeted therapy for BRCA-mutated cancers (Audeh, Carmichael et al. 2010, Fong, Yap et al. 
2010, Tutt, Robson et al. 2010). Olaparib was one of the first PARP inhibitors that have been tested 
in clinical trials as a single agent in heavily pre-treated breast cancers and advanced ovarian 
cancers with the BRCA1 or BRCA2 mutations (Fong, Boss et al. 2009, Audeh, Carmichael et al. 
2010, Tutt, Robson et al. 2010, Ledermann, Harter et al. 2012, Ledermann, Harter et al. 2014). It 
showed an overall response rate of around 41% and 33% in the breast and ovarian cancers 
respectively with a very tolerable side effect profile (Audeh, Carmichael et al. 2010, Fong, Yap et 
al. 2010, Tutt, Robson et al. 2010). The common side effects that occur in greater than 30% of 
patients taking olaparib are nausea, vomiting, diarrhea, abdominal pain, decreased hemoglobin, 
fatigue, decreased white blood cell count, anemia and increased serum creatinine (Fong, Boss et 
al. 2009). Olaparib has shown the most encouraging efficacy in platinum-sensitive high-grade 
serous ovarian cancer (Scott, Swisher et al. 2015), and in December 2014, United States Food and 
Drug Administration (FDA) approved it as a monotherapy to treat patients with advanced stage 
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ovarian cancer, who have germline BRCA1/2 mutations and have been through three or more 
rounds of chemotherapies. 
 At present, two additional PARP inhibitors, rucaparib and niraparib, have been approved by 
FDA for ovarian cancer. In December 2016, rucaparib was granted accelerated approval for 
treatment of advanced ovarian cancer patients with deleterious BRCA mutation (germline and/or 
somatic), who have been treated with two or more lines of chemotherapies. This approval was 
based on data from two multicenter, single-arm, open-label clinical trials (Kristeleit, Shapira-
Frommer et al. 2016, Oza, Tinker et al. 2017), in which efficacy of rucaparib was evaluated in 106 
patients with advanced ovarian cancer, who had cancer progression after treatment with two or 
more rounds of chemotherapies. The clinical trials showed an investigator-assessed objective 
response rate (ORR) of 54% (57/106). The median duration of response (DoR) for the responders 
was 9.2 months. Most interestingly, the investigator-assessed ORR in platinum-sensitive patients 
was 66%, compared to only 25% in platinum-resistant and 0% in refractory patients, suggesting a 
preferential response in platinum-sensitive cohort.  
 Niraparib was approved by FDA in March 2017 to be used as a maintenance therapy for 
adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who 
are in complete or partial response to platinum-based chemotherapy. The approval was based on 
results from a randomized trial (NOVA) of 553 patients (Mirza, Monk et al. 2016), who were 
divided into the germline BRCA-mutated (gBRCAmut) and non-gBRCAmut cohorts. Overall, 
patients with niraparib had a significantly longer median progression-free survival (PFS) than 
those with placebo. Not surprisingly, the gBRCAmut cohort showed the biggest difference, with 
21 months (niraparib) vs. 5.5 months (placebo). In addition, the preferential benefit was also seen 
with patients having tumors that showed HRD in the non- gBRCAmut cohort. In non-gBRCAmut 
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patients, the estimated PFS for patients taking niraparib was 9.3 months while only 3.9 months for 
those taking placebo.  
 Not only in ovarian cancer, PARP inhibitor also showed clinical activity in breast cancer. In 
Jan 2018, FDA extended the approved use of olaparib to treat patients with metastasized breast 
cancer and with a gBRCAmut. This is the first PARP inhibitor that has been approved to treat 
cancer other than ovarian cancer.  Presently, PARP inhibitors are actively tested in various clinical 
trials as mono- or combinational-therapy in different types of cancer, including advanced 
hematological malignancies, triple-negative breast cancer, NSCLC, prostate cancer, colorectal 
cancer and metastatic melanoma (Scott, Swisher et al. 2015). 
1.3.5 PARP inhibitor resistance 
Although PARP inhibitors have shown considerable promises, drug resistance is inevitable and it 
will become a substantial clinical issue in the near future (Lord and Ashworth 2013). Like many 
other cancer drugs, development of resistance is expected to be a major contributor to treatment 
failure with PARP inhibitors. PARP inhibitor resistance can be intrinsic, with no response from 
the very beginning of treatment, or acquired, which develops after the initial response. Several 
mechanisms have been identified for PARP inhibitor resistance, some of which have also been 
validated in clinic (Lord and Ashworth 2013, Bouwman and Jonkers 2014). Overall, these 
mechanisms can be characterized into two main categories: (1) restoration of normal HR function, 
such as BRCA revertant mutation, 53BP1 loss and EMSY downregulation; (2) other non-HR related 
mechanisms, such as upregulation of efflux transporters, ribosomal protein S6, NF-kB signaling, 
and CCNE1 amplification.  
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(I) Restoration of HR proficiency confers PARP inhibitor resistance 
As PARP inhibitor sensitivity is largely dependent on HR defects, it is not surprising that 
restoration of HR function is the most common mechanism of PARP inhibitor resistance. HR 
function restoration in tumor cells can be achieved by different mechanisms, including direct 
changes in the HR components, such as secondary mutations of BRCA genes (McCabe, Turner et 
al. 2006, Sakai, Swisher et al. 2008), and alterations of other non-HR components, such as loss of 
53BP1 and lack of EMSY amplification. 
Resistance through secondary mutations of BRCA genes 
Reversion mutations of BRCA1 or BRCA2 that resume the open reading frames (ORFs) to produce 
functional BRCA proteins is the most frequently observed mechanism to restore HR functionality 
in PARP inhibitor resistant tumors. The initial experimental evidence was provided by two 
independent studies (Edwards, Brough et al. 2008, Sakai, Swisher et al. 2008), showing that 
secondary mutations in mutated BRCA2 restored its ORF to produce functional BRCA2 and 
regained HR function, leading to drug resistance. Later on, this preclinical mechanism was 
validated in tumor samples from a patient who did not respond to chemotherapy (Norquist, Wurz 
et al. 2011). Even though direct evidence of BRCA1 reversion mutation leads to PARP inhibitor 
resistance is lacking, restored ORF of BRCA1 is reported in the acquired resistance to cisplatin in 
BRCA1-mutated tumor samples (Norquist, Wurz et al. 2011). This reversion mutation mechanism 
may also be applicable to the acquired resistance to PARP inhibitor according to the BRCA/PARP 
functional dependency as suggested by B. Lupo, et al. (Ashworth 2008, Lupo and Trusolino 2014).  
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Resistance through loss of 53BP1 
The restoration of a balance between HR and NHEJ activity is another mechanism that confers 
PARP inhibitor resistance. Loss of 53BP1, Tp53-binding protein 1, belongs to this category.  
PARP inhibitor cytotoxicity in HR-deficient cells is partly contributed by stimulation of the error-
prone NHEJ that enhances genome instability (Patel, Sarkaria et al. 2011). These results suggest 
that the NHEJ-dominant repair underlies PARP inhibitor sensitivity. Several studies have shown 
that 53BP1 loss can restore the balance between HR and NHEJ activities and confer PARP 
inhibitor resistance in BRCA1-mutated cancer cells (Cao, Xu et al. 2009, Bouwman, Aly et al. 
2010, Bunting, Callen et al. 2012, Jaspers, Kersbergen et al. 2013). 53BP1 deficiency promotes 
the processing of DSB DNA ends to produce single-stranded DNA, which reestablishes the use of 
HR pathway to repair DSBs (Lord and Ashworth 2013).  
Resistance through stabilization of mutant BRCA1 
Some mutations in BRCA1 produce less stable, misfolded and partially functional BRCA1 
proteins, thereby causing the loss-of-function effect. In tumor cells with these mutants, increasing 
the stability of mutant BRCA1 could restore HR function and lead to PARP inhibitor resistance. 
For example, HSP90 (heat shock protein 90) is a chaperone protein that assists in the folding of 
nascent proteins and unfolded proteins upon heat stress. HSP90 also assists in the folding of 
misfolded proteins caused by mutations and provides a phenotypic stability (Rutherford and 
Lindquist 1998, Queitsch, Sangster et al. 2002). It also stabilizes a number of proteins required for 
tumor growth (Richter and Buchner 2001), including mutant BRCA1. Johnson et al. showed that 
HSP90 contributes to PARP inhibitor (Rucaparib) resistance by stabilization of mutant BRCA1, 
which has a mutation in the BRCT domain affecting protein folding but retains a residual activity. 
Through HSP90-mediated stabilization, cells with this BRCA1 mutation regained HR function, 
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which can be reversed using HSP90 inhibitors, indicating the direct involvement of HSP90 in 
conferring PARP inhibitor resistance (Johnson, Johnson et al. 2013). 
Other possible mechanisms to restore HR function 
Besides the mechanisms discussed above, additional mechanisms may regulate HR and contribute 
to PARP inhibitor resistance. One mechanism is through the regulation of EMSY gene expression. 
Hughes-Davies et al. showed that EMSY gene encodes a BRCA2-associated protein (EMSY), 
which is frequently amplified in sporadic breast and ovarian cancers (Hughes-Davies, Huntsman 
et al. 2003). It is also considered as a key oncogene within the 11q13 amplicon in ovarian cancer 
(Brown, Irving et al. 2006). Increased level of EMSY was suggested to repress BRCA2 
transactivation and induce chromosomal instability, mimicking the effect of BRCA2 mutation in 
the development of hereditary breast/ovarian cancer through disrupting BRCA2/RAD51 pathway 
in the DNA-damage response (Cousineau and Belmaaza 2011). Therefore, downregulation of 
EMSY would reverse the effects described above and serve as a possible mechanism for PARP 
inhibitor resistance. 
(II) Non-HR related mechanisms 
Increase expression of drug efflux transporters 
PARP inhibitor response can be affected by ATP-binding cassette (ABC) transporters, which are 
transmembrane proteins that carry substrates, including many drugs, across cell membranes (Lord 
and Ashworth 2013). ABC transporters have been implicated in multidrug resistance (Bellamy 
1996). One example is P-glycoprotein efflux pump (also known as PgP, MDR1, and ABCB1), 
overexpression of which has been reported to reduce the efficacy of numerous drugs by increasing 
their efflux from the cells (Shen, Fojo et al. 1986, Fojo, Ueda et al. 1987, Parekh, Wiesen et al. 
 28 
1997, Choi and Yu 2014, Cooley, Fang et al. 2015). This is also a recognized molecular mechanism 
for treatment failure in cancer patients. Several studies have shown that PgP expression in cancer 
cells contributes to chemotherapy and PARP inhibitor resistance, which can be reversed by PgP 
inhibitors (Wurzer, Herceg et al. 2000, Dumitriu, Voll et al. 2004, Rottenberg, Jaspers et al. 2008, 
Lawlor, Martin et al. 2014). It is suggested by Lupo et al. (Lupo and Trusolino 2014) that inhibition 
of PARP would enhance efflux pump expression by various mechanisms. In addition, Patch et al. 
identified a new mechanism involving promoter sequence rearrangement between SLC25A40 and 
ABCB1 (Patch, Christie et al. 2015), which results in the high expression of ABCB1. This promoter 
rearrangement was found in tumor samples from patients with chemotherapy-resistant high-grade 
serous ovarian cancer. Olaparib was suggested to be a substrate of MDR1 (Rottenberg, Jaspers et 
al. 2008, Lawlor, Martin et al. 2014, Vaidyanathan, Sawers et al. 2016) and direct evidence is 
needed to support that MDR1 upregulation also contributes to resistance to other PARP inhibitors. 
In this regard, development of PARP inhibitors that are not substrates for MDR1 might decrease 
the possibility of PARPi resistance caused by MDR1 upregulation.  
Decreased PARP expression and activity 
A well-recognized mechanism of antibiotics resistance in bacteria is loss of their cellular targets 
(Dever and Dermody 1991). Likewise, this can be a potential mechanism for PARP inhibitor 
resistance. A study showed that cells with loss-of-function PARP1 mutants are 100-fold more 
resistant to olaparib than wild-type cells (Murai, Huang et al. 2012), and cells with low levels of 
PARP1 are less responsiveness to PARP inhibitors (Farmer, McCabe et al. 2005). In addition, 
human cancer cells that have acquired resistance to PARP inhibitor, veliparib, have lower 
expression of PARP1 (Liu, Han et al. 2009). These findings support the idea that loss of PARP1 
is one of the mechanism contributes to PARP inhibitor resistance.  
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Increased phosphorylation of ribosomal protein S6 
Studies conducted by Sun and colleagues (Sun, Zhang et al. 2014) suggest that activation of 
BRCA1-PI3K/Akt/mTOR axis contributes to acquired resistance to PARP inhibition, which might 
result from the enhanced DNA repair through the phosphorylation of ribosomal protein S6 
(Khalaileh, Dreazen et al. 2013). They showed that prolonged PARP inhibitor exposure leads to 
an increase in phosphorylation of ribosomal protein S6 in BRCA1-deficient cells but not in 
BRCA1-proficient cells, which is further validated by the observation that BRCA1-deficient cells 
with a mutation that impairs phosphorylation of ribosomal protein S6 did not develop PARP 
inhibitor resistance even after long-term exposure (Sun, Zhang et al. 2014). These findings suggest 
that the increased phosphorylation of ribosomal protein S6 represents a component of a signaling 
pathway that potentially contributes to PARP inhibitor resistance. 
Up-regulation of NF-kB signaling pathway 
NF-kB is a transcription factor and is often up-regulated in many types of cancers, leading to 
activation of cancer cell proliferation and migration as well as a decrease in apoptosis (Karin 2006). 
By comparing the gene expression between parental and PARP inhibitor-resistant UWB1.289 
cells, Nakagawa et al. showed that upregulation of NF-kB signaling is involved in PARP inhibitor 
resistance. Pharmacologically inhibition of NF-kB pathway and downregulation of its key 
components re-sensitize resistant cells to PARP inhibitors (Nakagawa, Sedukhina et al. 2015), 
suggesting that NF-kB pathway plays a role in PARP inhibitor resistance.  
Amplification of CCNE1 gene 
Besides the mechanisms mentioned above, new mechanisms of chemotherapy resistance are 
unveiled using next-generation sequencing analysis of tumor samples from patients. Patch et al. 
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conducted a whole-genome sequencing of tumors and germline DNA samples from 92 patients 
with refractory disease, primary resistance to chemotherapy, or matched pairs of sensitive and 
acquired resistant high-grade serous ovarian cancers (Patch, Christie et al. 2015). They found that 
CCNE1 gain/amplification was a common event in both primary resistant and refractory diseases 
(19% cases), and according to their clinical association analysis, the amplification of chromosome 
region involving CCNE1 was also the dominant structural variant associated with primary 
treatment failure. Interestingly, CCNE1 gain/amplification and BRCA1/2 pathway disruption are 
mutually exclusive. Genome-wide shRNA synthetic lethal screen indicates that BRCA1 is 
selectively required in cancers that harbor CCNE1 amplification (Etemadmoghadam, Weir et al. 
2013), confirming the mutual exclusivity of CCNE1 amplification and BRCA1/2 loss in high grade 
serous ovarian cancer. In cancer cells with CCNE1 amplification where BRCA or HR function is 
selectively retained, these cells are expected to be resistant to PARP inhibitors because BRCA or 
HR deficiency is a requirement for PARP inhibitor sensitivity in cancer cells (Bryant, Schultz et 
al. 2005, Farmer, McCabe et al. 2005).  
1.3.6 Enhancing therapeutic effects of PARP inhibitor 
In order to achieve a durable response to PARP inhibitor and expand the clinical indication of 
PARP inhibitors to benefit more cancer patients, it is urgent to find ways to overcome resistance 
and enhance their therapeutic effects. Combination therapies are effective strategies to decrease 
resistance and achieve better therapeutic effects of chemotherapies (Baselga, Cortes et al. 2012, 
Yap, Omlin et al. 2013, Quinn, Dash et al. 2015, Bayat Mokhtari, Homayouni et al. 2017). 
Similarly, combination therapies can be used to enhance PARP inhibitor therapeutic effects. 
Because PARP inhibition impairs the cells' ability to respond to DNA damage, many groups have 
tested PARP inhibitors in combination with standard cytotoxic chemotherapy agents to enhance 
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the cell killing (Rodon, Iniesta et al. 2009), such as in combination with platinum in ovarian cancer 
and breast cancer (Burgess and Puhalla 2014), and in combination with temozolomide in breast 
cancer, glioblastoma, melanoma and acute leukemia (Palma, Wang et al. 2009, Barazzuol, Jena et 
al. 2013, Murai, Zhang et al. 2014). PARP inhibitor was also used together with signal transduction 
inhibitors, for example, gefitinib, in EGFR-mutated non-small-cell lung cancer (Burgess and 
Puhalla 2014, O'Sullivan, Moon et al. 2014). However, the optimal combination of PARP inhibitor 
and other chemotherapy drugs remains to be established. The optimal dose, sequence, and 
treatment frequency of PARP inhibitor and chemotherapeutic drugs need to be determined to 
maximize efficacy while minimizing toxicity (Yap, Sandhu et al. 2011). For example, in Phase I 
and Phase II studies, olaparib in combination with carboplatin (Lee, Hays et al. 2014) or cediranib 
(Liu, Barry et al. 2014) has shown efficacy against ovarian cancer. However, hematologic toxicity 
prevented continuous dosing of olaparib when combined with typical carboplatin doses (Lee, Hays 
et al. 2014). 
 The mechanisms underlying the potential synergies of drug combinations can be attributed 
to the following: First, in cells with functional HR or Fanconi anemia (FA) pathway, the other 
agent suppresses the expression of HR repair genes and induce HRD, resulting in PARP inhibitor 
hypersensitivity. Various studies have shown that HRD can be induced by a variety of agents. For 
example, phosphatidylinositol 3-kinase (PI3K) inhibitors downregulate RAD51 or BRCA1/2 in 
breast cancer (Ibrahim, Garcia-Garcia et al. 2012, Juvekar, Burga et al. 2012), epidermal growth 
factor receptor (EGFR) inhibitors promote BRCA1 trafficking from the nucleus to the cytoplasm 
in triple-negative breast cancer (Nowsheen, Cooper et al. 2012), and ATR inhibitors diminish 
replication stress-induced activation of cell-cycle checkpoints and repair in ovarian cancer cells 
(Huntoon, Flatten et al. 2013). Second, these agents could interfere with other roles of PARP1 
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(Scott, Swisher et al. 2015). Besides its role in BER, PARP1 also participates in HR and NHEJ, 
and activation of NHEJ pathway after PARP inhibition is one of the potential mechanism 
contributing to cytotoxic effects of PARP inhibitor in cancer cells (Patel, Sarkaria et al. 2011). 
Accordingly, loss of 53BP1 suppresses NHEJ and restore the balance between HR and NHEJ 
repair, leading to PARP inhibitor resistance (Bunting, Callen et al. 2010). These studies suggest 
that strategies to activate NHEJ and inhibit HR at the same time may serve as an option to enhance 
PARP inhibitor sensitivity (Scott, Swisher et al. 2015).  
 Meanwhile, a better understanding of the PARP inhibitor resistance mechanisms would 
provide us additional options to develop more effective combinational therapies to overcome the 
resistance. The genome-wide, loss-of-function screen is an important tool to identify novel HR 
modifiers and to expand the growing list of potential therapeutic targets that control HR. These 
HR modifiers could serve as novel targets to enhance PARPi sensitivity. Genome-wide siRNA 
screen is the approach that has been used by several groups to find new modifers of DNA repair 
pathways (Lord, McDonald et al. 2008, Slabicki, Theis et al. 2010, Adamson, Smogorzewska et 
al. 2012). These studies identified candidate modifiers of PARP inhibitor sensitivity, and these 
genes are involved in DNA response and repair pathways as well as DNA replication (Lord, 
McDonald et al. 2008, Bajrami, Frankum et al. 2014). In addition, components of proteasome or 
RNA biology were identified as novel HR modifiers (Krajewska, Fehrmann et al. 2015).  These 
screens have greatly enhanced our understanding of human DNA repair processes and led to the 
discovery of a number of novel genes implicated in various aspects of DNA repair. In chapter 4, 
we used a genome-scale CRISPR/Cas9 knockout pooled library (GeCKO library) to conduct a 
genetic screen in ovarian cancer cells. This library contains 122,417 unique guide RNA sequences 
targeting 19,052 human genes, and has been shown to be appropriate for the loss-of-function 
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selection studies (Sanjana, Shalem et al. 2014, Shalem, Sanjana et al. 2014). We used PARP 
inhibitor sensitivity as a readout and identified candidates that were direct indicators of drug 
response. The identification of additional HR modifiers and PARPi sensitizers could provide new 
therapeutic targets to expand the clinical utility of PARP inhibitors.  
 In this regard, my dissertation focuses on the following two major objectives: (1) to identify 
experimental therapeutics that enhance the effect of PARP inhibitors (Chapter 2 & 3); and (2) to 
identify novel therapeutic targets that modify the HR pathway or the response to PARP inhibitor 
(Chapter 4). For the first objective, I focused on two different strategies that target the FOXM1 
pathway (Chapter 2) or the FOXM1-MYC nexus (Chapter 3) to enhance the effects of PARP 
inhibitor. For the second objective, I focused on TIGAR as a novel therapeutic target to enhance 
sensitivity to PARP inhibitor. 
1.4 Forkhead box protein M1 (FOXM1) and c-MYC in EOC 
Forkhead box protein M1 (FOXM1) is a protein encoded by the FOXM1 gene. It is also known as 
HNF-3, HFH-11, Trident, and MPP2. The human FOXM1 gene has 10 exons (Lam, Brosens et al. 
2013). Alternative splicing of exons Va and VIIa leads to 3 common isoforms of FOXM1: namely, 
FOXM1a, FOXM1b, and FOXM1c (Figure 1.4.1). FOXM1a does not have transactivation activity 
due to the presence of both Va and VIIa exons, which disrupt the transactivation domain. FOXM1b 
does not have either exon Va or VIIa. FOXM1c contains only exon Va. These two isoforms are 
active transcription factors. FOXM1b has been shown to be the predominantly overexpressed 
isoform in cancer cells, and functionally more active than FOXM1c (Lam, Ngan et al. 2013). 
However, studies from our lab (data not shown) and other groups have shown that FOXM1c is the 
most abundantly expressed isoform in ovarian cancer (Tassi, Todeschini et al. 2017).  
 34 
 FOXM1 is a member of FOX family of transcription factors (Lam, Brosens et al. 2013), 
which play important roles in regulating the expression of genes involved in cell growth, 
proliferation and differentiation (Hannenhalli and Kaestner 2009). FOXM1 is highly expressed in 
S and G2/M phases (Wierstra and Alves 2007) and has been shown to play crucial roles in G1-S 
and G2-M cell cycle progression and mitotic spindle integrity by regulating expression of many 




Figure 1.4.1: Alternative splicing of the human FOXM1 gene produces three different isoforms, 
namely FOXM1a, b, and c. NRD, N-terminal Repressor Domain; FKH, Forkhead winged helix DNA 
Binding Domain; TAD, Transactivation Domain.   
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 FOXM1 has been implicated in adult tissue homeostasis, embryonic development, and most 
importantly cancer initiation and progression (Bella, Zona et al. 2014). It is now recognized as a 
proto-oncogene, and its expression is frequently upregulated in many types of cancer, including 
liver, prostate, lung, breast, and ovary (Kalinina, Kalinin et al. 2003, Kalin, Wang et al. 2006, Kim, 
Ackerson et al. 2006, Madureira, Varshochi et al. 2006, Zhang, Cheng et al. 2014). The exact 
mechanisms of how FOXM1 promotes oncogenesis is still unknown. The fact that FOXM1 
overexpression is frequently found at early stages of cancer development suggests FOXM1 plays 
a key role in cancer initiation (Koo, Muir et al. 2012). It is also shown to facilitate angiogenesis, 
invasion, and metastasis (Wang, Banerjee et al. 2007), suggesting a potential role in cancer 
progression. In particular, the FOXM1 expression is essential for countering the oxidative stress 
induced by the oncogenic HRas mutant (Park, Carr et al. 2009). FOXM1 upregulates the 
expression of anti-oxidant genes that counteract reactive oxygen species induced by the HRas 
mutant and prevents cellular senescence. Emerging evidence also indicates that FOXM1 
overexpression leads to resistance to the genotoxic therapeutic agent (Wang, Wen et al. 2013, 
Zhang, Cheng et al. 2014, Tassi, Todeschini et al. 2017), and this effect is attributed to enhanced 
DNA damage response and DNA repair by FOXM1. FOXM1 transcriptionally regulates the 
expression of genes involved in DNA damage response and DNA repair, especially HR repair 
(Tan, Raychaudhuri et al. 2007, Kwok, Peck et al. 2010, Millour, de Olano et al. 2011, Zhang, Wu 
et al. 2012, Monteiro, Khongkow et al. 2013).  
 Evaluation of The Cancer Genome Atlas (TCGA) data indicate that FOXM1 transcriptional 
network is upregulated in over 84% of high-grade serous ovarian cancer tumors, and the FOXM1 
pathway positively regulates HR pathway by the direct regulation of BRCA2 (Cancer Genome 
Atlas Research 2011). FOXM1 is an attractive target in cancer because of its overexpression in 
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cancer and its role on the regulation of the HR pathway. However, the effect of FOXM1 inhibition 
on HR pathway and the role of FOXM1 in PARPi response in cancer cells have not been well 
characterized.  
 Thiostrepton is a natural, cyclic oligopeptide antibiotic, which is derived from 
streptomycetes. Previous studies showed that thiostrepton inhibits FOXM1 transcription factor 
activity and consequently downregulates FOXM1 expression (Kwok, Myatt et al. 2008, Halasi, 
Schraufnagel et al. 2009, Hegde, Sanders et al. 2011). Previous studies also showed that 
thiostrepton enhances the cytotoxicity effect of cisplatin and carboplatin (Zhang, Cheng et al. 
2014). However, the combination of thiostrepton and PARP inhibitor was not tested prior to my 
study, and the findings from my study described in Chapter 2 indicate thiostrepton enhances 
sensitivity to PARP inhibitor.  
 c-MYC is a bona fide oncogenic transcription factor encoded by MYC proto-oncogene (Dang 
2012). It plays important roles in the regulation of cell cycle progression, apoptosis, and most 
importantly in the cellular transformation to promote genesis of many human cancers (Adams, 
Harris et al. 1985, Leder, Pattengale et al. 1986, Nilsson and Cleveland 2003, Gabay, Li et al. 
2014). As a transcription factor, it activates the expression of many genes by binding to the 
enhancer box sequence and recruiting histone acetyltransferases (HATs) (Dang, Resar et al. 1999). 
It can also serve as a repressor through binding with the Miz-1 transcription factor to displace p300 
co-activator and inhibit expression of Miz-1 target genes (Schneider, Peukert et al. 1997). It is also 
reported to have other non-transcriptional function, such as in DNA replication (Dominguez-Sola, 
Ying et al. 2007) and cap-dependent translation (Cole and Cowling 2008). MYC gene amplification 
occurs in different types of cancer, such as uterine, colorectal, breast, pancreatic, and gastric 
cancers (Chen, McGee et al. 2014). Importantly, MYC gene was found to be amplified in a 
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significant number of tumor samples from patients with EOC (Ross, Ali et al. 2013). In some 
cancers, c-MYC expression is highly dependent on BRD4 (Shi and Vakoc 2014), which is a 
member of bromodomain and extra-terminal motif (BET) family of proteins. Recent studies have 
shown that c-MYC expression can be successfully blocked by BET inhibitors in cancer cells 
(Dawson, Prinjha et al. 2011, Delmore, Issa et al. 2011, Mertz, Conery et al. 2011, Zuber, Shi et 
al. 2011). BET inhibitors are a class of drug that is designed to reversibly bind the bromodomains 
of BET proteins (BRD2, BRD3, BRD4, and BRDT) to prevent their interactions with acetylated 
histones and transcription factors (Nicodeme, Jeffrey et al. 2010, Dawson, Prinjha et al. 2011) to 
decrease gene transcription. BET proteins, especially BRD4, have been shown to drive 
pathogenesis in various types of cancers, and BET inhibitors have been tested in cancers. In 
addition, BET inhibitors are also effective in overcoming resistance to other targeted therapies 
when used in combination therapies (Knoechel, Roderick et al. 2014, Korkut, Wang et al. 2015). 
Interestingly, BET inhibitors also downregulate FOXM1 expression (Zhang, Ma et al. 2016). 
However, the relationship between FOXM1 and c-MYC has not been very well characterized, and 
the potential role of targeting FOXM1-MYC nexus to suppress the expression of DNA repair genes 
has not been studied. To fill this gap, in Chapter 3, I will describe my studies on the role of FOXM1 
and c-MYC in the expression of HR repair genes and to explore the potential of using BET 
inhibitors to enhance the effect of PARP inhibitors in ovarian cancer. 
  
 39 
1.5 Specific Aims of the dissertation 
The ultimate goals of these thesis studies were to achieve a better understanding of the underlying 
mechanisms determining PARP inhibitor responses in ovarian cancer and to identify new 
strategies that enhance the therapeutic effects of PARP inhibitors. Results from these studies could 
ultimately advance precision cancer medicine by enabling the translation of genetic knowledge 
into clinical management of patients with ovarian or breast cancer. 
1.5.1 Specific Aim 1: To determine the effects of targeting FOXM1 pathway on PARP 
inhibitor sensitivity 
When aberrantly expressed, FOXM1 can act as an oncogenic transcription factor that has been 
shown to regulate the expression of genes involved in DNA damage response, DNA repair, and 
cell cycle progression. The FOXM1 pathway is activated in 84% of high-grade serous ovarian 
cancer (HGS-OvCa) (Cancer Genome Atlas Research, 2011). Overexpression of FOXM1 is 
correlated with chemotherapy resistance and poor outcome of patients treated with cytotoxic 
agents and targeted therapies (Park, Jung et al. 2012, Li, Qiu et al. 2013, Li, Yao et al. 2014, Zhao, 
Siu et al. 2014). Previous work from our lab has shown that FOXM1 inhibition by thiostrepton 
induces cytotoxicity and enhances the sensitivity to cisplatin and carboplatin in ovarian cancer 
(Zhang, Cheng et al. 2014). In this specific aim, I tested my hypothesis that FOXM1 pathway 
inhibition induces “BRCAness” in ovarian cancer cells and sensitizes them to PARP inhibitor. I 
investigated the extent to which FOXM1 pathway inhibition by siRNAs and FOXM1 inhibitor 
thiostrepton enhances the sensitivity to olaparib in ovarian cancer cells. Additionally, I explored 
the molecular mechanisms underlying the enhanced cytotoxic effects of olaparib in FOXM1 
pathway-disrupted ovarian cancer cells.   
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1.5.2 Specific Aim 2: To determine the effects of targeting FOXM1-MYC nexus on PARP 
inhibitor sensitivity 
Both FOXM1 and c-MYC are highly expressed in EOC (Cancer Genome Atlas Research 2011, 
Ross, Ali et al. 2013). My experimental data show that particular target genes of FOXM1 in HR 
pathway, BRCA1, BRCA2, FANCF and BRIP1, were not downregulated with FOXM1 siRNA. 
Concomitantly, I observed upregulation of c-MYC protein after the FOXM1 knockdown, 
suggesting that c-MYC upregulation may serve as a compensation to FOXM1 knockdown. The 
analysis of ENCODE (Encyclopedia of DNA Elements) data indicates that both FOXM1 and c-
MYC bind to overlapping regulatory regions in HR genes, including BRCA1 and RAD51. 
Considering that BET inhibitors downregulate both c-MYC and FOXM1 pathway, we hypothesize 
that HR genes are co-regulated by FOXM1 and c-MYC, and inhibition of both with BET inhibitor 
induces “BRCAness” leading to sensitivity to PARP inhibitor in cancer cells.  
1.5.3 Specific Aim 3: To identify novel genetic determinants of PARP inhibitor sensitivity by 
the CRISPR/Cas9 based loss-of-function genetic screen 
Based on the concept of synthetic lethality, cancer cells that have lost the ability to repair DSB by 
HR, including those with defects in BRCA1/2, are highly sensitive to PARP inhibitors (Bryant, 
Schultz et al. 2005, Farmer, McCabe et al. 2005). These results suggest that functional status of 
HR pathway is an important determinant of PARP inhibitor responses in cancer cells. However, 
the extent to which other genetic alterations in cancer can affect how cancer cells will respond to 
PARP inhibitors is not yet known. The genome-scale CRISPR-Cas9 knockout (GeCKO) library 
(containing 122,417 unique guide sequences targeting 19,052 human genes) was developed and 
has been shown to be successful in loss-of-function selection studies (Sanjana, Shalem et al. 2014, 
Shalem, Sanjana et al. 2014). We propose a working hypothesis that loss-of-function genetic 
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alterations in HR modifiers modify PARP inhibitor sensitivity and resistance in cancer cells. The 
objective of these studies is to perform a functional genetic screen to identify novel modifiers of 
PARP inhibitor response in ovarian cancer cells. 
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Chapter 2. Targeting FOXM1 pathway disrupts the adaptive response induced by olaparib 





FOXM1 transcription factor network is activated in over 84% of cases in high-grade serous ovarian 
cancer, and FOXM1 upregulates the expression of genes involved in homologous recombination 
(HR) repair pathway. However, the role of FOXM1 in poly (ADP-ribose) polymerase (PARP) 
inhibitor response has not yet been studied. In the present study, we showed that PARP inhibitor 
olaparib induced the expression and nuclear localization of FOXM1. Using ChIP-qPCR, we 
demonstrated that olaparib treatment increased the binding of FOXM1 to genes involved in HR 
repair. FOXM1 knockdown by RNAi or inhibition by thiostrepton decreased FOXM1 expression 
and the expression of HR repair genes, such as BRCA1 and RAD51. Consequently, both FOXM1 
knockdown and inhibition by thiostrepton enhanced sensitivity to olaparib. Comet assay and PARP 
trapping assay showed increased DNA damage and PARP trapping in FOXM1 inhibited cells 
treated with olaparib. Finally, thiostrepton decreased the expression of BRCA1 in rucaparib-
resistant cells and enhanced sensitivity to rucaparib. Collectively, these results suggest that 
FOXM1 plays an important role in the adaptive response induced by olaparib and FOXM1 
inhibition by thiostrepton induces “BRCAness” and enhances sensitivity to PARP inhibitors. In 
conclusion, FOXM1 inhibition represents an effective strategy to overcome resistance to PARP 
inhibitors, and thus targeting FOXM1-mediated adaptive pathway may produce better therapeutic 
effects for this class of inhibitors.  
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2.2 Introduction 
The primary cause of cancer-related mortality is the treatment failure resulting from intrinsic or 
acquired resistance to chemotherapy (Giaccone and Pinedo 1996, Yardley 2013, Hammond, 
Swaika et al. 2016). In epithelial ovarian cancer, although most patients initially respond to 
chemotherapy, they experience recurrences and the acquired resistance to chemotherapy (Pfisterer 
and Ledermann 2006). Consequently, epithelial ovarian cancer is the most lethal gynecologic 
malignancies in the United States (Siegel, Miller et al. 2015). Although overall survival from 
ovarian cancer has improved slowly over the past three decades (Bast, Hennessy et al. 2009), recent 
advances in PARP inhibitors as maintenance therapies are having positive impacts on the overall 
survival of patients with ovarian cancer (Bowtell, Bohm et al. 2015). Nonetheless, acquired 
resistance to PARP inhibitors are being reported (Fojo and Bates 2013, Johnson, Johnson et al. 
2013), and it is important to understand molecular mechanisms that contribute to acquired 
resistance to chemotherapeutic agents. 
 Intrinsic and acquired resistance to chemotherapeutic agents can be explained by the 
Darwinian selection of fitness-conferring genetic traits under drug treatment (Gerlinger and 
Swanton 2010). Under this principle, cells with pre-existing mutations that confer fitness under 
drug treatment are selected, thereby contributing to the development of resistance to treatment. 
Consistent with this principle, low-level revertant mutations in BRCA1 and BRCA2 are found in 
ovarian carcinoma samples prior to platinum-based chemotherapy, and these rare mutations 
become enriched in carcinoma samples from the corresponding patients during relapse (Patch, 
Christie et al. 2015), suggesting the selection of pre-existing fitness-conferring somatic mutations 
by chemotherapy. Although this principle explains intrinsic resistance, it cannot fully explain the 
acquired resistance.  
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 With respect to the acquired resistance in ovarian cancer, a subset of patients generally 
respond to platinum-based chemotherapy even after relapse from prior platinum-based 
chemotherapy (Pfisterer and Ledermann 2006). Recent evidence suggests adaptive cellular 
response may provide a transitional state that allows cells to acquire fitness-conferring genetic 
mutations after several rounds of treatment with chemotherapeutic agents (Goldman, Majumder et 
al. 2015). A non-genetic Lamarckian mechanism of drug-induced adaptive response has been 
proposed as a possible mechanism for the acquisition of resistance (Pisco, Brock et al. 2013). The 
‘transient adaptive resistance’ allows cells to be in ‘chemotherapy-tolerant state’, thereby produces 
‘persisters’ (Dawson, Intapa et al. 2011, Goldman, Majumder et al. 2015). Extracellular matrix 
and tumor microenvironment have been shown to provide such transient adaptive resistance to 
cancer cells (Chien, Kuang et al. 2013). These ‘persisters’ subsequently acquire fitness-conferring 
genetic and epigenetic alterations that promote resistance to chemotherapy (Sharma, Lee et al. 
2010). Consistent with this concept, recent studies indicate that in vitro selection with the PARP 
inhibitor rucaparib in MDA-MB-436 breast cancer cells resulted in resistant clones that 
overexpressed mutant BRCA1 at higher levels than in drug-sensitive parental MDA-MB-436 
(Johnson, Johnson et al. 2013). In this model, epigenetic rather than genetic alterations contribute 
to the acquired resistance to rucaparib. In the population of cells without preexisting genetic 
alterations that confer fitness under drug treatment, the adaptive cellular response may represent a 
critical step prior to the acquisition of acquired resistance. Therefore, adaptive cellular responses 
may be targeted to overcome acquired resistance to chemotherapeutic agents. 
 A critical step in the development of effective combination therapies to extend the efficacy 
of existing chemotherapeutic agents is to understand the molecular mechanisms regulating the 
adaptive cellular responses to existing chemotherapeutic agents. According to the landmark study 
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by TCGA scientists, the FOXM1 pathway is activated in approximately 84% of high-grade serous 
ovarian carcinomas (Cancer Genome Atlas Research 2011). FOXM1 regulates the expression of 
DNA repair genes (Tassi, Todeschini et al. 2017) as well as genes involved in adaptive response 
to cellular stress induced by oxidative stress and oncogenic stress (Park, Carr et al. 2009). 
However, the extent to which FOXM1 pathway contributes to the adaptive cellular response to 
chemotherapy and represents an important epigenetic molecular mechanism regulating the 
adaptive cellular response to chemotherapy is not yet characterized. 
 In this study, the FOXM1 pathway was identified as a component of the adaptive cellular 
response to PARP inhibitor olaparib. We found that olaparib induced FOXM1 expression which 
regulates several genes involved in homology recombination repair pathway. RNAi or FOXM1 
inhibitor thiostrepton decreased FOXM1 expression and attenuated the adaptive cellular response 
leading to enhanced sensitivity to olaparib. Finally, our results showed that FOXM1 inhibitor 
thiostrepton decreases the expression of BRCA1 and BRCA2, produces “BRCAness”, and enhances 
sensitivity to olaparib. Our results support an emerging paradigm that adaptive cellular responses 
may be targeted to prevent acquired resistance to chemotherapeutic agents and indicate that 
FOXM1 pathway may be targeted to prevent acquired resistance to PARP inhibitors. 
2.3 Materials and Methods 
Cell lines and cell culture 
ES-2, OVCAR3 and A2780 cells were maintained in MCDB105 and M199 (1:1) (Sigma, USA) 
containing 5% FBS (Sigma), OV90 cells were maintained in MCDB105 and M199 (1:1) with 15% 
FBS. OVCA420* cells were cultured in DMEM (Sigma and Caisson Labs, USA) supplemented 
with 10% FBS. ONCO-DG1 cells were grown in RPMI1640 (Sigma and Caisson Labs) with 10% 
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FBS. MDA-MB-436 and its derivative rucaparib resistant cells RR-1, RR-2, RR-3 were kind gifts 
from Dr. Neil Johnson laboratory at Fox Chase Cancer Center (Johnson, Johnson et al. 2013) and 
were maintained in RPMI1640 (Sigma and Caisson Labs) supplemented with 10% FBS. All the 
media were supplemented with 100 units/mL penicillin and 100 µg/mL streptomycin. ES-2, 
OVCAR3, OVCA420* and OV90 cells were gifts from Dr. Viji Shridhar (Mayo Clinic). A2780 
cells were provided by Dr. Andrew Godwin (The University of Kansas Medical Center). ONCO-
DG1 was purchased from Leibniz Institute DSMZ-German Collection of Microorganisms and Cell 
Cultures. All cell lines were subjected to cell line identity confirmation. All experiments performed 
on cells that were passaged less than 20 times. Mycoplasma testing was performed during the 
studies, and cell cultures were free of mycoplasma. Cell line identification was performed at the 
end of experiments. OV90 and ONCO-DG1 showed 100% STR profiles matching to 
corresponding cell lines reported in ATCC or ExPASy. STR profiles for ES-2 and OVCAR3 were 
performed in 2014 as a supplement to our recent publication (Zhang, Cheng et al. 2014). STR 
profiles for OVCA420* does not match with any reported cell lines in ATCC, ExPASy, DSMZ, 
or CLIMA, and therefore we placed an asterisk to differentiate it from the original cell line. 
Antibodies and Compounds 
Rabbit polyclonal anti-FOXM1 antibody (C-20, sc-502), rabbit polyclonal anti-BRCA1 antibody 
(C-20, sc-642), mouse monoclonal anti-FANCF antibody (D-2, sc-271952) were purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rabbit polyclonal anti-Histone H3 antibody 
(ab1791) and rabbit monoclonal anti-β-Tubulin antibody (ab108342) were obtained from Abcam 
(Cambridge, MA, USA). Mouse monoclonal anti-RAD51 antibody (5B3/6, GTX23638), rabbit 
polyclonal anti-Histone H3 antibody (GTX122148) and rabbit polyclonal anti-BRCC3 antibody 
(GTX31765) were from GeneTex (Irvine, CA, USA). Rabbit polyclonal anti-PARP antibody 
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(9542S) and rabbit monoclonal anti-Caspase 3 antibodies (9665S) were purchased from Cell 
Signaling Technologies (Danvers, MA, USA). Mouse monoclonal anti-Poly (ADP-ribose) 
antibody (PAR, 10H, ALX-804-220-R100) was obtained from Enzo Life Sciences (Alexis, San 
Diego, USA). Mouse monoclonal anti-beta actin antibody (A1978) was from Sigma-Aldrich (St 
Louis, MO, USA). For Secondary antibodies, horse anti-mouse IgG-HRP antibody (7076S) was 
purchased from Cell Signaling Technologies, Goat anti-rabbit IgG-HRP antibody (sc-2030) was 
from Santa Cruz Biotechnology. Olaparib (AZD2281, Ku-0059436) was purchased from 
Selleckchem (TX, USA). Olaparib stock solutions were made with DMSO at 50 mM and stored 
at -80°C. Thiostrepton powder was purchased from Santa Cruz Biotechnology (sc-203412A) and 
formulated as micelle-encapsulated thiostrepton (see supplement information, Materials and 
Methods 2) by Dr. Laird Forrest (School of Pharmacy, University of Kansas, Lawrence, KS, USA).  
Immunoblotting 
Cells were washed at least twice with PBS at the end of treatments if applicable and then lysed 
with an appropriate volume of 1X electrophoresis sample buffer (Bio-Rad Laboratories, CA, US) 
with 5% β-mercaptoethanol (Sigma-Aldrich). The cell lysates were then boiled at 95 °C for 5 
minutes before using. Immunoblotting procedures were performed as previously described 
(Zhang, Cheng et al. 2014). For apoptosis marker check, cells were collected at the end of 
treatments, and total proteins were extracted using RIPA buffer (1% NP-40, 0.5% sodium 
deoxycholate and 0.1% SDS in 1 X PBS) containing protease/phosphatase inhibitor cocktail 
(Roche). BCA protein assay reagent kit (Pierce) was used to determine protein concentrations. 
Equal amounts of total proteins were loaded for SDS-PAGE and transferred onto PVDF 
membranes (GE healthcare). For nuclear fractionation assays, cell pellets were collected and lysed 
with cytoplasmic extraction buffer (CEB) in Subcellular Protein Fractionation Kit (78840, Thermo 
 49 
Scientific, Rockford, IL, USA) and then centrifuged at 500 X g for 5 minutes, the supernatant was 
labeled as the cytoplasmic extract, while the pellets were further lysed in RIPA buffer. Protein 
concentration was determined by the BCA assay and equal amounts of proteins were loaded for 
western blot analysis. The densitometric analysis was performed with Image J software (NIH). 
PARP trapping assay  
4.5 x 105 cells were treated with the appropriate drug(s) for 4 hours before collection. The cell 
pellets were fractionated using Subcellular Protein Fractionation kit (78840, Thermo Scientific, 
Rockford, IL, USA) according to the manufacturer’s instructions and subjected to immunoblotting. 
Chromatin Immunoprecipitation (ChIP)-qPCR 
Chromatin immunoprecipitation was carried out as described before (Johnson, Mortazavi et al. 
2007). Briefly, after 20 µM Olaparib treatment for 12 hours or 24 hours, cells were cross-linked 
with 1% formaldehyde (Electron Microscopy Sciences, USA) for 10 min and quenched by cross-
linking by glycine. The chromatin was sonicated with a Bioruptor Twin (Diagenode) at maximum 
setting for 12 min. The sonicated chromatin with incubated with 1.0 µg FOXM1 antibody (C-20, 
sc-502, Santa Cruz Technology, USA) at 4°C for 2-4 hours before purification with 100 µL Protein 
A/G magnetic beads (88803, Pierce). The beads were washed 5 times with LiCl wash buffer (100 
mM Tris pH7.5, 500 mM LiCl, 1% NP-40, 1% sodium deoxycholate before washed with 1X TE 
buffer (10 mM Tris-HCl pH7.5 and 0.1 mM Na2EDTA) and eluted with Elution Buffer (1% SDS 
and 0.1 M NaHCO3). After reverse-crosslinking, the DNA was purified with the QIAQuick PCR 
cleanup kit (QIAGEN) and used for qPCR, which was performed on a CFX384 TouchTM Real-
Time PCR Detection System (Bio-Rad) using RT2 SYBR Green qPCR Mastermix (QIAGEN). 
The sequences of the primer pairs were listed in Table 2.3.1. 
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Real-time quantitative PCR (RT-qPCR) 
The total RNA was extracted with the Trizol reagent (15596-028, Invitrogen) according to the 
manufacturer’s manual. The cDNA was synthesized using SuperScript II reverse transcriptase 
(180604014, Invitrogen) with 1 µg of total RNA in a 20 µL reaction. The resulting cDNA was 
diluted 1:20 in nuclease-free water and 1 µL was used per qPCR reaction with triplicates. QPCR 
was carried out using Power SYBR Green PCR Master Mix (4367659, Thermo Fisher Scientific) 
on a CFX384 Real-Time PCR Detection System (Bio-Rad) including a non-template negative 
control. Amplification of GAPDH or 18S rRNA was used to normalize the level of mRNA 





Gene Forward Reverse 
FOXM1(total)  5ʹAGAATTGTCACCTGGAGCAG 5ʹTTCCTCTCAGTGCTGTTGATG 
FOXM1A   5ʹGGTACACCCATCACCAGCTT 5ʹATGGGTCTCGCTAAGTGTGG 
FOXM1B  5ʹCGTGGATTGAGGACCACTTT 5ʹTCGGTCGTTTCTGCTGCTT 
FOXM1C  5ʹCCCGAGCACTTGGAATCAC 5ʹTCCTCAGCTAGCAGCACCTT 
CCNB1 5’GGCTTTCTCTGATGTAATTCTTGC 5’GTATTTTGGTCTGACTGCTTGC 
FANCF 5’GCATTTGGGTTGGAACTGAG 5’CTTCAAAATCTCCATCCTGCG 
BRCA1 5’TAATGCTATGCAGAAAATCTTAGAG 5’TACTTTCTTGTAGGCTCCTTTTGG 
BRCA2 5’TTCATGGAGCAGAACTGGTG 5’AGGAAAAGGTCTAGGGTCAGG 
BRCC3 5’CCTCATGTCACTATCGGGAAAG 5’GGATCTTGGTTACTGAGTCCAG 
BRIP1 5’GCTTAGCCTTACTTTGTTCTGC 5’TTTCACTTACGCCCTCATCTG 
NBS1 5’AGACCAACTCCATCAGAAACTAC 5’AATGAGGGTGTAGCAGGTTG 
CsK1 5GAATGGAGGAATCTTGGCGTT 5’TCTTTGGTTTCTTGGGTAGTGGG 
Skp2 5’CTGGGTGTTCTGGATTCTCTG 5’GCTGGGTGATGGTCTCTG 
DDIT3 5’GTACCTATGTTTCACCTCCTGG 5’TGGAATCTGGAGAGTGAGGG 
DDIT4 5’GTTTGACCGCTCCACGAG 5’GTGTTCATCCTCAGGGTCAC 
GADD45A 5’GGAGAGCAGAAGACCGAAAG 5’AGGCACAACACCACGTTATC 
BCL-2 5’GTGGATGACTGAGTACCTGAAC 5’GCCAGGAGAAATCAAACAGAGG 
GAPDH 5’GAAACTGTGGCGTGATGGC 5’CACCACTGACACGTTGGCAG 
18S rRNA 5’GCCCGAAGCGTTTACTTTGA 5’TCCATTATTCCTAGCTGCGGTATC 
CCNB1 FOXM1 
BS 5’ CGCGATCGCCCTGGAAACGCA 5’CCCAGCAGAAACCAACAGCCGT 
BRCA1 FOXM1 
BS 5’CAAGGTACAATCAGAGGATGGG 5’TCCTCTTCCGTCTCTTTCCT 
RAD51 FOXM1 
BS 5’ACCAGGCAGAGAATCTTGTTC 5’TTCAAGTCTAACCCAGTGCAG 
FANCF FOXM1 
BS 5’AAGGCCCTACTTCCGCTTTC 5’CACGGATAAAGACGCTGGGA 
RAD51D 
FOXM1 BS 5’CACATTCGGCCTCTACCTTC 5’TTGGAACGGAAGCTGGC 
FANCD2 





FOXM1 specific siRNAs and scrambled negative control siRNAs were synthesized by Integrated 
DNA Technologies (IDT, Coralville, IA, USA). 3.5 x 105 cells/well were seeded in 6-well plates 
and incubated at 37 °C overnight. Next day, 20 nM of each siRNA was transfected into the cells 
with Oligofectamine Transfection Reagent (12252011, Invitrogen) according to manufacturer’s 
instructions. Culture media was added 6-8 hours after transfection without washing cells. 48 hours 
after transfection, the transfected cells were trypsinized and seeded on 96-well plates (for 
cytotoxicity assay) or 6-well plates (for colony formation assay). Drugs were added around 12 
hours after seeding. For cytotoxicity assay, cells were incubated with drug for 3 days before 
measurement of cell viability using sulforhodamine B assay. For colony formation assay, cells 
were exposed to drugs for 3 days and then changed to fresh media without drug until colonies 
formed and stained with sulforhodamine B for imaging. To check the downregulation of FOXM1 
expression, the transfected cells were collected to extract total RNA for qRT-PCR or proteins for 
western blot analysis 72 hrs after transfection. The sequences of siRNAs used are listed below: 
FOXM1 siRNA#1: sense rGrUrGrCrCrArArCrCrGrCrUrArCrUrUrGrArCrArUrUrGGA, 
antisense rUrCrCrArArUrGrUrCrArArGrUrArGrCrGrGrUrUrGrGrCrArCrUrG; 
FOXM1 siRNA#2: sense rGrCrGrCrUrArUrUrArGrArUrGrUrUrUrCrUrCrUrGrArUAA, 
antisense rUrUrArUrCrArGrArGrArArArCrArUrCrUrArArUrArGrCrGrCrArC. 
 
Cytotoxicity assay using Sulforhodamine B (SRB) and drug synergy studies 
SRB assays were performed as previously described (Vichai and Kirtikara 2006, Bastola, Neums 
et al. 2016) with modifications shown below. For OVCA420*, OV90, ES-2, ONCO-DG1, 
 53 
OVCAR3 cells, 3000 cells/well were seeded in 96-well plates and treated with drugs at least 12 
hours after seeding. Then the cells were incubated for another 3 days. For MDA-MB-436 rucaparib 
resistant cells RR-1, RR-2, and RR-3, 5000 cells were seeded and incubated for 5 days after drug 
treatment. Dose-response curves were fitted and the IC50 for each drug was determined using 
GraphPad Prism 6 four parameters. All curves were constrained with 100% on top. Synergy was 
determined by calculating the combination index (CI) obtained from the plate reading. CI was 
calculated based on dividing the expected effect by the observed effect.  
Colony formation assay 
For OVCA420*, OV90, and ES-2, 1000 cells were seeded in 6-well plates. For MDA-MB-436 
rucaparib resistant cells RR-1 and RR-2, 2000 or 3000 cells were seeded per well in 6-well plates. 
The cells were treated with drugs at least 12hours after seeding and further incubated for another 
3 days before changing to fresh media. The medium was changed every 2-3 days to allow colonies 
to form. At the end of experiments, SRB assay was performed to stain the colonies which were 
imaged with Molecular Imager ChemiDoc MP System (Bio-Rad). The colonies were further 
dissolved and measured with a plate reader. Analysis of colonies was performed in GraphPad 
Prism 6.  
Caspase 3 activity assay 
Caspase 3 activity assay was performed as previously described (Bastola, Neums et al. 2016). 
Briefly, 4 x 105 cells/well were seeded in 6-well plates and incubated overnight. The next day, 
cells were treated with appropriated drugs and incubated for 30 hours. Cells were then collected 
using a cell lifter and lysed in caspase buffer (pH 7.2, 20 mM PIPES, 100 mM NaCl, 1 mM EDTA 
(pH 8.0), 0.1% (w/v) CHAPS, 10% sucrose and 10 mM DTT) and quantified with BCA assay. 20 
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µg of total protein were used to combine with 2 µL of 2 mM DEVD-Afc (Millipore) in 96-well 
flat-bottom plates and added 200 µL/well caspase buffers. The plate was covered and incubated 
war 37 °C for 2 hours before measuring fluorescence at Excitation of 400 nm and Emission of 510 
nm. Measurements were analyzed using GraphPad Prism 6. 
Alkaline Comet assay 
We used the CometChip Electrophoresis Starter kit (TREVIGEN, 4260-096-ESK) to perform 
alkaline comet assay according to manufacturer’s instructions. For thiostrepton and olaparib 
combination experiment, cells were treated with vehicle or thiostrepton for 4 hours before seeding 
onto equilibrated 96-well CometChip. Then 100 µL/well of fresh culture media containing 
appropriate concentrations of both Thiostrepton and Olaparib was added to CometChip followed 
by another 4 hours’ incubation at 37°C. And alkaline comet assay was performed following the 
product instruction. For FOXM1 siRNA transient knockdown experiment, cells were transfected 
with scrambled siRNA or FOXM1 siRNA and waited 72 hours before seeding onto CometChip. 
Cells were then incubated with vehicle or Olaparib for 4 hours at 37 °C before alkaline comet 
assay. Comets were analyzed with Trevigen Comet Analysis Software after imaging under a 4X 
fluorescent microscope. 
Statistical analysis 
All data were analyzed using GraphPad Prism 6. Results were expressed as means ± standard error 
of the mean (SEM). Differences between treatment regimens were analyzed by one-way ANOVA 




2.4.1 Olaparib induces the expression of FOXM1 and HR repair genes 
To establish the potential role of FOXM1 in the adaptive cellular response induced by olaparib, 
Ovarian cancer cells ES-2 and OVCA420* were treated with olaparib and determined the 
expression of FOXM1, BRCA1, and RAD51 at different time points. We observed induction of 
FOXM1 expression by olaparib within six hours of treatment (Figure 2.4.1.A). In addition to the 
upregulation of FOXM1 expression, the increased nuclear location of FOXM1 was observed 
within three hours of olaparib treatment (Figure 2.4.1.B), indicative of FOXM1 pathway 
activation. Concomitant with FOXM1 pathway activation, we observed increased expression of 
BRCA1 and RAD51 in these cells (Figure 2.4.1.C-D). Consistent with the increase in FOXM1 
nuclear localization, FOXM1 binding to promoter regions of its target genes, such as BRCA1, 
RAD51, FANCF, RAD51D, and FANCD2, increased at 12 hours and 24 hours after olaparib 
treatment (Figure 2.4.1.E). These data suggest that FOXM1 plays an important role in adaptive 




Figure 2.4.1: Olaparib treatment increases FOXM1 expression. A) Olaparib induces FOXM1 
expression. The ES-2 and OVCA420* cells were treated with 10 µM olaparib for 0, 1, 3, 6, 12 or 24 hours 
and subjected to immunoblotting with the FOXM1 antibody. b-actin immunoblot is used as a loading 
control. B) Olaparib enhances nuclear localization of FOXM1. Cells were treated with 10 µM olaparib for 
0, 1, 3, 6, 8 or 12 hours before subcellular fractionation followed by Western blot of FOXM1 in nuclear 
and cytoplasmic fractions. Beta-tubulin and Histone H3 were used as loading controls for cytoplasmic and 
nuclear protein, respectively. C) Olaparib treatment is associated with increases in the expression of 
BRCA1 and RAD51. The whole cell lysates were prepared from both cell lines after exposure of 10 µM 
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olaparib for 0, 1, 3, 6, 12 or 24 hours and blotted with BRCA1 or RAD51 antibodies. D) RAD51 and 
BRCA1 protein levels changes with FOXM1 level changes. Quantification of protein levels of FOXM1, 
RAD51 and BRCA1 in ES-2 cells treated with olaparib for 0, 1, 3, 6, 12 and 24 hours. Data are shown as 
mean ± SEM from 3 independent experiments. Statistics was done with Student’s test. *p<0.05, **p<0.01, 
***p<0.001. E) Olaparib treatment is associated with increases of FOXM1 occupancy at promoter regions 
of its target genes. OVCA420* cells were treated with 20 µM olaparib for 12 hours or 24 hours before ChIP 
analysis using FOXM1 antibody. Results are representative of at least three experiments. 
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2.4.2 FOXM1 expression is higher in cancer cells that are less responsive to olaparib  
To determine the extent to which FOXM1 expression may be correlated with olaparib sensitivity, 
we assessed FOXM1 expression by qRT-PCR, the Western blot analysis, and olaparib sensitivity 
by SRB assay. Although all three forms of FOXM1 transcripts were expressed (Figure 2.4.2A), 
protein expression was reflected better by the levels of a FOXM1C transcript (Figure 2.4.2B). 
Consistent with these results, analysis of The Cancer Genome Atlas ovarian cancer dataset 
indicated that FOXM1C transcript is the most abundant among the three isoforms (data not shown), 
which is consistent with a report from Tassi et al (Tassi, Todeschini et al. 2017). The dose-response 
curves for olaparib sensitivity in these cell lines indicated that OVCA420* and OV90 with high 
expression of FOXM1 were less responsive to olaparib (Figure 2.4.2 C). Taken together, these 







Figure 2.4.2: FOXM1 expression is higher in cancer cells that are less responsive to olaparib. A) qRT-
PCR to quantify mRNA level of FOXM1 isoform a, b, and c in different ovarian cancer cells. mRNA 
expression was normalized to OVCA420* cell. Data are shown as mean ± SEM. B) Left: western blot 
analysis of FOXM1 expression in different cells. Right: quantification of FOXM1 protein levels. The 
FOXM1 level was normalized to beta-actin for each cell, which was normalized to normalized FOXM1 
level in OVCA420* cell. C) Cell viability assay to test olaparib sensitivity in different cells. 3-day SRB 
assay was done in 96 well plates. Data were plotted in line graph in Prism 6. Data are shown as mean ± 
SEM. N=3-4. Estimated IC50 values were obtained in Prism 6 and shown on the right. “Not predicted” 
represents that the IC50 cannot be accurately predicted.   
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2.4.3 FOXM1 knockdown results in enhanced sensitivity to olaparib 
To determine the extent to which FOXM1 expression contributes to olaparib sensitivity, we used 
two different siRNAs to downregulate FOXM1 expression. Although both siRNAs downregulated 
all three isoforms of FOXM1 transcripts, FOXM1B was affected more by these siRNAs (Figure 
2.4.3.A). Interestingly, FOXM1 expression was markedly decreased at the protein level, indicating 
that these siRNAs also affected the translation of FOXM1 protein (Figure 2.4.3.B); consistent with 
the translational repression of certain siRNAs (Aleman, Doench et al. 2007). SRB assays indicated 
that cells with decreased FOXM1 expression were significantly more sensitive to olaparib (Figure 
2.4.3.C). Similarly, we observed a significant decrease in clonogenic survival in FOXM1 knocked-
down cells treated with 4, 10 and 25 µM olaparib compared to scrambled control siRNA (scr 





Figure 2.4.3: FOXM1 knockdown results in enhanced sensitivity to olaparib. A) qRT-PCR analysis to 
measure the knockdown efficiency of two independent FOXM1 siRNAs in ES-2 cells. All three FOXM1 
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isoforms were downregulated with both siRNAs at 72 hours. Data are shown as mean ± SEM. FOXM1 
shown as expression relative to scr siRNA transfected cells. Knockdown was performed with two 
independent siRNAs. B) Western blot analysis to check FOXM1 protein with siRNA transfection in ES-2 
cells. Beta-actin was used as loading control. C) FOXM1 siRNA knockdown leads to increase sensitivity 
to olaparib in ES-2 cell by SRB assay. Left: SRB assay to test cell viability after siRNA transfection. 48 
hours after transfection, cells were treated with increasing concentrations of olaparib for additional 3 days. 
Right: Bar graph shows decreased IC50 of olaparib in FOXM1 siRNA knockdown cells. Results were 
derived from triplicates of representative experiments. D) Clonogenic assay with siRNA knockdown in ES-
2 cell. Left: Representative images of colonies in 6 well plate. Cells were treated with increasing 
concentrations of olaparib for 3 days and kept for 2 weeks without drug to allow colonies to form. Data are 
shown as mean ± SEM. Statistics was done using the Student’s t-test. p<0.05 was considered to be 
significant. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
  
 64 
2.4.4 FOXM1 inhibition with thiostrepton increases sensitivity to olaparib 
Next, we used pharmacologic means to inhibit FOXM1 expression and determined the extent to 
which FOXM1 inhibition results in enhanced sensitivity to olaparib. Thiostrepton, is a large cyclic 
antibiotic commonly used in topical antibiotic ointments. It is known to inhibit bacterial protein 
synthesis and block translation by interfering with elongation factors (EF) involved in ribosomal 
GTPase activity. In addition to these activities, previous studies have shown that thiostrepton can 
also repress the FOXM1 promoter (Kwok, Myatt et al. 2008) and in turn downregulate FOXM1 
expression (Hegde, Sanders et al. 2011, Zhang, Cheng et al. 2014). In three different ovarian cancer 
cell lines, we observed synergistic interactions between thiostrepton and olaparib at the 
concentrations tested in clonogenic assays (Figure 2.4.4.A-B) and mild synergistic activity in SRB 
assays (Figure 2.4.4.C). Collectively, these results indicated that FOXM1 inhibition enhances 





Figure 2.4.4: FOXM1 inhibition with thiostrepton increases sensitivity to olaparib. A) Colony 
formation assay to test the combinatory effect of thiostrepton and olaparib treatment. Representative images 
of colonies were shown. Cells were seeded in 6 well plates and exposed to vehicle, thiostrepton, olaparib 
or thiostrepton & olaparib for 3 days, and changed to fresh media without drugs every 3 days and kept for 
2 weeks to allow colonies to form. B) Quantification of colonies indicates a synergistic interaction between 
thiostrepton and olaparib. Data presented as colony formation relative to the vehicle group. Data are shown 
as mean ± SEM. Combination index (CI) was calculated with a function as: ((Ethio+(1-Ethio)*Eola)/Eobserved, 
where Ethio, Eola, and Eobserved represent drug effect of thiostrepton alone, olaparib alone, and the observed 
effects of the combination of both drugs, respectively. The two drugs are synergistic if CI<1.0, additive if 
CI=1.0, and antagonistic if CI>1.0. CI values were indicated in the graph. C) Mild synergistic interactions 
between thiostrepton and olaparib by SRB assay. CIs for different combinations were calculated and CIs 




2.4.5 Thiostrepton decreases the expression of DNA repair genes and increases the 
expression of pro-apoptotic genes 
To better characterize the effect of thiostrepton and define the molecular pathways affected by 
thiostrepton, our lab analyzed the publicly available dataset from the Connectivity Map 
(https://portals.broadinstitute.org/cmap/fileDownloadServlet?servletAction=input) project where 
cancer cells were treated with thiostrepton for six hours and drug-perturbed transcriptomes were 
profiled with array-based gene expression analysis.(Lamb, Crawford et al. 2006). The Metascape 
analysis (Tripathi, Pohl et al. 2015) of genes that are downregulated by thiostrepton at p<=0.001 
indicates these genes are associated with mitotic cell cycle, G1/S phase transition and FOXM1 
pathway (Fang, Madden et al. 2018). On the other hand, the Metascape analysis of genes that are 
upregulated by thiostrepton at p<=0.001 indicates these genes are associated with unfolded protein 
response, ER-associated degradation, and cellular redox homeostasis. At p <= 0.005, we observed 
716 genes that are differentially expressed between DMSO- and thiostrepton-treated cells. The 
classification of gene function through DAVID bioinformatics resources (Huang, Sherman et al. 
2007) indicates one of the pathways enriched by these genes is DNA damage and repair pathway. 
Genes involved in DNA damage and repair, such as MLH3, FANCF, and BRCC3 were 
downregulated while pro-apoptotic genes such as DDIT4, DDIT3, and GADD45A were 
upregulated (Fang, Madden et al. 2018).   
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 To further characterize the effect of thiostrepton on the expression of FOXM1 target genes, 
we also analyzed ENCODE dataset and focused on DNA repair genes identified from the FOXM1 
ChIP-sequencing. We focused on genes involved in HR repair pathway and analyzed the 
expression of FOXM1, FANCF, BRCA1, BRCC3, BRIP1, NBS1, Skp2, and Csk1. In three different 
cell lines, 5 µM (OVCA420* and OV90) and 2.5 µM (ES-2) thiostrepton treatment resulted in 
downregulation of the expression of FOXM1 target genes (Figure 2.4.5.A-C). Interestingly, 
thiostrepton treatment lead to variable upregulated FOXM1a and FOXM1b in ovarian cancer cells 
while consistent downregulation of FOXM1c and its canonical target gene CCNB1 was observed 
in these cells (Figure 2.4.5.D-F).  
 At protein levels, only BRCA1 and FOXM1 were consistently downregulated following 
treatment with thiostrepton (Figure 2.4.5.G). To resolve the inconsistency between mRNA and 
protein expression, we analyzed the stability of these proteins in question. Following the inhibition 
of protein synthesis by cycloheximide, we observed a decrease in BRCA1 and FOXM1. The half-
life of BRCA1 and FOXM1 was less than 60 minutes in OVCA420* (Figure 2.4.5.I-J). In contrast, 
the half-life for BRCC3 and FANCF was longer than 24 hours (Figure 2.4.5.I-J). Similarly, the 
half-life for BRCC3 and FANCF was longer than 24 hours in OV90 (Figure 2.4.5.K-L). The longer 
half-life of BRCC3 and FANCF may explain why a substantial decrease in mRNA does not 
correspond with a decrease in protein levels. Expression of DNA repair genes including BRCA1 
is known to be cell cycle dependent, and changes in expression of these genes may be secondary 
to cell cycle changes induced following thiostrepton treatment. However, we did not observe a 
marked change in cell cycle profile at 4 hours, in two different cell lines, when BRCA1 is 
downregulated by thiostrepton in these cells (Figure 2.4.5.M-N), suggesting that changes of 
expression of these genes including BRCA1 were not due to cell cycle arrest. These data suggest 
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that thiostrepton treatment leads to inhibition of FOXM1 expression and its target HR genes, and 










Figure 2.4.5: Thiostrepton downregulates FOXM1 target HR genes. A-C) qRT-PCR analysis to show 
that treatment of cells with thiostrepton results in downregulation of mRNA expression of FOXM1 and its 
target HR genes in A) OVCA420*, B) OV90, and C) ES-2 cells. D-F) qRT-PCR analysis to show that 
thiostrepton treatment leads to downregulation mRNA expression of all three FOXM1 isoforms and 
CCNB1, which is used as a control target of FOXM1, in all three cell lines. G) Western blot analysis to 
show a change of protein levels for BRCA1, FANCF, and BRCC3 with thiostrepton treatment. ES-2, 
OVCA420*, and OV90 cells were treated with 5 µM of thiostrepton for 0, 2,4,6,8,10,12,18, or 24 hours. 
Beta-actin was used as a loading control. H-K) Protein half-life analysis with cycloheximide (CHX) shows 
that FOXM1 and BRCA1 have short half-life, while BRCC3 and FANCF proteins are relatively stable. H) 
and J) Western blot analysis to check protein levels of FOXM1, BRCA1, FANCF, and RAD51 after 0, 2, 
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4, 6, 8, or 24 hr treatment of CHX (25µg/mL). I) and K) Quantification of protein levels in OVCA420* and 
OV90 respectively. L-M) Cell cycle analysis with thiostrepton treatment. L) OVCA420* and M) ES-2 cells 
were treated with vehicle or 5 µM thiostrepton for 4 hrs before PI staining. Cell cycle was analyzed by flow 
cytometry. Left: Representative cell cycle profiles of vehicle and thiostrepton treated cells. Right: 
Quantification of cells in different phases. Data are shown as mean ± SEM. *p<0.05, **p<0.01. One 
representative experiment with triplicates was shown from three independent experiments.  
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2.4.6 Thiostrepton induces apoptosis by increase of pro-apoptotic genes and decrease of anti-
apoptotic genes 
In addition to genes involved in DNA repair pathway, the analysis of microarray dataset from the 
Connectivity Map project also indicated that thiostrepton affects the expression of genes involved 
in apoptosis. Therefore, we sought to confirm the expression of pro- and anti-apoptotic genes 
affected by exposure to thiostrepton. QRT-PCR analysis indicated that thiostrepton treatment leads 
to upregulated DDIT3, GADD45A while the anti-apoptotic gene BCL-2 was downregulated 
(Figure 2.4.6.A-B). Consistent with these results, exposure to thiostrepton can induce PARP1 and 
caspase 3 cleavages in two different cell lines (Figure 2.4.6.C-D). Finally, results from the caspase 
3 activity assay demonstrated higher caspase 3 activity in cells treated with thiostrepton alone or 




Figure 2.4.6: Thiostrepton treatment induces apoptosis by increasing the expression of pro-apoptotic 
genes and decreasing the expression of anti-apoptotic genes. A-B) qRT-PCR analysis to measure mRNA 
levels of pro-apoptotic genes DDIT3, GADD45A and anti-apoptotic gene BCL-2. A) ES-2 cells were treated 
with vehicle, 1 µM or 2.5 µM thiostrepton, B) OV90 cells were treated with vehicle, 2.5 µM or 5 µM 
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thiostrepton for 24 hours. Results represent experiments performed in triplicates. C-D) Western blot 
analysis shows that thiostrepton increases PARP1 and Caspase 3 cleavage with and without olaparib in ES-
2 and OV90 cells. C) ES-2 and D) OV90 cells were treated with thiostrepton, olaparib or thiostrepton & 
olaparib for 30 hours. Beta-actin serves as loading control. E-F) Exposure to thiostrepton results in 
increased caspase 3 activity. Caspase 3 activity assay was performed 30 hours after drug treatment in E) 
ES-2 and F) OV90 cells. Data shown as mean ± SEM. Statistics was done with Student’s t-test, #p<0.05, 
##p<0.01, ###&***p<0.001, ****p<0.0001. Results represent experiments performed in duplicates. 
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2.4.7 Thiostrepton enhances DNA damage and PARP1 trapping in cells treated with olaparib 
Because thiostrepton treatment can lead to downregulation of FOXM1 and its target genes 
involved in DNA repair pathway, we also tested the extent to which thiostrepton can enhance DNA 
damage in cells treated with olaparib. The results from comet assay indicated that thiostrepton 
treatment alone increases DNA damage (Figure 2.4.7.A). In addition, higher levels of DNA in 
comet tail were observed in cells treated with 10 µM olaparib and thiostrepton. The increase in 
DNA damage following thiostrepton treatment could be explained in part by the downregulation 
of FOXM1 because FOXM1 knockdown by siRNA produces a similar increase in DNA damage 
(Figure 2.4.7.B). Meanwhile, increased level of phospho-H2AX (γH2AX) was seen with 
thiostrepton treatment and the increase was enhanced when combined with olaparib (Figure 
2.4.7.C-D). These results were consistent with a critical role of FOXM1 in regulating DNA repair 
genes, and a decreased expression of FOXM1 may compromise DNA repair function by 
downregulating several target genes involved in DNA repair. Consistent with an increase in DNA 
damage following FOXM1 inhibition, we also observed an increase in trapped PARP1 in cells 
treated with either 5 or 10 µM thiostrepton, or 40 µM olaparib (Figure 2.4.7.E). This observation 
provides an additional mechanism to explain the enhanced sensitivity to olaparib in ovarian cancer 
cells since PARP trapping onto chromatin after PARP inhibitor treatment is considered to be more 





Figure 2.4.7: Thiostrepton enhances DNA damage and PARP1 trapping in cells co-treated with 
olaparib. A) Comet assay shows that thiostrepton treatment can enhance DNA damage in cells treated with 
olaparib. OVCA420* cells were pretreated with vehicle or thiostrepton for 4 hours in 6-well plates before 
seeding onto CometChip (Trevigen). Then cells were treated with vehicle, 7.5 µM or 10 µM thiostrepton 
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and olaparib (10 µM) for another 4 hrs. Comets were analyzed with Trevigen Comet Analysis Software 
after imaging under a 4X fluorescent microscope. Data were shown as percent of DNA in comet tail. 
Representative comet images were shown on the right. The significance analysis was performed with One-
way ANOVA. *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001. Right: Representative images of comets. 
Results represent experiments performed in triplicates. B) Comet assay shows that FOXM1 siRNA 
knockdown leads to increase of DNA damage. Comet assay was performed 72 hours after siRNA 
transfection. C-D) Western blot analysis shows that thiostrepton increases gH2AX levels. C) OV90 or D) 
ES-2 cells were treated with the indicated drug(s) for 48 hours. Beta-actin serves as a loading control. E) 
PARP trapping analysis shows that thiostrepton enhanced PARP1 trapping to chromatin in the presence of 
olaparib. OVCA420* cells were treated with the indicated drug(s) for 4 hours and lysed to separate nuclear 
soluble and chromatin-bound fraction. First blotted with PARP1 antibody and secondly with Poly (Ribose-
ADP) antibody. * represents non-specific band detected by PAR antibody. Results were from a 
representative of two independent experiments.  
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2.4.8 Thiostrepton sensitizes resistant cells to rucaparib by downregulating stabilized mutant 
BRCA1 
Previous studies reported an enhanced protein level of mutant BRCA1 as an epigenetic mechanism 
associated with acquired resistance to rucaparib (Johnson, Johnson et al. 2013). Although the 
parental breast cancer cell line, MDA-MB-436, are sensitive to rucaparib due to the presence of a 
mutated BRCA1, the resistant clones derived from these cells expressed high levels of mutant 
BRCA1 that partially restore BRCA1 mediated HR function and confer resistance to rucaparib. 
We used these resistant clones to test the extent to which treatment with thiostrepton could restore 
sensitivity to rucaparib in these cells. Thiostrepton treatment lead to downregulation of the 
expression of FOXM1 as well as mutant BRCA1 (Figure 2.4.8.A). Consistent with this 
downregulation, we observed an increase in sensitivity to rucaparib in thiostrepton-treated cells 
(Figure 2.4.8.B-D). In addition, mild synergistic interactions between thiostrepton and rucaparib 
were observed at different combinations. Clonogenic assays further corroborated these synergistic 
interactions between the two drugs (Figure 2.4.8.E-G). This enhanced sensitivity to rucaparib was 
also observed in resistant cells following the FOXM1 knockdown by siRNA (Figure 2.4.8.H-J), 
indicating that enhanced sensitivity to rucaparib by thiostrepton could be explained in part by its 
effect on FOXM1 expression. These data suggest that inhibition of FOXM1 associated with 





Figure 2.4.8 Cont. 
 
Figure 2.4.8: Thiostrepton treatment can sensitizes resistant cells to rucaparib by downregulating 
FOXM1 and stabilized mutant BRCA1 (mtBRCA1). A) Western blot analysis to show downregulation 
of FOXM1 and mtBRCA1 in three rucaparib resistant MDA-MB-436 cells, RR-1, RR-2, and RR-3. Cells 
were treated with 5 µM thiostrepton for 0, 12 or 24 hours respectively. Beta-actin serves as a loading 
control. B) Mild synergistic interactions between thiostrepton and rucaparib by SRB assay. CIs for different 
combinations were calculated and CIs resulted from drug effects between 0.2-0.8 were used in the plot. 
Data are shown as mean with 95% confidence intervals. C-D) Thiostrepton sensitizes rucaparib resistant 
cells to rucaparib. Upper: Line-graphs show cell viability relative to the vehicle for C) RR-1 and D) RR-3. 
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Data shown as analyzed using the Student’s t-test, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
Bottom: Calculated CIs for different combinations of thiostrepton and rucaparib. Results represent 
experiments with four replicates (B-D). E-G) Clonogenic assay shows moderate synergistic effects of 
thiostrepton and rucaparib. Cells were exposed to the drug(s) for 3 days followed by around 3 weeks’ no 
drug incubation to allow colony formation. E) Representative images of colonies in 6 well plates. F-G) 
Quantification of colonies formed for each treatment. Line graphs show the percent of colony formation 
relative to the vehicle. Data are shown as mean ± SEM. CIs for different drug combinations were calculated 




In this study, FOXM1 was identified as a component of the adaptive cellular pathway response to 
olaparib. Olaparib treatment resulted in induced expression of FOXM1 and activation of the 
FOXM1 pathway as evidenced by the enhanced nuclear localization of FOXM1 and the increased 
binding of FOXM1 to its target genes. The disruption of FOXM1 pathway either by RNAi or 
chemical inhibition with thiostrepton decreased the levels of FOXM1 expression and sensitized 
the cancer cells to olaparib and carboplatin. Furthermore, thiostrepton decreased the levels of DNA 
repair genes involved in HR pathway and induces “BRCAness” in ovarian cancer cells, thereby 
resensitizing the rucaparib-resistant breast cancer cells to rucaparib. At the same time of this study, 
Tassi et al., reported that FOM1 expression is significantly associated with chemotherapy 
resistance, and that FOXM1 knockdown enhances the cytotoxic effects of chemotherapeutic agents 
including olaparib in non-serous epithelial cancer cells (Tassi, Todeschini et al. 2017) which is 
consistent with the observations I described in this chapter. 
 Previous studies indicate that FOXM1 regulates the expression of BRIP1 and DNA damage 
repair pathway following epirubicin treatment (Monteiro, Khongkow et al. 2013). In addition, a 
spontaneous increase in γH2AX foci has been reported in cancer cells following the depletion of 
FOXM1 by RNAi (Tan, Raychaudhuri et al. 2007). Consistent with these results, this study 
provided additional supporting evidence that FOXM1 knockdown and thiostrepton treatment 
results in increased γH2AX level, enhanced DNA damage, and PARP1 trapping to the damaged 
DNA in the presence of olaparib. Olaparib has been shown to produce moderate levels of PARP 
trapping (Murai, Huang et al. 2012). The increase of PARP trapping in thiostrepton and olaparib 
treated cells may be a result of increased DNA damage associated with thiostrepton exposure, 
which leads to the recruitment of DNA repair machinery to the damage sites, including PARP1 
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which is responsible for the base excision repair (BER). A significant increase in γH2AX foci 
either by RNAi or thiostrepton underlies the important role FOXM1 plays in regulating DNA 
repair genes and maintaining DNA repair efficacy (Zona, Bella et al. 2014). Accordingly, FOXM1 
is described as an “emerging master regulator of DNA damage response” (Zona, Bella et al. 2014). 
Therefore, my results indicating that FOXM1 is induced in cells following treatment with olaparib 
and that its enhanced expression regulates the adaptive cellular response to DNA damage signal 
provide an important biological basis for targeting FOXM1 pathway to overcome resistance to 
olaparib and carboplatin. 
 It is important to note that previous studies have also shown that FOXM1 is stabilized by 
DNA damaging agents, such as ionizing radiation, etoposide and UV (Tan, Raychaudhuri et al. 
2007, Teh, Gemenetzidis et al. 2010). Tan et al. reported that FOXM1 is phosphorylated by Chk2 
at S361, leading to the stability of FOXM1 (Tan, Raychaudhuri et al. 2007). They reported that 
FOXM1 regulates BRCA2 and XRCC1. In addition, Monteiro et al. reported that FOXM1 is 
required for HR pathway but indispensable for NHEJ (Monteiro, Khongkow et al. 2013). Finally, 
Zhang et al. reported that FOXM1 regulates RAD51 expression (Zhang, Wu et al. 2012). 
Consistent with these results, we observed FOXM1 occupancy to DNA repair genes, such as 
BRCA1, RAD51, FANCF, RAD51D, and FANCD2, in response to olaparib. In addition, inhibition 
of FOXM1 via thiostrepton treatment decreased the expression of DNA repair genes, such as 
BRCA1 and BRCA2, thereby disrupting an adaptive response mediated by FOXM1. 
 Considering that adaptive responses to chemotherapy provide transient resistance to 
chemotherapy and may facilitate the eventual acquisition of more stable traits associated with 
chemotherapy resistance, our study provides an important insight into a potential role of the 
FOXM1 pathway in the adaptive response to olaparib. Our studies also suggest the potential use 
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of thiostrepton as a chemotherapeutic agent to disrupt FOXM1 pathway and to enhance sensitivity 
to olaparib. Although thiostrepton was initially isolated from Streptomyces azureus and used as a 
topical antibiotic (Kutscher, Zegarelli et al. 1959), its current use in human is limited by the low 
solubility and bioavailability. However, recent studies have shown that micelle-formulated 
thiostrepton has better solubility and pharmacodynamic effect on the tumor in xenograft models 
(Wang and Gartel 2011). Also, several drug repurposing studies have tested the efficacy of 
thiostrepton in tumor xenograft mouse models, including ovarian cancer, leukemia and laryngeal 
squamous cell carcinoma (Zhang, Cheng et al. 2014, Buchner, Park et al. 2015, Jiang, Wu et al. 
2015). In addition to thiostrepton, siomycin A is another cyclic oligopeptide isolated from 
Streptomyces sioyanesis and shows inhibitory effects on FOXM1 transcriptional activity and 
expression (Radhakrishnan, Bhat et al. 2006). Finally, another inhibitor FDI-6 is a small molecule 
FOXM1 inhibitor that blocks FOXM1 binding to DNA (Gormally, Dexheimer et al. 2014). 
Although micro-molar concentrations of FDI-6 is required to inhibit FOXM1, further development 
of this compound may result in therapeutics that can effectively target FOXM1 and enhance 
sensitivity to existing chemotherapeutics, such as olaparib and carboplatin. 
 Data from this study showed that FOXM1 plays an important role in an adaptive response to 
PARP inhibitors. FOXM1 expression levels inversely correlated with olaparib sensitivity, and 
knockdown of FOXM1 sensitized ovarian cancer cells to olaparib and decreased the number of 
persisting cells that can produce colonies. The FOXM1 inhibitor, thiostrepton, induces a 
“BRCAness” like phenotype by downregulating homologous recombination repair genes, which 
in turn results in increased apoptosis, and enhanced therapeutic effects of olaparib and carboplatin 
in ovarian cancer cells. In addition, thiostrepton treatment overcome resistance to rucaparib by 
downregulating FOXM1 and stabilized mutant BRCA1 in resistant breast cancer cells. Inhibition 
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of FOXM1 represents an effective strategy to overcome PARP inhibitor resistance and that 
disrupting FOXM1-mediated adaptive pathway may produce better therapeutic effects for PARP 
inhibitors. 
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Chapter 3. Targeting FOXM1-MYC nexus with BET inhibitor enhances therapeutic effects 




FOXM1 and MYC are overexpressed in epithelial ovarian cancer (Cancer Genome Atlas Research 
2011, Ross, Ali et al. 2013).  FOXM1 regulates the expression of HR genes and modulates PARP 
inhibitor sensitivity. However, the potential role of c-MYC in PARP inhibitor sensitivity is not yet 
fully characterized. In this study, we found that expression of specific target genes of FOXM1 in 
HR pathway, BRCA1, BRCA2, FANCF and BRIP1, were not affected after the FOXM1 
knockdown by siRNAs. Interestingly, we observed an increase of c-MYC after FOXM1 
knockdown. ENCODE data analysis revealed that both FOXM1 and c-MYC bind to a subset of 
HR target genes, suggesting a potential co-regulation of these genes by FOXM1 and c-MYC. In 
addition, TCGA data analysis showed that FOXM1, MYC, and BRD4 are highly expressed in 
ovarian cancer. Considering that BET inhibitors inhibit BRD4 and downregulate both FOXM1 
and c-MYC, we investigated the effect of BET inhibitors on PARP inhibitor sensitivity in ovarian 
cancer cells. In three cancer cell lines with a lower sensitivity to PARP inhibitor, BET inhibitor, 
(+)-JQ1, attenuated the upregulation of c-MYC after FOXM1 knockdown and decreased the 
expression of FOXM1, BRCA1 and RAD51 genes. ChIP-qPCR demonstrated decreased binding 
of FOXM1 and c-MYC to BRCA1 and RAD51 promoters, suggesting that the decreased expression 
of BRCA1 and RAD51 can be attributable to the suppression of FOXM1 and MYC. Cell viability 
assays showed (+)-JQ1 decreased cell viability in a dose-dependent manner, and enhanced the 
cytotoxic effects of PARP inhibitor olaparib in these cells. Strikingly, multiple combinations at 
the sub-lethal doses of (+)-JQ1 and olaparib completely suppressed colony formation. Similarly, 
(+)-JQ1 also enhanced the cytotoxic effect of rucaparib in acquired resistance cells derived from 
MDA-MB-436 breast cancer cells. We showed that (+)-JQ1 treatment leads to downregulation of 
FOXM1, RAD51, and mutant BRCA1, which was originally stabilized to confer rucaparib 
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resistance in the resistant cells. Taken together, these data suggest that targeting the FOXM1-MYC 
nexus with BET inhibitor, (+)-JQ1, induces of “BRCAness” like phenotype by downregulating 
BRCA1 and RAD51 and in turn restores the sensitivity to PARP inhibitors in cancer cells with 




Cancer cells with deleterious BRCA1/2 mutations are hypersensitive to PARP inhibitor (Bryant, 
Schultz et al. 2005, Farmer, McCabe et al. 2005). This observation was later extended to other 
cancer cells with a broader deficiency in HR pathway (McCabe, Turner et al. 2006, Mendes-
Pereira, Martin et al. 2009, Drew, Mulligan et al. 2011). The extended clinical activity of PARP 
inhibitors is due to “BRCAness” or HR-deficient (HRD) phenotypes resulting from defects in HR 
pathway that phenocopy the sensitivity to PARP inhibitors that is similar to BRCA-mutated tumors. 
In high-grade serous ovarian cancer, approximately 50% of cases have HR defects (Cancer 
Genome Atlas Research 2011), which can result from either direct alterations of HR components, 
such as BRCA1/2 (Farmer, McCabe et al. 2005, Veeck, Ropero et al. 2010), or indirect alterations, 
such as EMSY amplification (Hughes-Davies, Huntsman et al. 2003). Ovarian cancer patients were 
among the first individuals to be evaluated for efficacy using PARP inhibitor (Fong, Boss et al. 
2009, Audeh, Carmichael et al. 2010, Tutt, Robson et al. 2010, Ledermann, Harter et al. 2012, 
Ledermann, Harter et al. 2014). The activity of PARP inhibitors was seen preferentially in ovarian 
cancer patients possessing a BRCA mutant tumor, leading to approval of PARP inhibitors as 
monotherapy and maintenance therapy for pre-treated ovarian cancer patients with mutated 
BRCA1/2 (either germline or somatic). Besides ovarian cancer, PARP inhibitors have shown 
activities in other cancer types, including breast cancer, prostate cancer, non-small cell lung cancer, 
and melanoma, and are being evaluated in clinical trials (Plummer, Lorigan et al. 2013, Bhalla and 
Saif 2014, Levra, Olaussen et al. 2014, Livraghi and Garber 2015, Ramakrishnan Geethakumari, 
Schiewer et al. 2017).  
 A clear survival advantage with PARP inhibitor was seen in patients with BRCA mutations 
and patients who are responsive to platinum-based chemotherapy. Unfortunately, the response rate 
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in patients with no BRCA mutations and those with platinum resistance disease is much less (Fong, 
Boss et al. 2009, Audeh, Carmichael et al. 2010, Mirza, Monk et al. 2016). This selective activity 
largely limits the broader application of PARP inhibitors in cancer treatment. Meanwhile, like 
chemotherapy, resistance to PARP inhibitor eventually develops in patients (Fojo and Bates 2013). 
One of the major causes of PARP inhibitor (PARPi) resistance in the clinic is the restoration of 
HR proficiency (Lord and Ashworth 2013). Drug combinations have been designed and evaluated 
in preclinical and early clinical trials to extend the therapeutic effect of PARP inhibitors and/or to 
overcome PARPi resistance (Benafif and Hall 2015). These combinations were mostly designed 
with the goal of enhancing the cytotoxic effects, including PARPi in combination with ionizing 
radiation or chemotherapeutic agents (Miura, Sakata et al. 2012, Al-Ejeh, Shi et al. 2013, Plummer, 
Lorigan et al. 2013), such as topotecan, dacarbazine, and temozolomide (Evers, Drost et al. 2008, 
Zander, Kersbergen et al. 2010, Norris, Adamson et al. 2014). Combination of PARPi with other 
agents, such as VEGF (Liu, Barry et al. 2014), PI3K (Wang, Li et al. 2016, Wang, Wang et al. 
2016), TGFb (Liu, Zhou et al. 2014), and immune checkpoint inhibitors (Gadducci and Guerrieri 
2017) have also been explored. Even though preclinical studies have shown promising therapeutic 
effects with these combinations, results from clinical trials were disappointing. The dose-limiting 
severe hematological adverse effects were observed in the combination of olaparib with 
topoisomerase I inhibitor, Topotecan (Samol, Ranson et al. 2012), or with a potent VEGF inhibitor, 
Cediranib (Liu, Barry et al. 2014). Therefore, there is an immediate need to explore new rational 
drug combinations that maximize clinical benefits and minimize adverse effects. These rational 
combinations must focus on compromising HR proficiency and restoring or enhancing PARP 
inhibitor sensitivity in cancer cells. 
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 In Chapter 2, I showed that FOXM1 positively regulates DNA repair genes, especially HR 
genes, and inhibition of FOXM1 as a result of thiostrepton exposure disrupts the FOXM1 
transcriptional network and enhances the sensitivity to PARP inhibitors in PARPi-resistant cancer 
cells. Although the in vivo efficacy of thiostrepton has been shown by several groups (Wang and 
Gartel 2011, Zhang, Cheng et al. 2014, Buchner, Park et al. 2015, Jiang, Wu et al. 2015), further 
studies are needed to validate its clinical activity. FOXM1 inhibition is only one of documented 
activities of thiostrepton, and it was shown to function as a proteasome inhibitor as well (Aminake, 
Schoof et al. 2011, Gartel 2011). In this regard, a more specific targeted drug may be desirable to 
combine with olaparib. Our data show that FOXM1 downregulation with siRNA is not sufficient 
to suppress the expression of downstream HR genes, such as BRCA1, BRCA2, FANCF and BRIP1. 
Meanwhile, c-MYC was upregulated after FOXM1 silencing via RNAi approaches. We suspect 
that c-MYC upregulation served as a compensation mechanism to regulate HR genes after FOXM1 
knockdown, and therefore we propose that targeting both FOXM1 and c-MYC may provoke better 
impairment of HR. 
 BET inhibitors are a class of drugs that were designed to reversibly bind the bromodomains 
of BET (bromodomain and extra-terminal motif) proteins (BRD2, BRD3, BRD4, and BRDT) to 
prevent their interactions with acetylated histones and transcription factors (Filippakopoulos, Qi 
et al. 2010, Nicodeme, Jeffrey et al. 2010, Loven, Hoke et al. 2013) to decrease the transcription 
of target genes. Since BRD4 was shown to drive pathogenesis in various types of cancers (Shi and 
Vakoc 2014), BET inhibitors have been studied in cancers (French, Ramirez et al. 2008, Da Costa, 
Agathanggelou et al. 2013, Li, Guo et al. 2016, McCleland, Mesh et al. 2016, Shu, Lin et al. 2016). 
Importantly, BET inhibitors have been shown to block the expression of c-MYC (Delmore, Issa et 
al. 2011, Sun and Gao 2017), which was long considered undruggable oncogenic transcription 
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factor (Koh, Sabo et al. 2016). In addition, in vitro and preclinical studies show that BET inhibitors 
are active in overcoming resistance to other targeted therapies when used in combination therapies 
(Knoechel, Roderick et al. 2014, Korkut, Wang et al. 2015). Interestingly, Zhang et al. show that 
BET inhibitor downregulates FOXM1 pathway, but the molecular mechanisms associated with 
FOXM1 downregulation by BET inhibitors are not fully investigated (Zhang, Ma et al. 2016). 
 In this chapter, we tested the effects of the combination of BET inhibitor (+)-JQ1 with 
olaparib or rucaparib in primary and acquired resistance cancer cells and showed that (+)-JQ1 
inhibits the expression of both FOXM1 and MYC. Consequently, their target genes in HR pathway, 
such as BRCA1 and RAD51 are downregulated, and the resulting HR impairment in these cancer 
cells sensitizes them to PARP inhibitors.   
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3.3 Materials and Methods 
Cell lines and cell culture 
ES-2 cell was maintained in MCDB105 and M199 (1:1) (Sigma, USA) containing 5% FBS 
(Sigma). OV90 cells were maintained in MCDB105 and M199 (1:1) with 15% FBS. OVCA420* 
cells were cultured in DMEM (Sigma and Caisson Labs, USA) supplemented with 10% FBS. 
MDA-MB-436 and its derivative rucaparib resistant cells RR-1, RR-2 were generated by Dr. Neil 
Johnson laboratory at Fox Chase Cancer Center (Johnson, Johnson et al. 2013) and were 
maintained in RPMI1640 (Sigma and Caisson Labs) supplemented with 10% FBS. All the media 
were supplemented with 100 units/mL penicillin and 100 µg/mL streptomycin.  
Antibodies and Compounds 
Rabbit polyclonal anti-FOXM1 antibody (C-20, sc-502) and rabbit polyclonal anti-BRCA1 
antibody (C-20, sc-642) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). 
Mouse monoclonal anti-RAD51 antibody (5B3/6, GTX23638) was from GeneTex (Irvine, CA, 
USA). Rabbit monoclonal anti-c-MYC antibody (Y69) was purchased from Abcam (Cambridge, 
MA, USA). Mouse monoclonal anti-beta actin antibody (A1978) was from Sigma-Aldrich (St 
Louis, MO, USA). For secondary antibodies, horse anti-mouse IgG-HRP antibody (7076S) was 
purchased from Cell Signaling Technologies, goat anti-rabbit IgG-HRP antibody (sc-2030) was 
obtained from Santa Cruz Biotechnology. Olaparib (AZD2281, Ku-0059436) and rucaparib was 
purchased from Selleckchem (TX, USA). Stock solutions were made with DMSO at 50 mM and 
stored at -80 °C. ZBC260 was provided by Dr. Shaomeng Wang from the University of Michigan. 
The stock solution was made with DMSO in 10 mM and aliquot to store at -80°C. (+)-JQ1 was 
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kindly provided by Bradner lab in Dana-Farber Cancer Institute. The stock solution was made in 
DMSO at 50 mM aliquots and stored at -80 °C. 
Immunoblotting 
Cells were washed at least twice with PBS at the end of treatments if applicable and then lysed 
with an appropriate volume of 1X electrophoresis sample buffer (Bio-Rad Laboratories, CA, USA) 
with 5% β-mercaptoethanol (Sigma-Aldrich). The cell lysates were heated to 95 °C for 5 minutes 
before using. Immunoblotting procedures were performed as previously described (Zhang, Cheng 
et al. 2014). For apoptosis markers, cells were collected at the end of treatments, and total proteins 
were extracted using RIPA buffer (1% NP-40, 0.5% sodium deoxycholate and 0.1% SDS in 1 X 
PBS) containing protease/phosphatase inhibitor cocktail (Roche). BCA protein assay reagent kit 
(Pierce) was used to determine protein concentrations. Equal amounts of total proteins were loaded 
for SDS-PAGE and transferred onto PVDF membranes (GE healthcare).  
Chromatin Immunoprecipitation (ChIP)-qPCR 
Chromatin Immunoprecipitation was carried out as described before (Johnson, Mortazavi et al. 
2007). Briefly, after 20 µM olaparib treatment for 12 hours or 24 hours, cells were cross-linked 
with 1% formaldehyde (Electron Microscopy Sciences, USA) for 10 min and quenched by cross-
linking with excess glycine. The chromatin was sonicated with a Bioruptor Twin (Diagenode) at 
maximum setting for 12 min (30 s on, 30 s off). The sonicated chromatin was incubated with 1.0 
µg FOXM1 antibody (C-20, sc-502, Santa Cruz Technology, USA) at 4 °C for 2-4 hours before 
purification with 100 µL Protein A/G magnetic beads (88803, Pierce). The beads were washed 
five times with LiCl wash buffer (100 mM Tris pH7.5, 500 mM LiCl, 1% NP-40, 1% sodium 
deoxycholate), one time with TE buffer (10 mM Tris-HCl pH7.5 and 0.1 mM Na2EDTA), and 
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were then eluted with Elution Buffer (1% SDS and 0.1 M NaHCO3). After reverse-crosslinking, 
the DNA was purified with the QIAQuick PCR cleanup kit (QIAGEN) and used for qPCR, which 
was performed in a CFX384 TouchTM Real-Time PCR Detection System (Bio-Rad) using RT2 




target Forward Reverse 
FOXM1(total) 5ʹAGAATTGTCACCTGGAGCAG 5ʹTTCCTCTCAGTGCTGTTGATG 




BRCA2 5’TTCATGGAGCAGAACTGGTG 5’AGGAAAAGGTCTAGGGTCAGG 
BRIP1 5’GCTTAGCCTTACTTTGTTCTGC 5’TTTCACTTACGCCCTCATCTG 
18S rRNA 5’GCCCGAAGCGTTTACTTTGA 5’TCCATTATTCCTAGCTGCGGTA
TC 
GAPDH 5’GAAACTGTGGCGTGATGGC 5’CACCACTGACACGTTGGCAG 
CCNB1 




FOXM1 BS 5’CAAGGTACAATCAGAGGATGGG 5’TCCTCTTCCGTCTCTTTCCT 
RAD51 
FOXM1 BS 5’ACCAGGCAGAGAATCTTGTTC 5’TTCAAGTCTAACCCAGTGCAG 
RAD51 MYC 
BS 5'GCTCCATTTCCCACTTCTATCC 5'CTTTTGGCACTTCTGGTCG 
BRCA1 MYC 




Real-time quantitative PCR (RT-qPCR) 
72 hours after siRNA transfection, total RNA from the cells was extracted with the Trizol reagent 
(15596-028, Invitrogen) according to the manufacturer’s protocol. The cDNA was synthesized 
using SuperScript II reverse transcriptase (180604014, Invitrogen) with 1 µg of total RNA in a 20 
µL reaction. The resulting cDNA was diluted 1:20 in nuclease-free water, and 1 µL was used per 
qPCR reaction in triplicates. qPCR was carried out using Power SYBR Green PCR Master Mix 
(4367659, Thermo Fisher Scientific) on a CFX384 Real-Time PCR Detection System (Bio-Rad) 
including a non-template negative control. Amplification of GAPDH or 18S rRNA was used to 
normalize the level of mRNA expression. The sequences of the primer pairs were listed in Table 
3.3.1. 
siRNA transfection and gene expression analysis 
FOXM1-specific siRNAs and scrambled negative control siRNAs were synthesized by Integrated 
DNA Technologies (IDT, Coralville, IA, USA). 3.5 x 105 cells/well were seeded in 6-well plates 
and incubated at 37 °C overnight. The next day, 20 nM of each siRNA was transfected into the 
cells with Oligofectamine Transfection Reagent (12252011, Invitrogen) according to 
manufacturer’s instructions. Culture media was added 6-8 hours after transfection without washing 
cells. 48 hours after siRNA transfection, cells were trypsinized and seeded in 6-well plates and 
kept overnight. Approximately 72 hours after siRNA transfection, cells were treated with vehicle, 
1 µM or 5 µM (+)-JQ1 for 24 hours before the Western blot analysis. To check the downregulation 
of FOXM1 expression, the transfected cells were collected to extract total RNA for qRT-PCR or 
proteins for the Western blot analysis at 72 hours after transfection. The sequences of siRNAs used 
are listed below: 
 99 
FOXM1 siRNA#1: sense rGrUrGrCrCrArArCrCrGrCrUrArCrUrUrGrArCrArUrUrGGA, 
antisense rUrCrCrArArUrGrUrCrArArGrUrArGrCrGrGrUrUrGrGrCrArCrUrG; 
FOXM1 siRNA#2: sense rGrCrGrCrUrArUrUrArGrArUrGrUrUrUrCrUrCrUrGrArUAA, 
antisense rUrUrArUrCrArGrArGrArArArCrArUrCrUrArArUrArGrCrGrCrArC. 
c-MYC siRNA#1: sense rArUrCrArUrUrGrArGrCrCrArArArUrCrUrUrArArArArAAA, 
antisense rUrUrUrUrUrUrUrArArGrArUrUrUrGrGrCrUrCrArArUrGrArUrArU; 
c-MYC siRNA#2: sense rCrGrArCrGrArGrArCrCrUrUrCrArUrCrArArArArArCrATC, antisense 
rGrArUrGrUrUrUrUrUrGrArUrGrArArGrGrUrCrUrCrGrUrCrGrUrC. 
Cytotoxicity assay using Sulforhodamine B (SRB) and drug synergy studies 
SRB assays were performed as previously described (Vichai and Kirtikara 2006) (Bastola, Neums 
et al. 2016) with some modifications shown below. For OVCA420*, OV90, and ES-2 cells, 3000 
cells/well were seeded in 96-well plates and treated with drugs after12 hours of seeding. The cells 
were incubated for another 3 days. Dose-response curves and IC50 for each drug were determined 
by GraphPad Prism (ver. 6) with four parameters. All curves were constrained with 100% at the 
top. Synergy was determined by calculating the combination index (CI) obtained from the plate 
reading. CI was calculated based on dividing the expected additive effect by the observed effect. 
Colony formation assay 
For OVCA420*, OV90, and ES-2, 1000 cells were seeded in 6-well plates. For MDA-MB-436 
rucaparib resistant cells (RR-1 and RR-2), 2000 or 3000 cells per well were seeded in 6-well plates. 
The cells were treated with drugs after 12 hours of seeding and further incubated for another 3 
days before changing to fresh media. The medium was changed every 3 days to allow colonies to 
form. At the end of experiments, colonies were stained with SRB and imaged with Molecular 
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Imager ChemiDoc MP System (Bio-Rad). Stained SRB was later dissolved and measured with a 
plate reader. The analysis of clonogenic assay was performed in GraphPad Prism (ver. 6).  
Statistical analysis 
All data were analyzed using GraphPad Prism (ver. 6). Results were expressed as means ± standard 
error of the mean (SEM.) unless otherwise indicated. Differences between treatment regimens 
were analyzed by one-way ANOVA or two-tailed Student’s t-test. p≤0.05 was considered to be 
statistically significant, *p=0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
3.4 Results 
3.4.1 FOXM1 knockdown results in the upregulation of c-MYC in ovarian cancer cells 
FOXM1 has been shown to regulate DNA repair genes (Raychaudhuri and Park 2011). Therefore, 
we tested the effects of FOXM1 knockdown by siRNAs on the expression of known FOXM1 
target genes in DNA repair pathway, including BRCA1, BRCA2, BRIP1, and FANCF. In ovarian 
cancer ES-2 cells at 72 hours after siRNA transfection, two independent FOXM1 siRNAs caused 
more than 50% reduction of FOXM1 mRNA levels (Figure 3.4.1.A) and a more dramatic decrease 
in protein levels (Figure 3.4.1.B). However, we did not observe a significant decrease in mRNA 
levels of BRCA1, BRCA2, and FANCF after FOXM1 knockdown in these cells. This finding 
suggests that FOXM1 might not be the main transcription factor that regulates the expression of 
these genes, which is consistent with previous reports (Kwok, Peck et al. 2010). Meanwhile, we 
observed a slight downregulation of BRIP1 mRNAs with both FOXM1 siRNAs, which indicates 
the direct regulation of BRIP1 by FOXM1 and consistent with a previous report (Monteiro, 
Khongkow et al. 2013). The slight downregulation also suggests that FOXM1 might be only one 
of many transcription factors regulating the expression of BRIP1. Taken together, we conclude 
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that FOXM1 downregulation is not sufficient to downregulate the tested target genes in the DNA 
repair pathway. Interestingly, we observed an increase in the levels of c-MYC protein after 
FOXM1 knockdown for 72 hours by siRNAs in ES-2 cell. The increase of c-MYC protein 
expression was suppressed with MYC siRNA transfection (Figure 3.4.1.B). In another cancer cell 
line OVCA420*, we also observed the upregulation of c-MYC at 72 hours after FOXM1 
knockdown (Figure 3.4.1.C). These data suggest that FOXM1 knockdown results in an increase in 
c-MYC expression, which might potentially serve as a compensatory mechanism to regulate the 





Figure 3.4.1: FOXM1 knockdown results in the upregulation of c-MYC in ovarian cancer cells. (A) 
FOXM1 knockdown is not sufficient to downregulate its target genes in HR pathway. ES-2 cells were 
transfected with scrambled siRNA (scr si) or two different FOXM1 siRNAs for 72 hours. Total RNAs were 
extracted and reverse transcribed to generate cDNA for qRT-PCR. Data are shown as mRNA expression 
level relative to scr siRNA with mean ± SEM. Results shown as one representative experiment with 
triplicates. (B-C) FOXM1 knockdown results in an increase in c-MYC expression. (B) 72 hours after siRNA 
transfection, ES-2 cells were collected for the Western blot analysis. Specific antibodies for FOXM1 and 
c-MYC were used, b-actin was used as a loading control. (C) Representative Western blots for ES-2 and 
OVCA420* cells. Experiments were done 72 hours after siRNA transfection. Results are representatives 
from at least three independent experiments. 
  
 103 
3.4.2 DNA repair genes are regulated by both FOXM1 and c-MYC 
Next, we are interested to know whether the target DNA repair genes are regulated by both 
transcription factors, FOXM1 and c-MYC. We analyzed data from the ENCODE (Encyclopedia 
of DNA Element) project available through the UCSC genome browser. We found 21,667 binding 
sites across the genome for FOXM1, and 96,959 binding sites for MYC. We observed 6,453 
regions that have at least 70% overlap of binding sites for both FOXM1 and MYC. Next, we 
limited our analysis to the overlapping binding sites located in regulatory regions next to the target 
genes (10 kb upstream and 1 kb downstream from transcription start site), and we observed 62% 
of those overlapping binding sites are proximity to genes (Figure 3.4.2.A). Annotation of 
overlapping regions to proximal genes identified several DNA repair genes (Table 3.4.1), 
including ATM, ATR, BRIP1, RAD51B, RAD51D, RAD50, XPC, XRCC3, and others. The disease 
ontology analysis of proximal genes associated with the overlapping binding sites for FOXM1 and 
MYC suggests that one of the most significantly disease is hereditary breast and ovarian cancer 
(HBOC) (Figure 3.4.2.B). These results suggest that FOXM1 and MYC share target genes that are 
associated with hereditary breast and ovarian cancer and these target genes are involved in DNA 
repair, DNA damage response, HR pathway, and Fanconi anemia pathway. This finding provides 
us a rationale to target both FOXM1 and c-MYC to induce “BRCAness” in the PARP inhibitor 








Figure 3.4.2: ENCODE data analysis reveals that DNA repair genes are regulated by both FOXM1 
and c-MYC. (A) ENCODE data analysis indicates FOXM1 and MYC share 6,453 binding sites with at 
least 70% overlap of regions for both transcription factors. 62% of these sites are located proximal (10 kb 
upstream or 1 kb downstream) to the genes. (B) Disease ontology analysis of genes with overlapping 
regulatory regions for FOXM1 and MYC reveals that one of the significantly associated diseases is 




Table 3.4.1 Genes associated with Disease Ontology for Hereditary Breast and Ovarian Cancer 
 
DNA repair genes are highlighted in bold. Values in parenthesis are distance in nucleotide base for 
overlapping binding sites for FOXM1 and MYC relative to transcription start site (TSS). Negative values 
represent upstream from TSS. Positive values represent downstream from TSS.  
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3.4.3 FOXM1, MYC, and BRD4 are highly expressed in ovarian cancer and their expressions 
are related to each other 
To corroborate our in vitro observation, we analyzed datasets from the Cancer Genome Atlas 
(TCGA). FOXM1 and MYC are found to have higher median mRNA expression levels across 24 
different types of cancer compared to normal tissue in TCGA datasets. Ovarian carcinomas have 
the second highest FOXM1 expression among these 24 types of cancer (Figure 3.4.3.A). Similarly, 
ovarian carcinomas have the fourth highest MYC expression following after Uveal melanoma, 
colorectal, and head & neck cancer (Figure 3.4.3.B). Bromodomain-containing protein 4 (BRD4) 
is a member of the BET (bromodomain and extra-terminal domain) protein family and has been 
implicated in promoting gene transcription through interaction with the transcription elongation 
factor P-TEFb and RNA polymerase II (Itzen, Greifenberg et al. 2014). MYC expression is 
positively regulated by BRD4 (Delmore, Issa et al. 2011). Studies have shown that BRD4 also 
regulates FOXM1 expression (Zhang, Ma et al. 2016). We also analyzed the expression of BRD4 
from TCGA datasets, and we found that BRD4 also has a higher median expression in multiple 
types of cancer, with ovarian carcinomas having the highest expression (Figure 3.4.3.C), which is 
consistent with the observation from Zhang et al (2016) (Zhang, Ma et al. 2016). Meanwhile, the 
expression correlation analysis indicates that expression of FOXM1 and MYC shows a mild 
negative correlation (Figure 3.4.3.D), which is consistent with our observation that FOXM1 
knockdown leads to upregulation of c-MYC (Figure 3.4.1.A-C). We also observed mild positive 
correlations between BRD4 and FOXM1 as well as between BRD4 and MYC, which is consistent 
with previous reports (Delmore, Issa et al. 2011, Zhang, Ma et al. 2016). Taken together, these 
data suggest that FOXM1, MYC, and BRD4 are highly expressed in ovarian cancer and BRD4 
expression is positively correlated with FOXM1 and MYC, suggesting that targeting BRD4 may 
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suppress the expression of both FOXM1 and MYC and downregulate their downstream target 
genes involved in DNA repair. The downregulation of consequential downstream target genes in 







Figure 3.4.3 Cont. 
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Figure 3.4.3: FOXM1, MYC, and BRD4 are highly expressed in ovarian cancer. (A-C) The analysis of 
TCGA datasets reveals high median expression of mRNAs of FOXM1 (A), MYC (B), and BRD4 (C) in 
many types of tumors, including ovarian tumors, compared to normal tissue. (D-F) Correlation analysis 
reveals that expression of FOXM1 and MYC shows a mild negative correlation, whereas FOXM1 and MYC 
expression are mildly positive-correlated with BRD4 expression.  
  
 111 
3.4.4 BET inhibitor (+)-JQ1 induces “BRCAness” in ovarian cancer cells 
BET inhibitors are small molecules that bind to the BET bromodomains and block the interaction 
of BET proteins (BRD2,3,4 and BRDT) with acetylated lysine residues on histone tails to regulate 
gene transcription (Garnier JM, et al., 2014; Junwei S, et al., 2014). They have been shown to 
block c-MYC expression in pre-clinical cancer models. BET inhibitors have also been reported to 
disrupt FOXM1 pathway and show efficacy in ovarian carcinomas (Zhang et al., 2016). We 
propose to use BET inhibitor to inhibit BRD4 to achieve downregulation of both c-MYC and 
FOXM1, thereby suppressing the expression of their downstream target DNA repair genes, 
especially the HR genes, such as BRCA1 and RAD51, and inducing “BRCAness” to sensitize 
cancer cells to PARP inhibitor. 
 We used one of the pre-clinical BET inhibitors, (+)-JQ1, which has been shown to work in 
nanomolar concentrations (Delmore, Issa et al. 2011). First, we tested whether (+)-JQ1 can 
downregulate c-MYC expression induced by FOXM1 knockdown. In ES-2 cell, we observed 
downregulation of both FOXM1 and c-MYC with (+)-JQ1 treatment in the control siRNA-
transfected group, with FOXM1 being downregulated to a greater extent than c-MYC (Figure 
3.4.4.A). (+)-JQ1 treatment also attenuated the c-MYC expression induced by the FOXM1 
knockdown at 72 hours, and (+)-JQ1 further decreases FOXM1 expression (Figure 3.4.4.A). The 
extent of c-MYC downregulation is not as robust as FOXM1, suggesting that c-MYC expression 
is not primarily dependent on BET proteins in these cells. Next, we tested if (+)-JQ1 can 
downregulate HR genes, BRCA1 and RAD51, in three cancer cell lines, OVCA420*, OV90, and 
ES-2, that are relatively insensitive to olaparib (as shown in chapter 2). Twenty-four hours after 
(+)-JQ1 treatment, we saw a consistent dose-dependent downregulation of FOXM1 in all three 
cell lines (Figure 3.4.4.B), and a consistent efficient downregulation of c-MYC with higher 
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concentrations of (+)-JQ1 in OVCA420* and OV90 cells (Figure 3.4.4.B). At the same time, we 
examined the expression of BRCA1 and RAD51, whose expression is regulated by both FOXM1 
and c-MYC according to our analysis of ENCODE data (Figure 3.4.4.C). We saw a consistent 
dose-dependent downregulation of both BRCA1 and RAD51 by (+)-JQ1 in all three cell lines 
(Figure 3.4.4.B). We also performed ChIP (chromatin immunoprecipitation) analysis with 
FOXM1 or c-MYC pull down after (+)-JQ1 treatment in OVCA420* cells and observed that the 
binding of both FOXM1 and c-MYC to the promoters of both BRCA1 and RAD51 decreased 
significantly in cells treated with 5 µM (+)-JQ1 for 24 hours compared to vehicle-treated groups 
(Figure 3.4.4.D). These data suggest that the downregulation of BRCA1 and RAD51 by (+)-JQ1 is 
in part due to a decrease in transactivation by both FOXM1 and c-MYC through decreased binding 






Figure 3.4.4: BET inhibitor, (+)-JQ1, induces “BRCAness” in ovarian cancer cells. (A) (+)-JQ1 
attenuates c-MYC expression induced by the FOXM1 knockdown. Forty-eight hours after siRNA 
transfection, vehicle, 1 µM or 5 µM of (+)-JQ1 were added to ES-2 cells and treated for another 24 hours 
before the Western blot analysis. (B) (+)-JQ1 downregulates FOXM1, c-MYC and their targets, BRCA1 
and RAD51, in a dose-dependent manner in three different cell lines, ES-2 (B), OV90 (C) and OVCA420* 
(D). (C) Both FOXM1 and c-MYC have binding sites in promoter regions of BRCA1 and RAD51. The 
image file was generated from ENCODE data in UCSC genome browser. (D) ChIP-qPCR analysis indicates 
the decreased binding of both FOXM1 and c-MYC to promoter sequences of BRCA1 and RAD51 in 
OVCA420* cells that were treated with (+)-JQ1. Cells were treated with vehicle or 1 µM (+)-JQ1 for 24 
hours before ChIP analysis. CCNB1 is a positive control for FOXM1 binding. Data are shown as % of 
enrichment relative to input with mean ± SEM. Statistics analysis was done using the Student’s t-test. 
**p<0.01, ****p<0.0001. Results are representatives from three independent experiments. 
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3.4.5 (+)-JQ1 sensitizes cancer cells with primary resistance to PARP inhibitor 
Next, we tested whether (+)-JQ1 can make PARP inhibitor resistant cancer cells more sensitive. 
First, we performed a short-term cell viability assay to test the effects of (+)-JQ1 in three different 
cancer cells, and we observed a dose-dependent decrease in cell viability with (+)-JQ1 treatment 
(Figure 3.4.5.A). We also observed that the IC50 for (+)-JQ1 in these cells are in micromolar range, 
and ES-2 cell is more sensitive to (+)-JQ1 compared to the other two cells. Next, we used SRB 
assay to test the effects of (+)-JQ1 in combination with the FDA-approved PARP inhibitor, 
olaparib. We observed a weak synergy between (+)-JQ1 and olaparib in ES-2 and OV90 cells, and 
an additive effect in OVCA420* cells (Figure 3.4.5.B). We also performed a long-term colony 
formation assay (Figure 3.4.5.C-E). (+)-JQ1 treatment by itself leads to a reduction of colony 
formation in all three cells and resulted in a complete inhibition of colony formation when 
combined with sub-lethal doses of olaparib. We calculated the combination indexes and observed 
a moderate synergistic effect between (+)-JQ1 and olaparib. These data suggest that (+)-JQ1 






Figure 3.4.5: (+)-JQ1 sensitizes PARP inhibitor-insensitive cells to olaparib. A) (+)-JQ1 dose-
dependently decreases cell viability in all three cancer cells. Cells were treated with increasing 
concentrations of (+)-JQ1 for 3 days in 96-well plates before Sulforhodamine B (SRB) cell viability assay. 
Data are shown as % of cell viability relative to the vehicle with mean ± SEM. Results represent one 
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representative experiments with triplicates. B) (+)-JQ1 and olaparib showed additive or weak synergistic 
effects when combined together in cancer cells by short-term SRB assay. Results represent one 
representative experiments with four replicates. C-D) Long-term colony formation assay showed moderate 
synergistic effects of (+)-JQ1 and olaparib. OVCA420*, OV90, and ES-2 cells were seeded in 6-well plates 
and treated with different concentrations of the single drug, olaparib or (+)-JQ1, or different combinations 
of two drugs. Drugs were washed away 3 days later, and cells were fed with fresh media every 3-4 days for 
two weeks. Colonies were stained with SRB, imaged and counted. CI was calculated and indicated in the 
line graph for each combination. Line graph data are shown as % of colony formation relative to the vehicle 
with mean ± SEM. Results were from one representative experiment with duplicates. 
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3.4.6 (+)-JQ1 enhances effects of PARP inhibitor in cancer cells with acquired resistance to 
rucaparib 
To test whether BET inhibitor can resensitize cancer cells with acquired resistance to PARP 
inhibitor, we used rucaparib-resistant cancer cells that were derived from a continuous exposure 
to PARP inhibitor rucaparib (Johnson, Johnson et al. 2013), named as RR-1 and RR-2. Using 
Western blot, we observed that (+)-JQ1 treatment consistently lead to decreased FOXM1 
expression in two different resistant clones, however, we only saw c-MYC being downregulated 
moderately with a high concentration of (+)-JQ1 in RR-1 and no decrease in RR-2 (Figure 
3.4.6.A). RAD51 protein was consistently downregulated by (+)-JQ1 treatment. The resistance to 
rucaparib was mediated by the stabilization of the mutant BRCA1 (mtBRCA1) protein in these 
cells, and the resistance can be overcome by HSP90 inhibitor, which leads to the downregulation 
of stabilized mtBRCA1 (Johnson, Johnson et al. 2013). Interestingly, we also saw a dramatic 
decrease of mtBRCA1 protein level with (+)-JQ1 treatment (Figure 3.4.6.A). Next, we performed 
colony formation assay to assess the effect of combining (+)-JQ1 and rucaparib. Similar to PARPi-
insensitive cancer cells, we observed a dose-dependent decrease of colony formation in these 
resistant cells with (+)-JQ1 treatment, with RR-1 being more responsive than RR-2. This is 
consistent with the Western blot results that demonstrated c-MYC is not downregulated by (+)-
JQ1 treatment in RR-2 but moderately downregulated in RR-1 (Figure 3.4.6.A). Consistent with 
the downregulation of both FOXM1 and c-MYC by (+)-JQ1 treatment, RR-1 showed a greater 
extent of the decrease in colony formation (Figure 3.4.6.B-C). Strikingly, in combinations of 1 µM 
rucaparib with 500 nM (+)-JQ1, or 2.5 µM rucaparib with 300 nM (+)-JQ1, the colony formation 
was completely inhibited in RR-1. In RR-2, combinations of 1 µM (+)-JQ1 and sub-lethal doses 
of rucaparib also completely inhibited colony formation (Figure 3.4.6.D-E). Combination indexes 
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indicate an overall moderate synergistic effect between (+)-JQ1 and rucaparib (Figure 3.4.6.C and 
Figure 3.4.6.E). Taken together, these data suggest that (+)-JQ1 treatment can help restore 
sensitivity to rucaparib in cancer cells with an acquired resistance to rucaparib in part by 
downregulating FOXM1 and c-MYC, RAD51 and mtBRCA1. These results indicate the potential 






Figure 3.4.6: (+)-JQ1 enhances the effects of PARP inhibitor in cancer cells with an acquired 
resistance to rucaparib. A) (+)-JQ1 treatment decreased the expression of FOXM1, c-MYC, RAD51 and 
mtBRCA1 in rucaparib-resistant cells. Cells were treated with (+)-JQ1 at indicated concentrations for 36 
hours. Representative results were shown from three independent experiments. B-E) colony formation 
assay to test the combined effect of (+)-JQ1 and rucaparib. Representative images and quantification of 
colonies were shown. Data are shown as mean ± SEM. CI is also indicated in the graph. Results were shown 
from one representative experiment with duplicates.  
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3.4.7 PROTAC-based BET domain protein degrader downregulates BRCA1 and RAD51 
As a BET inhibitor, (+)-JQ1 has not been evaluated in the clinic because of its short half-life 
observed in preclinical in vivo study (Filippakopoulos, Qi et al. 2010). Considering the potential 
clinical use of the BET inhibitor in combination with PARP inhibitor, we tested a recently 
developed PROTAC (proteolysis targeting chimera)-based BET domain protein degrader 
(ZBC260), which has been shown to degrade BRD proteins with a greater potency (Zhou, Hu et 
al. 2017). We tested the effects of ZBC260 in three different cell lines and observed that ZBC260 
efficiently downregulates BRD4 starting from as low as 3 nM, and BRD4 was completely depleted 
with concentrations > 10 nM (Figure 3.4.7.A-C). These preliminary results suggest that ZBC260 
is very efficient in suppressing and inhibiting BRD4 in our cells. In all three cell lines, FOXM1 
was consistently downregulated by ZBC260 following a decrease of BRD4 (Figure 3.4.7.A-C). 
However, only in OVCA420* and OV90, we saw downregulation of c-MYC (Figure 3.4.7.A-B). 
Tested target genes of FOXM1 and c-MYC, such as BRCA1 and RAD51, were also consistently 
downregulated following ZBC260 exposure to a greater extent at drug concentrations that are 
lower than (+)-JQ1 (Figure 3.4.4.B-D). We also tested the drug with short-term SRB assay and 
observed a dose-dependent reduction of cell viability with much lower concentrations of ZBC260 
compared to (+)-JQ1 (Figure 3.4.5.A). Similar to (+)-JQ1, three cells responded to ZBC260 
differently, with ES-2 cell being more sensitive than the other two cell lines (Figure 3.4.7.D). 
These data suggest that BET protein degrader is effective in downregulating FOXM1, c-MYC, 





Figure 3.4.7: PROTAC BET domain protein degrader ZBC260 downregulates BRCA1 and RAD51. 
A-C) Western blot shows the effect of ZBC260 in downregulating FOXM1, c-MYC, BRCA1, and RAD51. 
OVCA420* (A), OV90 (B) and ES-2 (C) were treated with vehicle, 3, 10, 30, 100 or 300 nM of ZBC260 
for 24 hours. Results represent one experiment from three independent experiments. (D) SRB cell viability 
assay with ZBC260. A dose-dependent decrease of cell viability with ZBC260 treatment is observed in all 
three cells. Data are shown as percent (%) of cell viability relative to the vehicle with mean ± SEM. IC50s 




In this chapter, we demonstrated that exposure of ovarian cell line to BET inhibitors can lead to 
suppression of the expression of FOXM1 and c-MYC and downregulate the expression of 
downstream overlapping target genes, BRCA1 and RAD51, which are involved in the HR pathway. 
Furthermore, we showed that the BET inhibitor, (+)-JQ1 can enhance the effect of PARP inhibitors 
in cancer cells with either primary or acquired resistance to PARP inhibitors. These data suggest 
that (+)-JQ1, as a BET inhibitor induces “BRCAness” in HR-proficient cancer cells to overcome 
PARP inhibitor resistance. Furthermore, BET inhibitor may be combined with PARP inhibitor to 
potentiate the effect of PARP inhibitor in patients with HR-proficient tumors.   
 In chapter 2, I showed that FOXM1 expression contributes to PARP inhibitor resistance, and 
upregulation of FOXM1 positively regulates HR genes, including BRCA1 and RAD51, to enhance 
DNA repair. We noted that PARP inhibitor resistance was reversed by FOXM1 inhibition with 
either siRNAs or FOXM1 inhibitor, thiostrepton. Thiostrepton treatment leads to downregulation 
of HR genes. In this chapter, using FOXM1 specific siRNA, we saw consistent downregulation of 
FOXM1 expression; however, its target genes, such as BRCA1, BRCA2, and FANCF, remained 
unchanged. Previous reports also failed to see the downregulation of FOXM1 target genes, such 
as BRCA2 and XRCC3, following the FOXM1 knockdown (Kwok, Peck et al. 2010), suggesting 
that other transcription factors also regulate the expression of these genes. Interestingly, following 
FOXM1 knockdown, we saw upregulation of c-MYC in two different cell lines. The analysis of 
ENCODE data showed that thousands of genes have binding sites for both FOXM1 and c-MYC 
in their regulatory regions. Furthermore, there are 6,453 shared binding sites of FOXM1 and c-
MYC that show at least 70% sequence overlap, including a list of DNA repair genes, such as ATM, 
ATR, BRIP1, RAD50, and etc. Also, disease ontology analysis of these genes suggests that one of 
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the most significantly associated diseases is the hereditary breast and ovarian cancer. Based on 
these observations, we hypothesized that FOXM1 and c-MYC co-regulate the expression of HR 
genes, such as BRCA1 and RAD51, and that inhibition of both genes is necessary to decrease the 
expression of HR genes, to induce “BRCAness”, and to sensitize resistant cancer cells to PARP 
inhibitors.  
 BET inhibitor (+)-JQ1 has been shown to successfully inhibit c-MYC expression and MYC 
pathway in preclinical studies (Delmore, Issa et al. 2011). Recent studies also indicate BET 
inhibitors, (+)-JQ1 and iBET, downregulate FOXM1, although the molecular mechanism is not 
well-characterized (Zhang, Ma et al. 2016). Therefore, we tested the effect of BET inhibitor in 
cancer cells. (+)-JQ1 is a widely used BET inhibitor for in vitro studies, and we demonstrated that 
it can attenuate c-MYC expression induced by the FOXM1 knockdown. We also observed a 
consistent downregulation of both FOXM1 and c-MYC, as well as the downregulation of BRCA1 
and RAD51 in at least two different cancer cells. Interestingly, compared to the other two cell lines, 
c-MYC in ES-2 cell was not efficiently downregulated even with high concentrations of (+)-JQ1. 
This inefficient suppression of c-MYC expression by (+)-JQ1 suggests that c-MYC expression in 
this cell line might not be solely dependent on BET proteins. In contrast, FOXM1 expression was 
consistently downregulated by exposure to (+)-JQ1, suggesting that FOXM1 expression is 
dependent on BET proteins in these cells. We also tested the cytotoxic effect of (+)-JQ1 in breast 
cancer cells with the acquired resistance to PARP inhibitor rucaparib. The two resistant cells were 
derived from the originally sensitive MDA-MB-436 breast cancer cell with a chronic exposure to 
rucaparib (Johnson, Johnson et al. 2013). The main mechanism of resistance in these cells is the 
restoration of HR function by the stabilization of mutant BRCA1 (mtBRCA1) protein, which 
otherwise was quickly degraded in MDA-MB-436 cells. From the original study (Johnson, 
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Johnson et al. 2013), the resistance in these cells can be overcome by HSP90 inhibitor, which leads 
to HSP90 inhibition and destabilization of mtBRCA1, resulting in HR deficiency and restoration 
of PARP inhibitor sensitivity. Interestingly, we found that (+)-JQ1 treatment resulted in 
downregulation of the originally stabilized mtBRCA1 protein in these cells, and this effect might 
be a result of decreased transcription caused by inhibition of FOXM1 and c-MYC. However, 
further studies are needed to unveil how (+)-JQ1 treatment led to decreased mtBRCA1 in these 
resistant cells.  
 Results from the short-term cell viability assay indicate a weak synergistic or additive effect 
between (+)-JQ1 and olaparib or rucaparib in cancer cells with primary or acquired resistance to 
PARP inhibitors, respectively. However, the long-term colony formation assay showed stronger 
synergistic interactions between (+)-JQ1 and PARP inhibitors. Colony formation assay is more 
relevant to our current study because drug effects of PARP inhibitors rely on cell cycling (Stordal, 
Timms et al. 2013). Although the synergy we observed is not very strong, combinations of sub-
lethal doses of (+)-JQ1 and PARP inhibitor markedly suppress colony formation, suggesting the 
effectiveness of BET inhibitor in reducing the development of PARP inhibitor resistance. 
 Even though (+)-JQ1 had shown effectiveness in both in vitro and in vivo studies, it’s 
potential use for clinical evaluation was reconsidered because of its short half-life in vivo 
(Filippakopoulos, Qi et al. 2010). Based on our observations that the combination of (+)-JQ1 and 
PARP inhibitors give better therapeutic effects, it is important test the efficacy of this combination 
in clinical trials, and clinical trials rely on the availability of an effective and safe BET inhibitor 
candidate. As a result, we tested effects of a recently developed PROTAC BET protein degrader, 
ZBC260, which has been tested as a single agent for in vivo studies (Zhou, Hu et al. 2017), but not 
in combination with PARP inhibitor. Our data showed that it is effective in downregulating 
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FOXM1, c-MYC, BRCA1 and RAD51. It also inhibited cell growth in a dose-dependent manner 
with IC50s in the nanomolar range, suggesting that it is more potent than (+)-JQ1. In the future, the 
combined effects of ZBC260 and PARP inhibitors should be tested in cells with the primary or 
acquired resistance to PARP inhibitors, followed by the determination of the combined effects in 
patient-derived xenograft models. PARP inhibitors in combination with (+)-JQ1 have already been 
tested in several tumor xenograft models in mouse (Karakashev, Zhu et al. 2017, Yang, Zhang et 
al. 2017) and patient-derived xenograft (Garcia, Miller et al. 2016). Additional studies should focus 
on determining the combined effect in patient-derive xenograft models derived from HR-proficient 
cancer to demonstrate the extent to which BET degraders can extend the clinical utility of PARP 
inhibitors in treating patients with HR-proficient cancers.  
 Overall, in this chapter, we showed that BET inhibitors can inhibit the FOXM1-MYC nexus 
in cancer cells, downregulate BRCA1 and RAD51 to induce “BRCAness”, and that (+)-JQ1 
treatment can sensitize resistant cells to PARP inhibitors, suggesting that the combination of BET 
inhibitor and PARP inhibitor might be a new strategy to enhance therapeutic effects of PARP 
inhibitors. 
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Chapter 4. Genome-scale CRISPR knockout screen identifies TIGAR as a novel modifier 
of PARP inhibitor sensitivity 
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4.1 Abstract 
Cancer cells harboring homologous recombination defects (HRD) are shown to be sensitive to 
poly (ADP-ribose) polymerase (PARP) inhibitors. However, to which extent the therapeutic 
potential of PARP inhibitor can be explored still remains an active area of research. One of the 
key challenges is fully understanding of the molecular mechanisms that lead to PARP inhibitor 
sensitivity. In this study, using the sensitivity of PARP inhibitor olaparib as a surrogate, we 
performed a CRISPR/Cas9 based genome-scale loss-of-function screen and identified C12orf5, a 
gene that encodes a metabolic regulator, TP53 induced glycolysis and apoptosis regulator 
(TIGAR) as a novel potential genetic determinant of PARP inhibitor response. Further studies 
showed that several mechanisms contribute to olaparib sensitivity in TIGAR knockdown cells: (1) 
the increase in intracellular reactive oxygen species (ROS) level leads to enhanced DNA damage 
after olaparib treatment; and (2) induction of “BRCAness” by downregulation of BRCA1 and the 
Fanconi anemia (FA) pathway. In addition, TIGAR knockdown inhibits cell growth by induction 
of senescence. Concomitantly, TIGAR knockdown results in the reduced efficacy in spheroid 
formation and the enhanced therapeutic effects of olaparib. Finally, TCGA data analysis showed 
that TIGAR is amplified in different types of cancer including ovarian cancer, and higher 
expression of TIGAR is associated with poor overall survival in high-grade serous ovarian cancer. 
Taken together, this study showed that TIGAR negatively regulates PARP inhibitor sensitivity and 




Following the discovery that poly (ADP-ribose) polymerase (PARP) inhibitors cause synthetic 
lethality in cancer cells with BRCA1 or BRCA2 deficiencies (Bryant, Schultz et al. 2005, Farmer, 
McCabe et al. 2005), a number of PARP inhibitors were approved by the Federal Drug 
Administration as anti-cancer drugs for various cancers with either germline or somatic BRCA1 
and BRCA2 mutations.. It is now well accepted that PARP inhibitors are also active in cancers 
with the so-called “BRCAness” phenotype (Turner, Tutt et al. 2004, Lord and Ashworth 2016). 
This phenotype is found in tumors with homologous recombination (HR) defects resulting from 
alterations of components other than BRCA1 or BRCA2 in the HR pathway (McCabe, Turner et al. 
2006, Gaymes, Mohamedali et al. 2013, Gilardini Montani, Prodosmo et al. 2013, Bajrami, 
Frankum et al. 2014, Smith, Hampton et al. 2015). In addition, alterations in genes not directly 
related to the HR pathway, such as PTEN loss (Mendes-Pereira, Martin et al. 2009) and 
translocation in TMPRSS2-ERG (Brenner, Ateeq et al. 2011) and EWSR1-FLI1 (Garnett, Edelman 
et al. 2012), also result in the increased sensitivity of PARP inhibitors. These findings suggest that 
other molecular pathways unrelated to the HR pathway may also contribute to PARP inhibitor 
sensitivity. A better understanding of genetic determinants that contribute to PARP inhibitor 
sensitivity will extend the clinical utility of PARP inhibitors. 
 One of the challenges to further development of PARP inhibitors is to fully understand the 
molecular mechanisms contributing to PARP inhibitor sensitivity (Yap, Sandhu et al. 2011). To 
address this challenge, several studies have reported candidate genes that cause synthetic lethality 
with PARP inhibitors from genome-wide RNAi profiling and functional studies (Lord, McDonald 
et al. 2008, Turner, Lord et al. 2008, Bajrami, Frankum et al. 2014). These studies identified genes 
involved in DNA damage response (DDR) and repair pathways such as BRCA1, NBN, FANCD, 
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FANCC, RAD51, LIG3, RAD51C, RAD51D, RAD21, ESCO1, and SMC3, as well as genes 
involved in replication and cell cycle progression such as MCM proteins, TOP3A, POLB, and 
CDK7 as modulators of sensitivity to PARP inhibitors (Bajrami, Frankum et al. 2014). However, 
the clinical benefit of targeting these genes to enhance PARP inhibitor sensitivity is questionable 
given that the chemical inhibition of these genes may likely sensitize both normal and cancer cells 
to PARP inhibitors. Therefore, there is an urgent need to explore additional synthetic lethal targets 
for PARP inhibitors. 
 Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-directed Cas9-
mediated endonuclease activity can disrupt specific genetic sequences in the genome and provide 
a means to perform loss-of-function genetic screens (Koike-Yusa, Li et al. 2014, Shalem, Sanjana 
et al. 2014, Wang, Wei et al. 2014). When combined with sub-lethal doses of a PARP inhibitor, 
this approach may allow for the identification of genetic factors that, when disrupted, contribute 
to PARP inhibitor sensitivity or resistance. Unlike RNAi approaches, the CRISPR/Cas9 system 
provides a more thorough depletion of target gene expression with less off-target effects when the 
guide RNA (gRNA) is appropriately designed (Hart, Chandrashekhar et al. 2015, Munoz, Cassiani 
et al. 2016, Fei, Chen et al. 2017).  
 Therefore, we used the CRISPR/Cas9 system to perform a genome-scale loss-of-function 
screen to identify modifiers of olaparib sensitivity in cancer cells. From this screen, we identified 
C12ofr5, a gene that encodes a metabolic regulator, i.e., TP53-induced glycolysis and apoptosis 
regulator (TIGAR), as a candidate that modifies olaparib sensitivity in cancer cells. We found that 
downregulation of TIGAR results in the enhanced cytotoxic effect of olaparib. Our results indicate 
that TIGAR knockdown produces two complementary effects. Together, these effects enhance 
sensitivity to olaparib: (1) TIGAR knockdown inhibits the pentose phosphate pathway (PPP), 
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resulting in an increase in intracellular reactive oxygen species (ROS) that enhances DNA damage 
upon olaparib treatment, and (2) TIGAR knockdown induces “BRCAness” by downregulation of 
BRCA1 and the Fanconi anemia (FA) pathway.  Finally, relevant to the therapeutic effect, TIGAR 
knockdown inhibits cell growth by the induction of cellular senescence. While the first two effects 
provide mechanisms for how TIGAR downregulation sensitizes cancer cells to olaparib, the latter 
reveals TIGAR as a promising strategy to prevent cancer progression. Most importantly, these in 
vitro findings were further supported by data from The Cancer Genome Atlas (TCGA). These data 
show that TIGAR is amplified in different cancer types, including ovarian cancer and a higher 
expression of TIGAR is associated with the poor overall survival of patients with high-grade 
serous ovarian cancer. Collectively, these results indicate that TIGAR modifies the cellular 
response to PARP inhibitors in cancer cells and represents a therapeutic target for developing 
cancer therapies. 
4.3 Materials and Methods 
Cell lines and cell culture 
A2780 cells and ES-2 cells were maintained in MCDB105 and M199 (1:1) (Sigma, USA) 
containing 5% FBS (Sigma). OV90 cells were maintained in MCDB105 and M199 (1:1) with 15% 
FBS. OVCA420* cells were cultured in DMEM (Sigma and Caisson Labs, USA) supplemented 
with 10% FBS. All the media were supplemented with 100 units/mL penicillin and 100 µg/mL 
streptomycin. All cell lines were subjected to cell line identity confirmation. A2780-Cas9 stable 
cells were established by transducing A2780 cells with pLenti-cas9 followed by selection with 400 
ug/mL blasticidin for 2 weeks.  
Pooled Genome-Wide CRISPR Screen 
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Genome-scale CRISPR knock-out (GeCKO) v2.0 pooled libraries (Two-vector system) were 
purchased from Addgene. GeCKO library B was amplified and prepared as previously described 
(Sanjana, Shalem et al. 2014, Shalem, Sanjana et al. 2014). A2780 cells were infected with 
lentiviral particles of lenti-Cas9 at a multiplicity of infection (MOI) of ~1.0 followed by selection 
with blasticidin for 2 weeks to obtain the stable cell line expressing Cas9. The stable cells were 
then infected with the amplified lentiviral library B at an MOI of ~0.3. 3X107 cells were used and 
seeded in 100 mm dishes with 3×106 cells per dish. Puromycin was added the second day after 
lentiviral library infection and kept for 7 days. After selection, surviving cells were pooled together 
and split into three groups in duplicates and treated with DMSO, 5 µM or 10 µM olaparib for one 
week. For each treatment, 3×107 cells were used per replicate. Genomic DNA was extracted, and 
PCR was performed to prepare sequencing library as described before (Shalem, Sanjana et al. 
2014). The library was sequenced using a HiSeq 2500 (Illumina). Data analysis was performed by 
MAGeCK tool (Li, Xu et al. 2014). 
Lentiviral particle production 
Viral particles were produced by transient transfection of specific plasmids (GeCKO library B, 
lentiCas9-Blast, individual shRNA expressing plasmids) with psPAX2 and pMD2.G (Addgene) 
into HEK293T cells using Lipofectamine 2000 (Life Technologies). Media was collected 48 hours 
after transfection and centrifuged at 2,000 rpm at 4 °C for 10 min to pellet cell debris. The 
supernatant was filtered through a 0.45 µm low protein binding membrane (Millipore Steriflip 
HV/PVDF), and aliquots were stored at -80 °C. 
Antibodies and Chemicals 
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Mouse monoclonal anti-FLAG HRP-conjugated antibody (A8592) was purchased from Sigma. 
Rabbit polyclonal anti-TIGAR antibody (GTX110514) was from GeneTex (Irvine, CA, USA). 
Rabbit anti-Phospho-Histone H2A.X (Ser139) antibody (#2577) was purchased from Cell 
Signaling Technologies (Danvers, MA, USA). Rabbit polyclonal anti-BRCA1 antibody (C-20, sc-
642) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Mouse monoclonal 
anti-beta actin antibody (A1978) was from Sigma-Aldrich (St Louis, MO, USA). For secondary 
antibodies, horse anti-mouse IgG-HRP antibody (7076S) was purchased from Cell Signaling 
Technologies, and goat anti-rabbit IgG-HRP antibody (sc-2030) was from Santa Cruz 
Biotechnology. 
Olaparib (AZD2281, Ku-0059436) was purchased from Selleckchem. Olaparib stock solutions 
were made with DMSO at 50 mM and stored at -80°C. X-gal was purchased from Gold 
Biotechnology (St. Louis, MO), dissolved at 20 mg/mL in dimethylformamide, and stored at -20 
°C in dark. 
Immunoblotting 
Cells were washed at least twice with PBS at the end of treatments if applicable and then lysed 
with an appropriate volume of 1X electrophoresis sample buffer (Bio-Rad Laboratories, CA, USA) 
with 5% β-mercaptoethanol (Sigma-Aldrich). The cell lysates were heated to 95 °C for 5 minutes 
before using. Immunoblotting procedures were performed as previously described (Zhang, Cheng 
et al. 2014). Equal amounts of total proteins were loaded for SDS-PAGE and transferred onto 
PVDF membranes (GE healthcare).  
siRNA transfection 
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Gene-specific siRNAs and scrambled negative control siRNAs were synthesized by Integrated 
DNA Technologies (IDT, Coralville, IA, USA). 3.5 × 105 cells/well were seeded in 6-well plates 
and incubated at 37 °C overnight. Next day, 20 nanomolar of each siRNA was transfected into the 
cells with Oligofectamine Transfection Reagent (12252011, Invitrogen) according to 
manufacturer’s instructions. Culture media was added 6 to 8 hours after transfection without 
washing cells. 24 to 48 hours after transfection, the transfected cells were trypsinized and seeded 
on 96-well plates (for cytotoxicity assay) or 6-well plates (for colony formation assay). Drugs were 
added approximately 12 hours after seeding. For cytotoxicity assay, cells were incubated with drug 
for 3 days before measurement of cell viability using sulforhodamine B assay. For colony 
formation assay, cells were exposed to drugs for 3 days and then changed to fresh media without 
drug for at least 10 days until colonies were observed and stained with sulforhodamine B for 
imaging. To check the downregulation of gene expression, the transfected cells were collected to 
extract total RNA for qRT-PCR or proteins for the Western blot analysis three days after 




Table 4.3.1: DsiRNA sequences for candidate genes. 
siRNA Sense Strand Antisense Strand 
















































The total RNA was extracted with the Trizol reagent (15596-028, Invitrogen) according to the 
manufacturer’s manual. The cDNA was synthesized using SuperScript II reverse transcriptase 
(180604014, Invitrogen) with 1 µg of total RNA in a 20 µL reaction. The resulting cDNA was 
diluted 1:20 in nuclease-free water and 1 µL was used per qPCR reaction in triplicates. qPCR was 
carried out using Power SYBR Green PCR Master Mix (4367659, Thermo Fisher Scientific) on a 
CFX384 Real-Time PCR Detection System (Bio-Rad) including a non-template negative control. 
Amplification of GAPDH or 18S rRNA was used to normalize the level of mRNA expression. 
Primers used in the assays are shown in Table 4.3.2. 
shRNAs transduction 
shRNAs for C12orf5 were purchased from Sigma (SHCLNG-NM_020375). Lentiviral particles 
for shRNAs were produced as described above. Forty-eight hours after transfection, viral 
supernatant was collected and transduced into OVCA420* or OV90 cells. Experiments were 
conducted 2 days after viral transduction. 
Cytotoxicity assay using Sulforhodamine B (SRB) 
SRB assays were performed as previously described (Vichai and Kirtikara 2006) (Bastola, Neums 
et al. 2016) with a few modifications shown below. 3,000 cells/well were seeded in 96-well plates 
and treated with drugs after 12 hours of seeding. Cells were incubated for another 3 days. Dose-
response curves and IC50 were calculated for each drug using GraphPad Prism (ver. 6) employing 




Table 4.3.2: qRT-PCR primer sequences. 
 
Gene Forward Reverse 
C12orf5 5ʹGGAAGAGTGCCCTGTGTTTAC 5ʹAGTTGCTTGGAGATCCTTGG 
PARP1 5ʹAGAGAAAAGGCGATGAGGTG 5ʹTTAGCTCGTCCTTGATGTTCC 
NME2  5ʹCGAGCAGAAGGGATTGGC 5ʹTTCATGTACTTCACCAGCCC 
OR5J2  5ʹCAGCATTTGTGTTTCGGAGTG 5ʹAGCAAGGGACTCACAATGG 
IL21 5’ATCAAGCTCCCAAGGTCAAG 5’AGCTGACCACTCACAGTTTG 
GGT6 5’CTGAGACACAGCCGGAAAG 5’CCTCCTCCACTTCCTCCCTC 
NBPF9 5’TTGAATGAGCATCTCCAGGC 5’TCTTCGTCATTTTCTGGGCTG 
PA2G4 5’TTGTGGTTGATGTAGCTCAGG 3’GCAACTTTGTTCCAGGCTTC 
PIK3C2G 5’GCAAATTTACTGGCGTGGAC 5’GACTTACATCCCACACTCCTG 
BRCA1 5’TAATGCTATGCAGAAAATCTTAGAG 5’TACTTTCTTGTAGGCTCCTTTTGG 
CCNE2 5’CTGCCTTGTGCCATTTTACC 5’GTCTTCAGCTTCACTGGACTAG 
BLM 5’TGCTCTTGCTTACCATGCTG 5’GAATCACAAATCGCACGTCC 
ASF1B 5’CCTTTCCACAGCCCCTTC 5’AAATTCCTCACTCTCAGCCG 
CDC45 5’GGTTCAAGCACAAGTTTCTGG 5’GTACAGCTTGTCCAGGTTACTC 
ECSO2 5’CTGTGGGATAAGTAGAATCTGGG 5’GGTGTTGGGTCAGAAAATGC 
MAD2L1 5’GACAGATCACAGCTACGGTG 5’GGCGGACTTCCTCAGAATTG 
MCM10 5’AACCAGCCATCAAGTCCATC 5’TGGGCTCTCAACTTCACTTG 
MKI67 5’AAAAGAATTGAACCTGCGGAAG 5’AGTCTTATTTTGGCGTCTGGAG 
MYBL2 5’TGTGGATGAGGATGTGAAGC 5’TGAGGCTGGAAGAGTTTGAAG 
PCNA 5’CCGAAACCAGCTAGACTTTCC 5’GATGAGGTCCTTGAGTGCC 
TCF19 5’TGGCCTCATCTCTGGGATC 5’TCTCCATCACTCAATTCCAGC 
UBE2C 5’TCTGGCGATAAAGGGATTTCTG 5’CTTGAGTTTCTCTGGGACCG 
GAPDH 5’GAAACTGTGGCGTGATGGC 5’CACCACTGACACGTTGGCAG 
18S rRNA 5’GCCCGAAGCGTTTACTTTGA 5’TCCATTATTCCTAGCTGCGGTATC 
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Colony formation assay 
500 to 1,000 cells were seeded in 6-well plates and treated with drugs after 12 hours of seeding. 
Cells were incubated for another 3 days before changing to fresh media. The medium was changed 
every 2 to 3 days to allow colonies to form. At the end of experiments, colonies were stained with 
SRB and imaged with Molecular Imager GelDoc XR System (Bio-Rad). The stained SRB was 
solubilized in Tris buffer and measured with a plate reader. The analysis of colonies was performed 
in GraphPad Prism (ver. 6).  
Analysis of apoptosis with Annexin V/PI staining 
Cells were transfected with scrambled siRNA or C12orf5 siRNA and reseeded into 6-well plates 
after 24 hours of transfection, followed by treatment with Vehicle, 10 µM or 20 µM of olaparib 
for additional 48 hours. Cells were then subject to Annexin V/PI staining following manufacturer’s 
instruction (#640906, Biolegend). Briefly, cells were washed twice with PBS and stained with 
Annexin V and PI solution for 15 minutes at room temperature in the dark before analysis by flow 
cytometry. 
Measurement of Intracellular Reactive Oxygen Species (ROS) 
Intracellular ROS levels were measured by the oxidant-sensitive fluorescent probe 5-(and-6)-
chloromethyl-2’, 7’-dichlorodihydrofluorescein diacetate acetyl ester (CM-H2DCFDA, Molecular 
Probes). Forty-eight hours after transfection with scramble siRNA or C12orf5 siRNA, cells were 
trypsinized, washed twice with PBS, and incubated with 5 µM CM-H2DCFDA in PBS at 37 °C 
for 30 minutes. Propidium iodide (PI) was added 10 minutes before flow analysis to exclude dead 
cells from ROS analysis.  
Neutral comet assay 
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Neutral comet assay was performed according to Tregvigen instructions for Comet Assay with 
some modifications. Briefly, 48 hours after siRNA transfection, cells were treated with vehicle, 5 
µM or 20 µM olaparib for 24 hours. Cell suspension in PBS with 1x105 cells/mL was mixed with 
molten LMA agarose (Trevigen) at a ratio of 1:10 and transferred onto Comet Slide (Trevigen). 
After cooling slides at 4 °C for 10 minutes, slides were immersed in the Lysis solution (Trevigen, 
4250-050-01) at 4 °C for 1 hour and immersed in 50 mL of 1X Neutral Electrophoresis Buffer (0.5 
mM Tris Base and 1.5 mM Sodium Acetate) for 30 minutes at 4 °C. One hour of electrophoresis 
was performed at 4°C using Wide Mini-Sub Cell GT Horizontal Electrophoresis System (Bio-
Rad) at 17 volts. Slides were then immersed in the DNA Precipitation Solution (1M NH4Ac and 
82.27% ethanol) for 30 minutes at room temperature followed by 30 minutes incubation in 70% 
ethanol. Then slides were dried at 37 °C for 10-15 minute stained with SYBR Green I and imaged 
using ZEISS fluorescent microscope (10X). Comets were analyzed using a free comet assay 
software from Casp Lab (1.2.3beta2 version). 
Cell cycle analysis 
Cells were transfected with scrambled (scr) siRNA or C12orf5 siRNA and reseeded into 6-well 
plates after 24 hours of transfection, followed by treatment with different concentrations of 
olaparib for additional 24, 48 or 72 hours. After treatment, cells were washed twice with 1X PBS 
and trypsinized before centrifuging at 1,000 rpm at 4 ℃ for 10 minutes in 15 mL conical tubes. 
Cells were resuspended in 300 µL of ice-cold PBS after wash, fixed by adding 300 µL of ice-cold 
95% ethanol dropwise, and kept in dark at 4 ℃ overnight.  The next day, cells were washed twice 
with ice-cold PBS and incubated in RNase A solution (1 mg/mL) at 37 °C for 15 minutes. Cells 
were then stained with 50 µg/mL propidium iodide solution in dark at room temperature for 15 
minutes before flow cytometry analysis. 
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Senescence-Associated b-Galactosidase Assay (SA-b-Gal) 
Two days after transducing with individual C12orf5 shRNAs, cells were trypsinized and reseeded 
in 6-well plates at the plating density of 1 × 105 cells per well and incubated at 37 °C for 24 hours. 
SA-b-Gal staining was performed as described before for adherent cultured cells (Itahana, Campisi 
et al. 2007). Briefly, cells were washed twice with 1X PBS, fixed with freshly prepared 3.7% 
formaldehyde in PBS for 5 minutes at room temperature, and washed twice with PBS. Cells were 
incubated in 2 mL of X-gal staining solution [1 mg/mL of X-gal, 40 mM citric acid/sodium 
phosphate buffer (pH 6.0), 5 mM potassium ferricyanide (Sigma, St. Louis, MO), 5 mM potassium 
ferrocyanide (Sigma), 150 mM NaCl, and 2 mM MgCl2] at 37 °C for 16 hours before taking images 
with 10X objective under Leica DMI3000 B Inverted Phase Contrast Microscope. SA-b-Gal stain-
positive cells were quantified in Image J software (NIH). 
Spheroid formation assay 
OVCA420* cells stably expressing inducible C12orf5 shRNAs (TRIPZ inducible lentiviral 
shRNAs were purchased from Dharmacon, US) were established by selection with puromycin 
after viral transduction. Stable cells were treated with 1 µg/mL doxycycline for 72 hours to induce 
expression of shRNAs. Then 3,000 cells/well were seeded into 96 well plates (plates were pre-
coated with 100 µL 1.5% (wt. /vol) agarose) and treated with vehicle or different concentrations 
of olaparib for 10 days. At the end of the experiment, pictures of spheroid were taken under a 




Total RNA was extracted 54 hours after cells were transduced with TIGAR shRNA viral 
supernatant. One µg of total RNA was used to synthesize cDNA and sequencing library was 
prepared using Illumina TruSeq RNA Sample Preparation Kit v2 following manufacturer’s 
instructions. Cells transduced with non-targeting shRNA serves as a control. RNA-seq libraries 
were generated from three replicates from the control and experimental groups. Next-generation 
sequencing was performed with NextSeq 500 at the Oklahoma Medical Research Foundation 
(OMRF) Clinical Genomics Center (OK, USA). FASTQ sequences were mapped to the human 
reference genome (hg19) using STAR aligner (Dobin, Davis et al. 2013). Read count for 
quantitation of gene expression was performed by RSEM (Li and Dewey 2011). Differentially 
expressed genes in TIGAR knockdown cells were determined by DESeq2 (Love, Huber et al. 
2014). Differentially expressed genes were further analyzed with Metascape (Tripathi, Pohl et al. 
2015). 
Statistical analysis 
All data were analyzed using GraphPad Prism (ver. 6) unless otherwise indicated. Results were 
expressed as the mean ± standard error of the mean (SEM.) or standard deviation of the mean 
(S.D). Differences between treatment regimens were analyzed by one-way ANOVA or two-tailed 
Student’s t-test. p<0.05 was considered to be statistically significant. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
4.4 Results 
4.4.1 Genome-scale CRISPR knockout screen identifies C12orf5 (TIGAR) as a modifier of 
olaparib sensitivity 
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To identify modifiers of olaparib sensitivity, we first established a cell line that stably expressed 
Cas9 endonuclease (A2780-Cas9) (Figure 4.4.1.A-B) by transducing the A2780 cells with lenti-
Cas9 viral particles followed by two weeks of blasticidin selection. Cas9 expression in this stable 
cell line was confirmed by western blot (Figure 4.4.1.A). Sulforhodamine B (SRB) assay showed 
that Cas9 expression and blasticidin S (an antibiotic that is produced by Streptomyces 
griseochromogene) selection had a minimal effect on sensitivity to olaparib in A2780-Cas9 
compared to the parental A2780 cell (Figure 4.4.1.B). The screening was performed by following 
the time scheme shown in Figure 4.4.1C. We transduced the Cas9-expressing cells with Genome-
scale CRISPR Knock-Out Library B, which contains 58,031 gRNAs targeting 19,050 human genes 
with three gRNAs per gene. After seven days of puromycin selection, cells expressing gRNAs 
were split into duplicates and treated with DMSO or olaparib (5 µM or 10 µM). The DMSO-treated 
cells served as a control. One week after DMSO or olaparib treatment, the remaining cells were 
collected, gRNAs were amplified, and the sequence library was prepared as previously described 
(Sanjana, Shalem et al. 2014, Shalem, Sanjana et al. 2014). Amplicons were sequenced by Illumina 
next-generation sequencing. Enriched or depleted gRNAs were identified using the Model-based 
Analysis of Genome-wide CRISPR-Cas9 Knockout (MAGeCK) tool to compare DMSO- and 
olaparib-treated groups (MAGeCK) tool (Li, Xu et al. 2014). Ten top candidates were identified 
for enrichment (Figure 4.4.1.D-E) or depletion (Figure 4.4.1.F-G) analysis. The enrichment 
analysis identified candidate genes whose disruptions led to olaparib resistance, including PARP1 






Figure 4.4.1: Genome-scale CRISPR knockout screening and candidate identification. A) A2780-
Cas9 cells stably express Cas9 endonuclease. Flag-tagged Cas9 was detected by Western blot with anti-
Flag antibody. b-actin was used as a loading control. B) A2780-Cas9 showed similar sensitivity to olaparib 
as parental A2780 cells. 3-day SRB assay was used to determine cell viability after treatment of different 
concentrations of olaparib. Cell survival curves were plotted in Prism 6 software. Data shown as mean ± 
SEM. IC50 was calculated in Prism 6 software. C) Flowchart shows time scheme of the CRISPR/Cas9 
knockout screen. D-G) Potential dropout and enriched candidates were identified after olaparib selection. 
(D) and (E) show top 10 candidates which were most significantly depleted after olaparib selection. (F) and 
(G) show top 10 candidates which were most significantly enriched with olaparib selection. Candidates 
were identified with MAGeCK tool (Li, Xu et al. 2014) by comparison of olaparib treated groups with 
DMSO treated groups. 
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 All three gRNAs showed consistent, dose-dependent increases in abundance following 
olaparib treatment (Figure 4.4.2.A). These results are consistent with a previous report indicating 
that PARP1 depletion results in resistance to PARP inhibitors (Liu, Han et al. 2009, Pettitt, Rehman 
et al. 2013). While the enrichment of gRNAs following olaparib selection indicates that target 
genes contribute to olaparib sensitivity, the depletion of gRNAs following olaparib selection 
indicates that target genes contribute to olaparib resistance. We identified C12orf5 (TIGAR) as 
one of the genes that negatively modulated olaparib sensitivity (Figure 4.4.1.F-G) because gRNAs 
for C12orf5 were depleted following olaparib treatment. This suggests that disruption of the 
C12orf5 gene sensitized the cells to olaparib. We also identified PI3K3C2G and NME2 as other 
candidate genes that decreased sensitivity to olaparib (Figure 4.4.1.F-G). Next, we transiently 
knocked down individual genes with pooled small interfering RNAs (siRNAs) to validate the 
potential candidates. We selected for validation those candidates that had at least two different 
gRNAs that were consistently and dose-dependently enriched or depleted after olaparib treatment, 






Figure 4.4.2: Validation of potential candidates. A) Profiles of dropout candidate. 3 different gRNAs for 
each candidate were shown. Each dot represents corresponding treatment condition: DMSO-1, DMSO-2, 
olaparib 5 µM-1, olaparib 5 µM-2, olaparib 10 µM-1 and olaparib 10 µM-2. gRNA read count decreases 
with olaparib treatment in a dose-dependent manner, such as C12orf5. B) Profiles of enrichment candidates. 
gRNA read count increases with olaparib treatment in a dose-dependent manner, such as PARP1. 
Candidates with red boxes were selected for further validation with pooled siRNAs. C) SRB cell viability 
assay indicates no change of sensitivity to olaparib after transfection of pooled siRNAs of indicated 
potential candidates. 48 hours after siRNA transfection, cells were treated with olaparib for 3 days. Data 
are shown as mean ± SEM. Results are representatives from one experiment with triplicates. D) Colony 
formation assay also indicates no change in olaparib sensitivity after transfection with pooled siRNAs for 
each candidate. 48 hours after siRNA transfection, cells were treated with olaparib for 3 days and kept to 
allow colonies to grow for 2 weeks before colony. Data are shown as mean ± SEM. Results are 
representatives of experiments with duplicates. 
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4.4.2 TIGAR knockdown by siRNA enhances sensitivity to olaparib in cancer cells 
To validate the selected candidates, we used pooled siRNAs with two different siRNAs for each 
gene to downregulate their expression in the A2780 cells from the initial screen. Forty-eight hours 
after siRNA transfection, we performed SRB and colony formation assays to assess the sensitivity 
to olaparib (Figure 4.4.3.A-C, Figure 4.4.2C-D). The results showed that a transient knockdown 
of TIGAR (Figure 4.4.3.B) led to an approximate 5-fold decrease in IC50 of olaparib in the A2780 
cells (Figure 4.4.3.A). Clonogenic survival analysis also indicated a decrease in colony formation 
in TIGAR knockdown cells when combined with various concentrations of olaparib (Figure 
4.4.3.C). Similar results were obtained with SRB assay in two additional cancer cell lines that were 
less sensitive to olaparib (Figure 4.4.3.E-F), suggesting that downregulation of TIGAR sensitized 
these cells to olaparib. Meanwhile, we observed that by itself TIGAR knockdown significantly 
decreased colony formation (Figure 4.4.3.D). Similar results were also observed in cancer cell 
OVCA420* (Figure 4.4.3.G-H). These observations are consistent with a previous report on 
glioblastoma cells (Pena-Rico, Calvo-Vidal et al. 2011). These results suggest that TIGAR 






Figure 4.4.3: TIGAR knockdown with siRNAs sensitizes cancer cells to olaparib. A) TIGAR 
knockdown results in a decrease in IC50 of olaparib, while PARP1 knockdown results in an increase in IC50 
of olaparib in A2780 cells. 3-day SRB cell viability assay was performed 48 hour after pooled siRNAs 
transfection in A2780 cells. Cell survival curves were plotted using Prism 6 software with IC50 indicated. 
B) Real-time PCR to validate knockdown of TIGAR and PARP1 with corresponding pooled siRNAs. Total 
RNA was extracted 72 hours after siRNA transfection and used for qRT-PCR. C) Colony formation assay 
shows that TIGAR knockdown enhanced decrease of colony formation with olaparib treatment and PARP1 
knockdown attenuated it. Left: Representative images of colonies. Right: Quantification of colonies. The 
clonogenic assay was performed 72 hours after siRNA transfection. Cells were exposed to vehicle or 
different concentrations of olaparib for 3 days. Data are shown as mean ± SEM. D) TIGAR knockdown 
results in decreased colony formation. Colony quantification for scr siRNA and TIGAR (C12orf5) siRNAs 
transfected cells. Data shown as mean ± SEM. Statistics analysis was done with Student’s t-test. **p<0.01. 
E-F) TIGAR siRNA knockdown increases sensitivity to olaparib in OVCA420* cell (E) and ES-2 cell (F) 
respectively. SRB cell viability assay was performed and cell survival curves were generated in Prism 6 
software with IC50 indicated. Data shown as mean ± SEM. G-H) TIGAR knockdown decreases cell survival 
in OVCA420* cell. G) Western blot of TIGAR expression 72 hours after siRNA transfection. b-actin was 
used as a loading control. H) SRB cell viability assay. 48 hours after siRNA transfection, cells were treated 
with olaparib for 3 days. Data are shown as mean ± SEM. A representative of experiment with triplicates 
is shown.  
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 We were also able to validate the effect of PARP1 knockdown on olaparib sensitivity. PARP1 
knockdown showed a decrease in sensitivity to olaparib in the A2780 cells (Figure 4.4.3.A-C). 
This is consistent with previous reports that PARP1 depletion leads to PARP inhibitor resistance 
(Liu, Han et al. 2009, Pettitt, Rehman et al. 2013). However, we were unable to validate the effect 
of other candidate genes on olaparib sensitivity (Figure 4.4.2.C-D). It should be noted that we only 
observed a marginal decrease in sensitivity to olaparib with the transient knockdown of PARP1 by 
siRNAs. This effect was not as dramatic as previous studies that showed a 10-fold decrease in 
PARP inhibitor sensitivity with the genetic disruption of PARP1 expression (Liu, Han et al. 2009, 
Pettitt, Rehman et al. 2013). This difference may be the result of the incomplete knockdown of 
PARP1 by siRNAs in our study. Differences in the efficiency of candidate gene suppression by 
the siRNAs and CRISPR could be one reason to explain our failure to validate some candidate 
genes from the CRISPR knockout screen. 
4.4.3 TIGAR knockdown induces apoptosis, increases DNA damage and enhances 
cytotoxicity of olaparib 
Next, we determined the mechanisms by which TIGAR downregulation leads to olaparib 
sensitivity. TIGAR shows sequence similarity to the bisphosphatase domain of fructose-2,6-
bisphosphatase (F-2,6-BPase) (Bensaad, Tsuruta et al. 2006). TIGAR has been shown to 
negatively regulate glycolysis by lowering the intracellular levels of fructose-2,6-bisphosphate, 
thereby promoting the oxidative PPP shunt. The PPP is critical for the production of NADPH and 
ribose-5-phosphate, which is a precursor for the synthesis of nucleotides (Bensaad, Tsuruta et al. 
2006, Wanka, Steinbach et al. 2012). TIGAR expression also protects cells from DNA-damaging 
ROS through the regeneration of reduced glutathione via NADPH and provides some levels of 
protection from DNA damage-induced apoptosis (Bensaad, Tsuruta et al. 2006, Bensaad, Cheung 
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et al. 2009, Wanka, Steinbach et al. 2012, Cheung, Athineos et al. 2013). Therefore, we tested the 
effect of TIGAR knockdown on apoptosis with or without olaparib treatment. With Annexin V/PI 
staining, we observed a dramatic increase in apoptotic cells after TIGAR knockdown with pooled 
siRNAs in two different cells (Figure 4.4.4.A-C). The increase in apoptosis was further enhanced 
when combined with olaparib, suggesting that TIGAR knockdown can potentiate the cytotoxicity 





Figure 4.4.4: TIGAR knockdown induces apoptosis. A) TIGAR knockdown increases apoptosis and 
enhances the cytotoxicity of olaparib in OVCA420* cell. Representative flow cytometry analysis profiles 
of Annexin V/PI stained cells with vehicle or olaparib treatment after scrambled (scr) siRNA or TIGAR 
siRNAs transfection. 48 hours after siRNA transfection, cells were seeded for the vehicle, 10 µM or 20 µM 
olaparib treatment for another 48 hours before Annexin V/PI staining. B-C) Quantification analysis shows 
that TIGAR knockdown results in the increase in apoptosis and enhanced cytotoxicity by olaparib in 
OVCA420* and ES-2 cells. Annexin V (+) cells represent both early and late apoptotic cell. For 
OVCA420*, data are shown as mean with S.D and results shown as one representative experiment with 
triplicates. For ES-2, one representative experiment was shown. 
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 Given that TIGAR enhances antioxidant NADPH regeneration by promoting the PPP, 
TIGAR knockdown results in increased levels of intracellular ROS as shown in previous studies 
(Bensaad, Tsuruta et al. 2006, Bensaad, Cheung et al. 2009). To test this possibility, we determined 
cellular ROS levels by H2DCFDA dye staining. After knockdown of TIGAR with an individual 
siRNA or pooled siRNAs, we observed higher H2DCFDA fluorescence compared to scrambled 
siRNA (scr siRNA)-transfected cells (Figure 4.4.5.A), with a 1.35-fold and 1.33-fold increase of 
mean fluorescence intensity in TIGAR siRNA#1 and siRNA#2 respectively, and the pooled 
siRNAs leads to 1.52-fold increase of mean fluorescence intensity compared to scr siRNA 
transfected cells. This indicates that TIGAR downregulation increased ROS levels in the cells. 
Consistent with increased levels of ROS, neutral comet assay showed a significant increase in 
DNA damage after TIGAR knockdown (Figure 4.4.5.B). Moreover, TIGAR knockdown 
significantly enhanced DNA damage caused by olaparib treatment. Consistent with higher levels 
of DNA damage, cells with TIGAR knockdown displayed higher levels of γH2AX at 24 and 48 
hours following olaparib treatment than cells transfected with scr siRNA (Figure 4.4.5.C). Yu et 
al. (2015) have shown that TIGAR knockdown increased DNA damage by inhibiting the PPP in 
hepatocellular carcinoma cells (Yu, Xie et al. 2015). We supplemented cells with NADPH, ribose 
or N-acetyl cysteine and observed a partial decrease in γH2AX with NAC and Ribose (Figure 
4.4.5.D), suggesting that enhanced DNA damage after TIGAR knockdown is at least partially due 





Figure 4.4.5: TIGAR knockdown results in an increase of DNA damage through induction of 
intracellular ROS. A) TIGAR knockdown leads to increase of intracellular ROS levels. Upper: 48 hours 
after siRNA transfection, cells were loaded with 5 µM H2DCFDA for 30 minutes before flow cytometry 
analysis. Dead cells were excluded by PI staining. Mean fluorescence intensity and fold change were shown 
in the chart. Western blot shows that TIGAR is downregulated with siRNAs. b-actin was used as a loading 
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control. B) TIGAR knockdown results in significantly increased DNA damage and further significantly 
enhanced with olaparib treatment. 48 hours after siRNA transfection, OVCA420* cells were treated with 
vehicle or olaparib for 24 hours. DNA damage was detected by Neutral Comet Assay. Representative image 
of each group was shown on the top. Individual comets were analyzed using Capslab free comet tail analysis 
software. Quantification data are shown in the graph at the bottom. Olive Tail Moment = (Tail.mean - 
Head.mean) X Tail%DNA/100. Each dot represents one comet. Data are shown as median with S.D. 
Statistics were done with One-way ANOVA analysis in Prism 6 software. **=p<0.01, ****=p<0.0001. C) 
TIGAR knockdown increases gH2AX level in OVCA420* cells. 48 hours after siRNA transfection, 
OVCA420* cells were treated with vehicle or olaparib for 24 hours or 48 hours. b-actin was used as a 
loading control. D) The increase of gH2AX level after olaparib treatment in TIGAR knockdown cells can 
be partially attenuated with NAC, NADPH or ribose. 48 hours after transfection, cells were pretreated with 
10 µM NAC, 20 µM NADPH or 10 mM ribose respectively for 2 hours, followed by 24 hours treatment 
with vehicle or 20 µM olaparib. Result is from one experiment. Bottom bar graph shows quantification of 
western blots.  
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 We also performed a cell cycle analysis in ES-2 cells with or without TIGAR siRNA 
knockdown and in combination with olaparib treatment. Consistent with a previous report (Farmer, 
McCabe et al. 2005), the 24-hour treatment of scr siRNA-transfected ES-2 cells with olaparib 
resulted in dose-dependent cell cycle arrest at the G2 or M phase in cells transfected with scr 
siRNA, with almost 2-fold increase of G2 or M phase cells in 20 µM olaparib treated group 
compared to DMSO treated group (Figure 4.4.6.A). Interestingly, we observed S-phase arrest after 
TIGAR knockdown (Figure 4.4.6.A). TIGAR knockdown leads to 1.35-fold increase of S-phase 
cells in comparison with scr siRNA transfected cells. Moreover, more cells were arrested in the S-
phase instead of the G2 or M phases in TIGAR knockdown cells treated with olaparib. 39.2% of 
TIGAR knockdown cells were at S-phase when treated with 20 µM of olaparib versus only 22.9% 
of scr siRNA transfected cells. Similar increase of S-phase arrest were observed at 48 and 72 hours 
after olaparib treatment (Figure 4.4.6.B-D). These data are consistent with the notion that an 
increase in DNA damage after TIGAR knockdown requires more time to resolve DNA damage 
during the S-phase in TIGAR knockdown cells. In addition, TIGAR knockdown may also affect 
the expression of genes associated with S-phase progression and altered cell cycle-related gene 






Figure 4.4.6: TIGAR knockdown leads to S-phase arrest. A) TIGAR knockdown leads to cell cycle arrest 
in S-phase and the arrest is further enhanced when combined with olaparib treatment. ES-2 cells were 
transfected with siRNA for 48 hours and treated with vehicle, 5, 10 or 20 µM olaparib for additional 24 
hours before flow cytometry cell cycle analysis with PI staining. Data are shown as mean ± SD. B) 
Quantification of cell cycle analysis in ES-2 cells treated with olaparib for 48 hours after siRNA 
transfection. C-D) Cell cycle analysis in ES-2 cells treated with olaparib for 72 hours after siRNA 
transfection. C) Representative cell cycle profiles analyzed in FlowJo. D) Quantification of cells distributed 
at different cell cycle phases with 72 hours’ of olaparib treatment. 
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4.4.4 Downregulation of BRCA1 and the Fanconi anemia (FA) pathway underlies sensitivity 
to olaparib after TIGAR knockdown 
Studies have shown that TIGAR modulates the DDR after treatment with different DNA-damaging 
agents, such as epirubicin (Yu, Xie et al. 2015) and radiation (Pena-Rico, Calvo-Vidal et al. 2011) 
and TIGAR downregulation enhances DNA damage with these agents. Together with the data 
presented in our present study, these effects largely depended on PPP reduction after TIGAR 
knockdown.  
 To investigate whether there are other potential mechanism(s) involved in PARP inhibitor 
sensitivity after TIGAR knockdown, we performed RNA sequencing analysis in OVCA420* cells 
that were transduced with non-targeting control (NTC) shRNA (short hairpin RNA) or TIGAR-
specific shRNA. The efficiencies of three individual TIGAR-specific shRNAs were different in 
knocking down TIGAR (data not shown), and we found that shRNA #3 gave the most efficient 
knockdown. Following a 54-hour transduction with lentiviral supernatant, we analyzed changes in 
the transcriptome using Illumina mRNA sequencing. A total of 380 genes were downregulated by 
at least two-fold at false discovery rate (FDR) ≤ 0.001 in TIGAR knockdown cells compared to 
NTC-transduced cells. A total of 144 genes were upregulated by at least two-fold at FDR ≤ 0.001 
in TIGAR knockdown cells compared to NTC-transduced cells (Figure 4.4.7.A). Surprisingly, 
BRCA1 was one of the most significantly downregulated genes following TIGAR knockdown. 
Downregulation of BRCA1 was validated with qRT-PCR and Western blot (Figure 4.4.7.B). 
Similar results were obtained from another cell line (Figure 4.4.7.F). Interestingly, the extent of 
BRCA1 downregulation depended on how efficiently TIGAR was knocked down, suggesting a 
dose-dependent effect. Gene set enrichment analysis (GSEA) indicated that the TIGAR 
knockdown cells produced a gene set enrichment similar to BRCA1 downregulated cells (Figure 
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4.4.7.C). It is well accepted that downregulation of BRCA1 leads to PARP inhibitor sensitivity. 
Our data suggest that TIGAR knockdown induces “BRCAness” by phenocopying the gene 
expression pattern produced by BRCA1 downregulation, thereby sensitizing cancer cells to 
olaparib. We also analyzed the differentially expressed genes using Metascape bioinformatics web 
resources (Tripathi, Pohl et al. 2015). The annotation and enrichment analysis of genes 
downregulated by TIGAR knockdown indicated that the gene set was enriched for the FA pathway, 
DNA replication, and cell cycle progression (Figure 4.4.7.D). We validated the downregulation of 
genes involved in the FA pathway, such as BRCA2 and RAD51, after TIGAR knockdown with two 
different shRNAs (Figure 4.4.7.E-F). We also validated the decreased expression of 
downregulated genes with two different shRNAs in two cell lines using qRT-PCR (Figure 
4.4.7.G). In general, the extent of the downregulation of these genes was greater when TIGAR was 
more efficiently downregulated with shRNA. We also performed an analysis for genes upregulated 
in TIGAR knockdown cells. The results indicated the enrichment of gene ontology for the positive 
regulation of cell death, response to drug, regulation of PI3K activity, and the positive regulation 
of intracellular signal transduction (Figure 4.4.7.H). The upregulated genes involved in the positive 
regulation of cell death is consistent with our observation of an increase in apoptosis after TIGAR 








Figure 4.4.7: RNA sequencing analysis after TIGAR knockdown reveals downregulation of BRCA1 
and key DNA repair pathways. A) Genes that are significantly changed were identified with Metascape 
bioinformatics web program. B) BRCA1 is downregulated in OVCA420* cells with C12orf5 shRNAs. qRT-
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PCR and Western blot to check the expression of BRCA1 mRNA and protein levels after TIGAR knockdown 
with shRNAs. For qRT-PCR, data shown as mean ± SEM. Results represent experiment with triplicates. 
Representative blot was shown for protein expression check.  Bar graph shows densitometry analysis of the 
western blots. C) GSEA analysis reveals enrichment of gene signature that is similar as BRCA1 
downregulated cells after TIGAR knockdown. D) Statistically enriched terms associated with genes 
downregulated in TIGAR knockdown are related to the Fanconi anemia (FA) pathway, cell cycle 
progression and etc. E-F) The FA pathway components BRCA1, BRCA2, and RAD51 were downregulated 
after TIGAR knockdown with shRNAs. QRT-PCR was performed in OVCA420* and OV90 cells at 72 
hours after transduction of TIGAR shRNA. Data shown as mean ± SEM. Results represent experiment with 
triplicates. G) Validation of expression for downregulated genes in TIGAR shRNA transduced OVCA420* 
and OV90 cells respectively. In general, the extent of downregulation of these genes is bigger when the 
TIGAR is more efficiently downregulated with shRNA. To be specific, C12orf5 sh#3 downregulate TIGAR 
more efficient and is accompanies with more downregulation of affected genes. H) Statistically enriched 
terms that are associated with genes upregulated in TIGAR knockdown, including positive regulation of cell 




4.4.5 Efficient knockdown of TIGAR induces senescence and decreases clonogenicity in 
cancer cells  
Our RNA sequencing data analysis revealed that gene sets involved in DNA replication and cell 
cycle progression were significantly downregulated. To further characterize the effect of TIGAR 
knockdown on cancer cell growth, we used three different shRNAs to stably knockdown TIGAR 
expression in two different cancer cell lines, OVCA420* and OV90. Western blot analysis 
indicated that three individual shRNAs knocked down TIGAR expression with different 
efficiencies and were generally more effective in OVCA420* cells (Figure 4.4.8.A). This might 
be the result of different viral transduction efficiencies between the OVCA420* and OV90 cells. 
Colony formation assay indicated a marked decrease in clonogenicity following TIGAR 
knockdown in OVCA420* cells treated with DMSO (Figure 4.4.8.B). Similarly, a decrease in 
clonogenicity that corresponded with TIGAR knockdown levels was observed in OV90 cells. 
Clonogenic growth was further decreased by olaparib treatment in OV90 cells. 
 A previous report by Peña-Rico et al. (2011) showed that TIGAR knockdown with a siRNA 
in glioblastoma cells induced senescence (Pena-Rico, Calvo-Vidal et al. 2011). To examine if the 
marked decrease in clonogenicity after TIGAR knockdown with shRNAs is associated with 
senescence, we performed a senescence-associated b-galactosidase (SA-b-gal) analysis on 
OVCA420* cells that were transduced with a NTC shRNA or three different shRNAs targeting 
TIGAR. We consistently observed an increase in SA-b-gal staining in the TIGAR knockdown 
cells and the extent of cells that underwent senescence was inversely correlated with the level of 
TIGAR expression (Figure 4.4.8.C-D). These data suggest that more efficient knockdown of 
TIGAR leads to the induction of senescence and severe cell growth defects in cancer cells, 
resulting in decreased colony formation. These results suggest that efficient downregulation of 
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TIGAR by itself may prevent cancer cells from growing, indicating that TIGAR might be a good 





Figure 4.4.8: Efficient TIGAR knockdown increases senescence and decreases clonogenicity of cancer 
cells. (A-B) TIGAR knockdown with individual shRNAs decreased colony formation. (A) Western blot to 
check knockdown efficiency with individual shRNAs. NTC is non-targeting control shRNA. b-actin was 
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used as a loading control. Bar graphs on the right show the densitometry of western blots in OVCA420* 
and OV90 cells respectively. (B) Colony formation assay after TIGAR shRNA knockdown in OVCA420* 
and OV90 cells. 72 hours after shRNA viral transduction, cells were seeded for clonogenic assay and treated 
with vehicle and increasing concentrations of olaparib. Representative images of colonies were shown. 
Graph on the left showed the quantification of colonies in OV90 cells. (C-D) More efficient TIGAR 
knockdown is associated with an increase of senescence in OVCA420* cell. (C) SA-b-gal staining of 
OVCA420* cells with NTC or individual TIGAR shRNAs. Representative images were shown of duplicates 
from one representative experiment. (D) Quantification of SA-b-gal staining positive cells in each group. 
The bar graph shows result from one representative experiment with duplicates. Images were taken from 
different areas in each well for each replicate and combined quantified positive staining cells. 
Representative western blot showing the corresponding knockdown of TIGAR with individual shRNAs. 
Statistics was done with Student’s t-test. p<=0.05 was considered to be significant.  ***p<=0.001, 
****p<=0.0001.  
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4.4.6 TIGAR knockdown enhances therapeutic effects of olaparib in cancer cells 
Three-dimensional (3D) cell culture models are used as intermediate models between in vitro two-
dimensional (2D) monolayer cancer cell culture and in vivo tumors (Weiswald, Bellet et al. 2015). 
Emerging evidence suggests that 3D culture systems represent more accurately the actual tumor 
microenvironment than 2D culture systems (Edmondson, Broglie et al. 2014). Further, 3D culture 
models are considered more representative than 2D systems in testing the therapeutic effects of 
drugs in vitro (Edmondson, Broglie et al. 2014, Weiswald, Bellet et al. 2015, Zanoni, Piccinini et 
al. 2016). To test the therapeutic effects of the combination of olaparib with TIGAR 
downregulation, we decided to use inducible shRNAs to perform the 3D spheroids formation 
assay. With two different inducible shRNAs against TIGAR, we observed a significant decrease 
in cell viability in spheroids and sizes of spheroids when olaparib treatment was combined with 
TIGAR knockdown (Figure 4.4.9.A-C). These data indicate that TIGAR knockdown enhances the 
therapeutic effects of olaparib, which is consistent with our findings in RNA sequencing analysis 






Figure 4.4.9: TIGAR knockdown enhances therapeutic effects of olaparib. A-C) 3D spheroid formation 
assay indicates enhanced therapeutic effects of olaparib combined with TIGAR knockdown using two 
different inducible shRNAs. (A) Representative images of spheroids from each group. Two different 
spheroids were shown from each group. OVCA420* cells stably carrying inducible shRNAs were induced 
with 1 µg/mL doxycycline for 72 hours before seeded into 1.5% agarose coated 96 well plate with 3000 
cells per well. Cells were treated with vehicle, 20 µM or 40 µM olaparib for 10 days after spheroids formed. 
1 µg/mL of doxycycline was kept in the media throughout the whole experiment. Expression of RFP (Red 
Fluorescent Protein) is an indication of shRNA expression. BF, bright field. (B) Cell viability of spheroids 
was determined with CellTiter-Glo Luminescent Cell Viability Assay. Data are shown as mean ± SEM. 
Statistics was done with Student’s t-test. p<=0.05 was considered to be significant. *p<=0.05, **p<=0.01, 
***p<=0.001, ****p<=0.0001. (C) Western blot to show that TIGAR was knocked down with doxycycline 




4.4.7 TIGAR expression in ovarian carcinomas is associated with poor survival outcome 
Finally, data analysis from TCGA indicated that TIGAR was amplified across different cancer 
types. This includes ovarian cancer, which was amplified in over 11% of cases (Figure 4.4.10.A). 
Further, TIGAR amplification was correlated with a higher expression of TIGAR (Figure 
4.4.10.B). We also analyzed the RNA sequencing dataset of high-grade serous ovarian carcinomas 
from TCGA. We classified patients into two groups depending on the levels of TIGAR expression 
in the tumor. Tumors with TIGAR expression above the mean were considered tumors with a high 
expression of TIGAR whereas tumors with TIGAR expression at or below the mean were 
considered tumors with a low expression of TIGAR. The analysis indicated that patients with high 
TIGAR expression in tumors had a significantly poorer overall survival outcome compared to 
patients with low TIGAR expression in tumors (Figure 4.4.10.C). Collectively, these results 
suggest an important role of TIGAR in cancer development and in modifying the response to the 
PARP inhibitor. Finally, targeting TIGAR in cancer represents a potential strategy to overcome 






Figure 4.4.10: Clinical relevance of therapeutically targeting TIGAR in ovarian cancer. A) TIGAR is 
amplified in ~10% of serous ovarian tumor samples analyzed through The Cancer Genome Atlas (TCGA). 
These levels are derived from the copy-number analysis algorithms GISTIC or RAE, and indicate the copy-
number level per gene. "-2" is a deep loss, possibly a homozygous deletion, "-1" is a shallow loss (possibly 
heterozygous deletion), "0" is diploid, "1" indicates a low-level gain, and "2" is a high-level amplification. 
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And these calls are putative. B) TIGAR amplification was correlated with a higher expression. (C) Higher 
TIGAR expression is associated with poor survival in high-grade serous ovarian cancer patients. 489 
patients from TCGA publication was included in the analysis. mRNA expression was quantified by Agilent 




Several mechanisms have been proposed for PARP inhibitor resistance, such as alterations that 
directly or indirectly restore HR function, including the reversion mutation of BRCA1/2, 
epigenetic re-expression of BRCA1, and overexpression of 53BP1 and stabilization of partially 
truncated BRCA1 (Lord and Ashworth 2013, Ter Brugge, Kristel et al. 2016, Incorvaia, Passiglia 
et al. 2017). Other non-HR mechanisms, such as the loss of PARP1 expression, PI3K/AKT 
pathway, and an increase in the drug transporter P-glycoprotein to facilitate the efflux of drugs 
also contribute to PARP inhibitor resistance (Tapodi, Debreceni et al. 2005, Liu, Han et al. 2009, 
Pettitt, Rehman et al. 2013, Lawlor, Martin et al. 2014, Durmus, Sparidans et al. 2015). However, 
our knowledge about PARP inhibitor resistance is far from complete and more effective 
combination therapies need to be developed to overcome the resistance. RNAi-based functional 
genetic screens are valuable techniques to efficiently identify a set of genes underlying a particular 
cellular process (Fire, Xu et al. 1998, Brummelkamp, Bernards et al. 2002, Moffat, Grueneberg et 
al. 2006, Ngo, Davis et al. 2006). Although they are powerful tools to disrupt gene function, they 
suffer from the low suppression of gene levels and frequent off-target effects, resulting in high 
rates of false positive and negative results (Echeverri, Beachy et al. 2006, Booker, Samsonova et 
al. 2011, Kaelin 2012). The CRISPR/Cas9-based system has been shown as advantageous in these 
aspects and pooled gRNA screens as effective in loss-of-function screens in mammalian cells as 
well as in vivo screens in mice (Shalem, Sanjana et al. 2014, Wang, Wei et al. 2014, Chen, Sanjana 
et al. 2015, Parnas, Jovanovic et al. 2015). Several published studies reported siRNA or shRNA 
library screens to characterize modifiers of the PARP inhibitor response (Lord, McDonald et al. 
2008, Bajrami, Frankum et al. 2014). Although our report is not the first to perform the 
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CRISPR/Cas9 screen to identify modifiers of the PARP inhibitor response (Pettitt, Krastev et al. 
2017), it is the first to report TIGAR as a candidate modifier of the response to olaparib. 
 TIGAR was originally described as a p53-induced gene that regulates glycolysis and 
apoptosis (Bensaad, Tsuruta et al. 2006). However, subsequent studies described its additional role 
in DNA damage signaling, mitophagy, autophagy, and senescence (Bensaad, Tsuruta et al. 2006, 
Bensaad, Cheung et al. 2009, Yu, Xie et al. 2015). In cancer cells, TIGAR plays an important role 
in regulating glycolytic flux and promotes NADPH and antioxidant regeneration through oxidative 
PPP (Lee, Vousden et al. 2014). TIGAR knockdown results in a decrease in NADPH, an increase 
in ROS, and higher basal levels of DNA damage (Bensaad, Tsuruta et al. 2006, Yu, Xie et al. 
2015). A previous report indicated that TIGAR knockdown results in the senescence of 
glioblastoma cells (Pena-Rico, Calvo-Vidal et al. 2011). Given its pivotal role in antioxidant 
regeneration, it is not surprising that our genome-scale CRISPR/Cas9 screen identified C12orf5 
(TIGAR) as a dropout candidate gene involved in sensitizing cancer cells to PARP inhibitor 
olaparib. 
 Our screen indicated that all three specific gRNAs for TIGAR were significantly depleted 
following exposure to 5 or 10 µM olaparib (Figure 4.4.2). Our studies showed that TIGAR-
deficient cells were more sensitive to olaparib (Figure 4.4.3). TIGAR knockdown by RNAi 
resulted in increased levels of ROS and higher basal levels of DNA damage (Figure 4.4.5). 
Consistent with previous studies (Farmer, McCabe et al. 2005), the cancer cells in our study show 
an increased accumulation in the G2 or M phase when they were treated with olaparib. In contrast, 
TIGAR-deficient cells showed an increased accumulation in the S-phase when they were treated 
with olaparib (Figure 4.4.6). These results are consistent with our observation that TIGAR-
deficient cells sustained more DNA damage, thereby requiring a longer time to resolve DNA 
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damage in the S-phase. TIGAR knockdown also led to growth inhibition and is supported by our 
observations of an increase in apoptosis (Figure 4.4.4) and induction of senescence (Figure 4.4.8). 
These results correlate with the analysis of the global changes in the transcriptome following 
TIGAR knockdown that showed that genes involved in cell cycle progression were most 
significantly affected by TIGAR knockdown (Figure 4.4.7). More interestingly, TIGAR 
knockdown led to downregulation of BRCA1 (Figure 4.4.7). GSEA from RNA sequencing 
indicated that TIGAR knockdown produced a gene signature similar to BRCA1 downregulated 
cancer cells (Figure 4.4.7). Moreover, pathway analysis showed that one of the significant gene 
ontology (GO) terms associated with downregulated genes is the FA pathway (Figure 4.4.7). 
BRCA1 is a tumor suppressor that is involved in a handful of important cellular processes and its 
role in HR and transcriptional regulation in DDRs draws the most attention (Yoshida and Miki 
2004, Silver and Livingston 2012). BRCA1 deficiency leads to HR defects and the sensitization 
of cancer cells to the PARP inhibitor (Farmer, McCabe et al. 2005). The FA pathway regulates 
DNA repair by HR and defects in the FA pathway lead to DNA repair defects, resulting in a low 
tolerance for DNA-damaging agents (Kennedy and D'Andrea 2005). Accordingly, downregulation 
of BRCA1 and the FA pathway in TIGAR-deficient cells may provide a molecular mechanism 
attributable to the increased sensitivity to olaparib after TIGAR knockdown in cancer cells. 
Targeting TIGAR may induce “BRCAness” in cancer cells and serve as a combination strategy to 
overcome PARP inhibitor resistance or to enhance the therapeutic effects of the PARP inhibitor. 
Our data from spheroids formation assay suggest that downregulation of TIGAR enhanced the 
therapeutic effects of olaparib (Figure 4.4.9). In the future, it will be informative to test the effects 
of TIGAR downregulation in combination with the PARP inhibitor in vivo. Importantly, TCGA 
data analysis indicated that a higher expression of TIGAR was observed in many different cancer 
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types and patients with a higher TIGAR expression showed poor overall survival outcome in high-
grade serous ovarian cancer (Figure 4.4.10). These data suggest that the clinical relevance of 
TIGAR expression in cancer and the targeting of TIGAR might be a useful strategy to improve 
cancer treatments. 
 Along with our present study, several studies have shown the potential of targeting TIGAR 
to enhance the therapeutic effects of cancer therapies. These include the direct targeting of TIGAR 
with a siRNA (Pena-Rico, Calvo-Vidal et al. 2011) or miR-144 (Chen, Li et al. 2015) and indirect 
downregulation with a cell-penetrating peptide inhibitor of MUC1-C (Yin, Kufe et al. 2014, 
Ahmad, Alam et al. 2017) or c-Met TKIs (Lui, Wong et al. 2011). Therefore, the future 
development of pharmacological methods to directly target TIGAR is an attractive direction to 
pursue. TIGAR is characterized as an F-2,6-BPase that could be targeted by specific phosphatase 
inhibitors to inhibit its activity and inhibit the PPP to enhance the cytotoxicity of cancer therapies 
as suggested by our data and reports from other groups (Pena-Rico, Calvo-Vidal et al. 2011, Yin, 
Kufe et al. 2014). Degraders based on proteolysis targeting chimera that specifically target TIGAR 
can also be developed. 
 One potentially promising aspect of targeting TIGAR in cancer is that it regulates the 
Warburg effect. This effect acts as a metabolic switch that enables cancer cells to utilize higher 
amounts of glucose by shunting glucose-6-phosphate to the PPP, which is in part mediated by 
TIGAR. This metabolic feature is almost universal in cancer. Therefore, it may represent a critical 
step in cancer progression. The beneficial effect of this metabolic feature for cancer cells is that it 
provides critical substrates for DNA and, thus, enables replication. Further, the feature provides 
critical substrates for the regeneration of antioxidants, thereby protecting cancer cells from 
excessive oxidative damage through accelerated cellular metabolism. Therefore, targeting TIGAR 
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may not only deplete the cancer cells with critical substrates required for proliferation but also 
deprive them of the substrates required for antioxidant regeneration. The combined effect of 
TIGAR inhibition results in increased ROS, DNA damage, cellular senescence, and increased 
sensitivity to PARP inhibitors. 
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Although considered a rare cancer (representing only 1.3% of all new cancer cases in the U.S), 
ovarian cancer is the deadliest gynecological cancer among women in the US (American Cancer 
Society 2017). Due to the lack of reliable early detection biomarkers (Einhorn, Sjovall et al. 1992, 
DePriest and DeSimone 2003, Wilder, Pavlik et al. 2003, Jacobs and Menon 2004, Olivier, 
Lubsen-Brandsma et al. 2006), the majority of ovarian cancer patients are diagnosed at advanced 
stages (stage III or IV) where the disease has spread outside the pelvis. Because accurate early 
detection methods are not yet available and are challenging to develop (Visintin, Feng et al. 2008), 
effective cancer treatments become more important to improve the outcome of patients with 
ovarian cancer. The standard chemotherapy, consisting of a platinum and a taxane agent, is 
considered the standard of care for advanced ovarian cancer patients following surgical debulking 
(Cannistra 2004). Though these chemotherapies are effective, they are not durable (Cannistra 
2004, Chien, Kuang et al. 2013). Efforts to uncover oncogenic driver mutations that can be targeted 
with molecularly targeted therapies were unsuccessful because high-grade serous ovarian cancer 
commonly harbor mutations in tumor suppressor genes than mutations in oncogenes (Cancer 
Genome Atlas Research 2011). However, genomics studies uncovered HR-deficiencies in 
approximately 50% of high-grade serous ovarian cancer. Recent advances in targeted therapies 
that exploit synthetic lethal genetic interactions indicate that HR-deficiencies in cancer can be 
exploited with PARP inhibitors. Two fundamental landmark studies showed that BRCA-deficient 
cancer cells are hypersensitive to PARP inhibitor (Bryant, Schultz et al. 2005, Farmer, McCabe et 
al. 2005). These studies extended the historically “old” concept of synthetic lethality to cancer 
treatment and for the first time provided a new approach to target the loss-of-function mutations 
in tumor suppressor genes. Since then, PARP inhibitors have been brought into clinical trials 
(Fong, Boss et al. 2009, Audeh, Carmichael et al. 2010, Tutt, Robson et al. 2010, Ledermann, 
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Harter et al. 2012, Ledermann, Harter et al. 2014, Mirza, Monk et al. 2016), and based on their 
promising activities in cancer patients, they were finally approved for treating ovarian cancer 
patients with deleterious germline or somatic BRCA mutations. PARP inhibitors are now evaluated 
in different phases of clinical trials in various types of cancers, with the hope of expanding their 
clinical applications. It is now well documented that clinical activities of PARP inhibitors extend 
beyond BRCA deficiencies, and tumors with HR deficiencies are also sensitive to PARP inhibitors. 
 In both preclinical and clinical studies, PARP inhibitors are shown to be more effective in 
cancer cells with HR deficiency and in patients with the platinum-sensitive disease (Bryant, 
Schultz et al. 2005, Farmer, McCabe et al. 2005, Fong, Boss et al. 2009, Audeh, Carmichael et al. 
2010, Tutt, Robson et al. 2010, Lord and Ashworth 2013, Kristeleit, Shapira-Frommer et al. 2016, 
Coleman, Oza et al. 2017). For example, results from a clinical trial with niraparib showed a clear 
benefit in the BRCA-deficient group and the platinum-sensitive group (Oza, Tinker et al. 2017), 
with no response in platinum-resistant BRCA-proficient patients. HR deficiency was shown to 
confer sensitivity to platinum agents (Yang, Khan et al. 2011, Bolton, Chenevix-Trench et al. 2012, 
Pennington, Walsh et al. 2014, Konstantinopoulos, Ceccaldi et al. 2015), suggesting that functional 
status of HR determines the responsiveness of cancer cells to PARP inhibitor and platinum-based 
chemotherapy. Hence, the intrinsic PARP inhibitor resistance can be explained by the lack of HR 
defects in cancer cells while the acquired PARP inhibitor resistance is attributed to the restoration 
of HR proficiency. Therefore, overcoming the HR proficiency is a major challenge in expanding 
the clinical application and maintaining clinical benefits of PARP inhibitors in cancer treatment. 
Given that only half of the patients with high-grade serous carcinomas have HRD tumors, current 
application of PARP inhibitors as a treatment for ovarian cancer will be limited. For the other half, 
some patients have tumors that maintain HR proficiency due to CCNE1 amplification, and they 
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are refractory to platinum agents and expected to be insensitive to PARP inhibitors. In these 
patients with CCNE1 amplification, the induction of a “BRCAness” phenotype may represent a 
therapeutic approach because CCNE1 amplification and BRCA deficiency are mutually exclusive, 
suggest a potential synthetic lethality. Our results indicate that targeting FOXM1-MYC nexus with 
BET inhibitor or BET degrader induce “BRCAness” by causing the downregulation of HR repair 
genes. Therefore, these agents may be active in treating patients with CCNE1 amplifications who 
are refractory to platinum-based chemotherapy. 
 The HR status is unknown for the remaining group that does not have CCNE amplification 
nor known defects in HR genes. For this group of patients, there is no indication that PARP 
inhibitors will be effective, and this group lacks known predictive signatures of HR defects or HR 
proficiency (Konstantinopoulos, Ceccaldi et al. 2015). To address this gap in knowledge, more 
efforts are needed to identify determinants and modifiers of the HR function and PARP inhibitor 
response. More studies are also needed to explore strategies to induce HR deficiency or 
“BRCAness” in cancer cells with primary resistance to PARP inhibitors so that more patients will 
benefit from PARP inhibitor treatment. One approach is to combine therapies that impair HR 
proficiency with PARP inhibitors and make cancer cells sensitive to PARP inhibitors. However, 
this approach has serious limitations that have to be overcome before it can become a valid clinical 
option. The primary limitation is that such approach may also induce “BRCAness” in normal cells, 
thereby increasing the risk of adverse side effects. However, novel approaches can be envisioned 
that selectively induce “BRCAness” in cancer cells through exploiting vulnerabilities in protein 
quality control system in cancer cells. Due to copy number alterations and mutations that 
exacerbate proteotoxic stress in cancer cells, inhibition of protein chaperones and proteasomal 
degradation may have more pronounced effects in cancer cells than in normal cells. Prior studies 
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have shown that HSP90 inhibitors and proteasomal inhibitors induce “BRCAness” and sensitize 
cancer cells to PARP inhibitors. Therefore, it may be possible to selectively cause severe 
proteotoxic stress and induce “BRCAness” while causing minimal effects in normal cells. Under 
this condition, PARP inhibitors may be more active in cancer cells than in normal cells. 
 In this dissertation, I focused on two main parts. In Chapters 2 and 3, I described the 
development of new combination strategies to induce “BRCAness” in HR-proficient cells so that 
these cells become sensitive to PARP inhibitor. I demonstrated that “BRCAness” can be induced 
in cancer cells with either the intrinsic resistance or the acquired resistance to PARP inhibitors and 
induced “BRCAness” in these cells enhances sensitivity to PARP inhibitors. In Chapter 4, I 
described the characterization of TIGAR as novel modifier of PARP inhibitor response, and this 
discovery may provide us with additional predictive biomarkers to evaluate the functional status 
of HR and better predict the PARP inhibitor response. It can also provide us a new potential 
therapeutic target to explore for development of novel combinational therapies to enhance PARP 
inhibitor effects.  
 In Chapters 2 and 3, I focused on inducing “BRCAness” by targeting FOXM1 pathway. 
FOXM1 is an oncogenic transcription factor that has been implicated in many cellular processes 
(Lam, Brosens et al. 2013, Konstantinopoulos, Ceccaldi et al. 2015). Emerging evidence suggests 
that FOXM1 can be considered as a master regulator of DNA damage response, oxidative stress 
response, and resistance to genotoxic agents (Zona, Bella et al. 2014), because FOXM1 
transactivates genes involved in DNA damage response, oxidative stress response, and DNA 
repair, leading to enhanced DNA repair and resistance to DNA damaging agents (Raychaudhuri 
and Park 2011). In high-grade serous ovarian cancer, FOXM1 pathway is activated in more than 
84% of cases (Cancer Genome Atlas Research 2011), thus making it a valid therapeutic target to 
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explore. In Chapter 2, I showed a new role of FOXM1 in the adaptive response to PARP inhibitor 
olaparib in cancer cells. I showed that olaparib induces FOXM1 expression which in turn induces 
the expression of DNA repair genes, thus constitution an adaptive response to olaparib-induced 
DNA damages. Upon induction by olaparib, FOXM1 translocates to the nucleus, binds to the 
promoters of genes involved in DNA repair, and upregulates their expression. Knockdown or 
chemical inhibition of FOXM1 sensitizes cancer cells to PARP inhibitor. Thiostrepton, as a 
FOXM1 inhibitor, increases the sensitivity of cells to PARP inhibitor. We showed that thiostrepton 
treatment leads to inhibition of FOXM1 and downregulation of HR genes, thereby inducing 
“BRCAness” and sensitizing resistant cells to PARP inhibitors. Meanwhile, we observed that 
DNA damage is enhanced when thiostrepton was combined with PARP inhibitor, and this result 
is consistent with the downregulation of HR genes, which would result in decreased DNA repair. 
The decrease of HR genes after FOXM1 inhibition with thiostrepton might partially explain the 
increase of DNA damage that we observed. Thiostrepton has been shown to induce intracellular 
ROS levels (Bowling, Doudican et al. 2008), which might also contribute to the increase of DNA 
damage. FOXM1 regulates anti-oxidant genes involved in scavenging ROS, and therefore 
inhibition of FOXM1 by thiostrepton may attenuate the expression of anti-oxidant genes and 
exacerbate ROS levels. Besides being a FOXM1 inhibitor, thiostrepton was also shown to be a 
proteasome inhibitor (Aminake, Schoof et al. 2011, Gartel 2011). Proteasome inhibition can 
induce cellular apoptosis (Concannon, Koehler et al. 2007). Our observation of increased cellular 
apoptosis after thiostrepton treatment might partially due to its proteasome inhibitor activity. 
Collectively, these results suggest that the sensitization of resistant cancer cells to PARP inhibitor 
by thiostrepton can only be partially explained by inhibition of FOXM1. In this aspect, more 
specific FOXM1 inhibitors may be more advantageous and desirable. Two additional FOXM1 
 187 
inhibitors siomycin A (Gartel 2013) and FDI-6 (Gormally, Dexheimer et al. 2014) are now 
available, and FDI-6 has been shown to be a more specific FOXM1 inhibitor compared to 
thiostrepton and siomycin. However, FDI-6 was soluble in DMSO, and high concentrations are 
needed to suppress FOXM1, which might present a challenge for in vivo study. It is questionable 
whether the effect of FDI-6 can be obtained at the clinically achievable doses. In the future, the 
focus should be put on the development of more specific and more drug-like FOXM1 inhibitors. 
 In Chapter 3, we first evaluated the extent to which FOXM1 knockdown affects the 
expression of HR genes. Surprisingly, the mRNA levels of FOXM1 target genes in HR pathway, 
such as BRCA1, BRCA2, BRIP1 and FANCF were maintained after FOXM1 knockdown by 
siRNAs. Interestingly, c-MYC was seen to be upregulated in these FOXM1 knockdown cells. So, 
we tested the hypothesis of HR genes may be co-regulated by both FOXM1 and c-MYC. Our 
hypothesis was supported by data from ENCODE, which indicates overlapping binding sites for 
both FOXM1 and c-MYC in the regulatory regions of target genes. TCGA data analysis reveals 
that expression of FOXM1 and MYC are elevated in ovarian cancer, and their expressions are 
negatively correlated, further supporting our in vitro finding that FOXM1 knockdown upregulates 
c-MYC expression. Given that BRD4 regulates the expression of both FOXM1 and MYC, we also 
analyzed the expression of BRD4 in TCGA datasets, and our analysis shows that BRD4 expression 
is the highest in ovarian carcinoma samples compared to 23 other cancer types. Consistent with 
the literature that BRD4 regulates the expression of FOXM1 and MYC, we observed a positive 
correlation in gene expression between BRD4 and FOXM1 or MYC. Given that BRD4 is highly 
expressed in ovarian cancer and that it positively regulates FOXM1 and MYC, we posit that BRD4 
inhibition will suppress the expression of FOXM1 and MYC and attenuate the expression of DNA 
repair genes, thereby inducing “BRCAness”. We also posit that the ensuing “BRCAness” will 
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enhance sensitivity to PARP inhibitors. Given that BRD4 inhibitor and degrader are available as 
experimental therapeutics (Filippakopoulos, Qi et al. 2010), we tested their effects on FOXM1 and 
c-MYC expression in ovarian cancer cells. We observed that BRD4 inhibitor (+)-JQ1 suppresses 
the expression of FOXM1 and c-MYC and efficiently downregulates of HR genes, such as BRCA1 
and RAD51, suggesting BET inhibitor is effective in induction of “BRCAness”. We observed 
similar effects with BET degrader ZBC260. With BET inhibitor (+)-JQ1, we demonstrated 
increased sensitivity to PARP inhibitors in HR-proficient PARP inhibitor resistant cancer cells. 
Our ChIP data indicates a decrease binding of FOXM1 and c-MYC to the promoters of BRCA1 
and RAD51 following (+)-JQ1 treatment, which may provide a molecular mechanism by which 
(+)-JQ1 downregulates the expression of BRCA1 and RAD51. These results also support our initial 
analysis of ENCODE data indicating that these genes may be co-regulated by both FOXM1 and 
c-MYC. Our study provided new insight into the regulation of DNA repair genes especially HR 
genes by c-MYC and the interplay between FOXM1 and c-MYC in this process. The FOXM1 
pathway was shown to be downregulated by BET inhibitors (Zhang, Ma et al. 2016), which was 
suggested to be a therapeutic strategy in ovarian cancer. Our data provide additional evidence to 
support this by showing downregulation of HR genes resulted from FOXM1 inhibition by BET 
inhibitors. The observation that combinations of sub-lethal doses of BET inhibitor and PARP 
inhibitor completely inhibited colony formation provides a new basis for the further clinical 
development of combination therapies targeting these two components. Lu et al., has tested the 
potential of BET inhibitor to enhance effects of olaparib in HR-proficient tumor xenografts from 
primary resistant cancer cells, however, the in vivo activity of this combination has not been shown 
in the acquired resistant cancer cells, and the potential has not yet been tested in MYC-amplified 
tumor models neither. In addition, we tested a more potent PROTAC-based BET inhibitor, 
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ZBC260, which has been shown active in in vivo models (Zhou, Hu et al. 2017).  Future studies 
are needed to evaluate the in vivo combined effects of ZBC260 and PARP inhibitor.  
 In addition, there are other important questions that need to be addressed. First, it will be 
important to understand how FOXM1 is downregulated following exposure of cells to BET 
inhibitors, which might involve the mechanisms of how BRD4 regulates FOXM1 expression. 
Second, it is possible that downregulation of BRCA1 and RAD51 is independent of FOXM1 and 
is the direct effect of BRD4 inhibition. A newly published study showed that transcription of 
BRCA1 and RAD51 was impaired by the depletion of BET proteins, and BET inhibitor (+)-JQ1 
directly repressed the promoter activities of BRCA1 and RAD51 (Yang, Zhang et al. 2017). 
However, the contribution of FOXM1 in JQ1-mediated downregulation of BRCA1 and RAD51 
was not addressed in the study. Given that BET proteins are chromatin readers and serve as co-
transcription factors, these proteins may bind to the regulatory regions and recruit additional 
transcription factors, such as FOXM1 and c-MYC for transactivation of target genes. Taken 
together, it is possible that downregulation of BRCA1 and RAD51 by BET inhibitor might be the 
result of a combined effects of inhibition of FOXM1, c-MYC, and BET proteins, such as BRD2, 
BRD3, and BRD4. Third, in ES-2 cells, we did not observe efficient downregulation of c-MYC 
by BET inhibitors, suggesting that MYC expression in this cell line is not primarily dependent on 
BET proteins. It would be interesting to know what factors regulate MYC expression in these cells. 
Interestingly, we detected efficient downregulation of BRCA1 and RAD51 in these cells by the 
BET inhibitor, which suggest BRCA1 and RAD51 are directly regulated by BET proteins or MYC-
independent transcription factors. The role of FOXM1 in transactivation of BRCA1 and RAD51 
cannot be ruled out because (+)-JQ1 consistently downregulates FOXM1 expression in cancer 
cells. Fourth, it will be informative to determine changes in the expression of DNA repair genes 
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regulated by FOXM1 and c-MYC after deletion of either one or both of them. We previously used 
siRNAs to knockdown FOXM1, c-MYC, or both FOXM1 & c-MYC, but we did not observe 
downregulation of candidate DNA repair genes even in a double knockdown (data not shown). 
However, we were unable to come to a conclusion that FOXM1 and c-MYC do not regulate the 
expression of these genes because the gene expression was performed at 72 hours after siRNA 
transfection, and other transcription factors could have upregulated the expression of these genes 
as a compensation mechanism to accommodate the downregulation of FOXM1 and c-MYC. A 
transient knockdown of FOXM1 and MYC by inducible shRNAs may be needed to resolve this 
issue. 
 In order to achieve a better understanding of the regulation of HR pathway and to identify 
novel modifiers of PARP inhibitor response in ovarian cancer cells, in Chapter 4, I described the 
CRISPR/Cas9-based knockout genetic screen that we performed. Using the sensitivity to the FDA-
approved PARP inhibitor olaparib as a readout, we identified top candidates that are contributing 
to PARP inhibitor sensitivity and resistance, respectively. For example, PARP1 is one of the 
sensitivity candidates, loss of which leads to PARP inhibitor resistance. This finding is consistent 
with the previous report that loss of PARP1 leading to PARP inhibitor resistance (Liu, Han et al. 
2009, Pettitt, Rehman et al. 2013), and the fact that PARP1 was picked up from the screen suggests 
that our screen worked. In addition, we identified C12orf5 (TIGAR) as one of the candidate genes 
that confer PARP inhibitor resistance. C12orf5 gene encodes TIGAR (TP53-Induced Glycolysis 
and Apoptosis Regulator), which is described as a fructose-2, 6-bisphosphatase (Bensaad, Tsuruta 
et al. 2006). TIGAR functions primarily as a regulator of glucose breakdown and promote pentose 
phosphate pathway (PPP) shunt by increasing production of fructose-6-phosphate, resulting in 
increased production of antioxidant NADPH and nucleotide synthesis precursor, ribose-5-
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phosphate (Bensaad, Cheung et al. 2009, Lui, Lau et al. 2010, Lui, Wong et al. 2011, Yin, Kosugi 
et al. 2012). TIGAR has also been shown to have a role in DNA damage response and repair, as 
evidenced by the induction of TIGAR expression with DNA damaging agent epirubicin and a 
decrease in DNA repair in TIGAR-knockdown cells through the regulation of the CDK5-ATM 
pathway (Yu, Xie et al. 2015). Consistent with the prior reports, we showed that TIGAR 
knockdown leads to the increase in intracellular ROS levels and DNA damage. TIGAR has also 
been shown to regulate cellular apoptosis and autophagy (Bensaad, Cheung et al. 2009), and confer 
radiotherapy resistance (Pena-Rico, Calvo-Vidal et al. 2011).  
 In these studies, we showed for the first time that TIGAR also plays an important role in 
PARP inhibitor resistance. Through a genetic screening approach and subsequent validation 
studies, we found that TIGAR knockdown leads to olaparib sensitivity in a panel of ovarian cancer 
cell lines. Then, we showed that TIGAR knockdown enhanced the olaparib-induced cytotoxicity 
possibly through increasing DNA damage, which might largely be attributed to increased 
intracellular ROS levels as a result of the decreased production of antioxidant NADPH. We 
hypothesize that this effect might be related to the inhibition of PPP after TIGAR silencing (Lee, 
Vousden et al. 2014). Interestingly, results from our RNA sequencing analysis indicated that 
TIGAR knockdown leads to significant downregulation of genes related to cell cycle progression. 
Consistently, we observed the increase in the number of cells arrested in S-phase, and this arrest 
was more profound in TIGAR knockdown cells treated with olaparib.  This finding is very different 
from the G2/M arrest observed in TIGAR-proficient cells treated with olaparib. It is possible that 
increased DNA damage in TIGAR-deficient cells prolongs the S-phase to complete the repair. The 
lack of nucleotides for DNA synthesis might be another factor causing the S-phase arrest since the 
generation of nucleotide precursor ribose-5-phosphate through PPP is inhibited in TIGAR-
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knockdown cells (Bensaad, Tsuruta et al. 2006). However, further studies are needed to clarify the 
underlying mechanisms involved in the S-phase arrest. We also observed induction of senescence 
with TIGAR knockdown in ovarian cancer cells, implying that targeting TIGAR as a monotherapy 
may be sufficient to stop cancer growth and prevent cancer progression. The highest level of 
senescence was seen when TIGAR was efficiently depleted, suggesting that complete depletion of 
TIGAR might produce more profound effects. Further studies are needed to test this concept.  
 The most exciting finding from this study is that TIGAR silencing via RNAi approaches leads 
to downregulation of BRCA1 expression and the FA pathway, suggesting loss of TIGAR 
negatively affects the HR process, leading to induction of “BRCAness”. This finding provides a 
molecular basis for enhanced sensitivity to PARP inhibitor after TIGAR knockdown because 
induction of “BRCAness” in HR-proficient cancer cells is shown to re-sensitize them to PARP 
inhibitor (Neri, Ren et al. 2011, Ha, Fiskus et al. 2014, Li, Karanika et al. 2017). Our finding is the 
first to show the potential role of TIGAR in HR pathway regulation. However, further studies are 
needed to investigate how the loss of TIGAR contributes to the decreased levels of BRCA1 
transcripts and the suppression HR pathway. The spheroid formation assay highlighted the 
potential for targeting TIGAR to enhance the therapeutic activities of PARP inhibitors. A search 
of TCGA databases found that aberrant TIGAR expression is common in various types of cancer, 
including testicular germ cell cancer, ovarian cancer, lower grade glioma, and non-small cell lung 
cancer. The higher levels of TIGAR expression are associated with a less favorable patient 
outcome.  Together, these results suggest that targeting TIGAR might be a viable approach to treat 
many types of cancers. In the future, in vivo study would be needed to evaluate the therapeutic 
effects of combing PARP inhibitor with inhibition of TIGAR.  
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 Overall, our studies showed an exciting avenue to develop new combination therapies to 
induce “BRCAness” and thus enhance the efficacy of PARP inhibitor in those tumor cells with 
acquired or primary resistance. We have shown that FOXM1 plays an important role in adaptive 
response to PARP inhibitor and contributes to PARP inhibitor resistance. Therefore, inhibition of 
FOXM1 represents a potential strategy to overcome PARP inhibitor resistance. We also 
demonstrated that FOXM1 coordinates with c-MYC to regulate HR genes, such as BRCA1, 
RAD51, and BRIP1, and that BET bromodomain inhibitor can induce “BRCAness” and enhance 
the activity of PARP inhibitors. In addition, we showed the great potential of CRISPR/Cas9-based 
functional genetic screen to identify novel modifiers of PARP inhibitor response. We identified 
TIGAR as a novel modifier of HR pathway, and we showed that TIGAR knockdown enhances the 
sensitivity of ovarian cancer cells to PARP inhibitor olaparib. Our studies provided a new 
understanding of potential mechanisms contributing to PARP inhibitor sensitivity and suggest 
TIGAR as a new therapeutic target to explore for advancement of combination therapies to 
enhance PARP inhibitor therapeutic effects.  
5.2 Future directions 
 As I mentioned in Chapter 1, various mechanisms have been suggested to contribute to PARP 
inhibitor resistance, among them restoration or enhancement of HR function is well recongnized 
and the most extensively studied. In this dissertaion, my studies mainly focused on new strategies 
to enhance the effect of PARP inhibitors by identifying factors that impair HR pathway. Besides 
HR repair, BRCA1 and BRCA2 were also shown to be involved in regulating replication stress 
(Pathania, Nguyen et al. 2011, Schlacher, Christ et al. 2011, Schlacher, Wu et al. 2012, Ying, 
Hamdy et al. 2012, Pathania, Bade et al. 2014, Ray Chaudhuri, Callen et al. 2016). Emerging 
evidence show that the enhancement of replication fork protection serves as an mechanism for 
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PARP inhibitor resistance in BRCA1/2-deficient cancer cells with no revertant mutations in BRCA 
genes (Ray Chaudhuri, Callen et al. 2016, Rondinelli, Gogola et al. 2017). RAD51 and the Fanconi 
anemia pathway components, such as FANCD2 and FANCD1/BRCA2, were shown to increase 
replication fork stability (Schlacher, Wu et al. 2012). Since data from our studies suggest FOXM1 
and c-MYC positively regulate RDA51 and BRCA2, it would be interesting to test the potential 
impact of  FOXM1 and c-MYC on replication fork stability. In addition, our data showed that 
TIGAR knockdown leads to S-phase arest, and downregulation of BRCA1 and the FA pathway. It 
would be informative to study the impact of TIGAR deficiency on replication stress, especially on 
replication fork stability, which might provide us additional mechanistic explanation on the 
enhanced sensitivity of TIGAR-deficient cells to PARP inhibitor. 
 Moreover, it would be informative to find answers for the folowing questions arising from 
the results of my studies. First, the enhanced effect of PARP inhibitor in thiostrepton-treated cells 
might not depend only on the downregulation of HR genes. Thiostrepton also functioned as a 
proteasome inhibitor (Aminake, Schoof et al. 2011, Gartel 2011) and induces intracellular ROS 
production (Qiao, Lamore et al. 2012). Studies have shown that proteasome inhibitors can sensitize 
cancer cells to PARP inhibitor (Neri, Ren et al. 2011, Gu, Bouwman et al. 2014). Therefore, the 
effect that we observed with thiostrepton may be the combined effects on thiostrepton on multiple 
cellular targets rather than its specific effect on FOXM1 inhibition. In order to evaluate the exact 
role of FOXM1 in modifying the PARP inhibitor response, it would be important to develop and 
use specific FOXM1 inhibitors. In addition, in vivo studies should be conducted to evaluate the 
therapeutic index of drug combinations consisting of PARP inhibitors and specific FOXM1 
inhibitors. These studies should address the extent to which the combination of FOXM1-specific 
inhibitor with PARP inhibitors induce “BRCAness” and enhance sensitivity to PARP inhibitors in 
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vivo without causing detrimental effects on immune cells and normal tissues. Second, although we 
showed that the suppression of both FOXM1 and c-MYC by the BET inhibitor (+)-JQ1 results in 
the downregulation of BRCA1 and RAD51 and the sensitization of resistant cancer cells to PARP 
inhibitor, it would be informative to show the effects is dependent on FOXM1 and c-MYC. Rescue 
of BRCA1 and RAD51 expression and resistance to PARP inhibitors in cells with enforced 
expression of FOXM1 and c-MYC in the presence of (+)-JQ1 will clarify the direct of FOXM1 
and c-MYC in the regulation of BRCA1 and RAD51 in (+)-JQ1-treated cells. Moreover, the 
assessment of PARP inhibitor sensitivity in cancer cells with genetic depletion of both FOXM1 
and c-MYC will further clarify the role of these proteins in PARP inhibitor sensitivity. However, 
the generation of mutant clones with genetic depletion of both FOXM1 and MYC may not be 
possible because cells may be addicted to these oncogenes. Even in cases where viable clones are 
generated, it is possible that such clones may have acquired adaptive responses to compensate for 
the loss in FOXM1 and MYC, and these adaptive responses may modify PARP inhibitor 
sensitivity. Therefore, inducible systems where both FOXM1 and MYC can be knockdown 
transiently in controlled manner may be needed to test the role of dual inhibition of FOXM1 and 
MYC in PARP inhibitor sensitivity. More importantly, in order to facilitate the translation of in 
vitro observations into clinic, it would be important to test the combined effects of BET inhibitor 
and PARP inhibitor in vivo. These studies should evaluate not only the pharmacokinetics of BET 
degraders and inhibitors in combination with PARP inhibitors but also the pharmacodynamics of 
these agents on inducing “BRCAness” in cancer cells as well as in normal cells and the potential 
toxicity and adverse effects of the combination. Third, we performed in vitro studies to 
demonstrate that TIGAR knockdown increases PARP inhibitor sensitivity in ovarian cancer cells, 
and these results suggest a therapeutic potential of targeting TIGAR to enhance effects of PARP 
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inhibitor. Although the clinical relevance is partially supported by the observation that TIGAR is 
amplified in tumor samples from TCGA studies and that higher TIGAR expression is associated 
with poor survival outcome in high-grade serous ovarian cancer, additional in vivo studies are 
needed to further evaluate the feasibility of targeting TIGAR. Besides genetic manipulation of 
TIGAR expression, it would be important to develop specific TIGAR inhibitors. Further studies 
are also needed to unveil how TIGAR downregulation leads to cellular senescence. In addition, it 
would be informative to perform further studies to unveil the detailed mechanisms affecting 
BRCA1 expression and the FA pathway. 
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